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ABSTRACT OF DISSERTATION

ANALYSIS OF INFORMATION VALUE CHAINS FOR GOUT SELF-CARE
MANAGEMENT

This value chain analysis study sought to identify information needed by gout
patients to successfully manage their disease, leading to a model for information extraction
from patient health records. A scoping review was conducted to identify the types of
information needed by gout patients. The findings of each included study were divided and
analyzed according to the stages of the care delivery value chain. The results of the review
were then used to create a gout information value chain as criteria for annotating the
information deemed important for gout patients contained in publicly available patient
education materials according to the stages of care delivery. The resulting annotations were
used to develop a named entity recognition model capable of automatically labelling
medical concepts from clinical notes by value chain stage. To identify concepts specifically
relevant to gout patients, the concepts extracted from patient notes were used as candidate
features in a phenotyping algorithm to identify concepts associated with gout flares. While
this study was able to develop a model for identifying information relevant to gout flares,
the findings suggest that there is information missing from patient education materials and
their clinical notes that could be valuable to gout patients for self-management.
KEYWORDS: care delivery value chain, patient information, cNLP, gout management
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CHAPTER 1. INTRODUCTION

The purpose of this study was to identify the information gout patients require to
optimize their healthcare. Recent regulatory changes have made it impossible for health
professionals to ignore health information technology, particularly electronic health record
systems (EHRs) (Blavin, Ramos, Shah, & Devers, 2013). Studies have emerged indicating
that these technologies can increase the ability of clinicians and patients to manage health
care (Businger, et al., 2007). Initial studies on patient portals, a required feature of EHRs,
have shown great potential for chronic disease management. These portals allow patients
to access their health records through a secure website.
Early research demonstrated that patients with this easy access to their health
information are more involved in their health care and this involvement can lead to long
term benefits, especially for low income patients (Lake Research Partners, 2010).
However, as illustrated in later chapters, gout patients have thus far been unable to
consistently leverage available information to adequately improve health outcomes.
Though much research has been done on related topics, particularly regarding patient
education for effective treatment options, what information is valuable to gout patients
throughout the continuum of care remains largely unanswered.

1.1

Background
In 2012, results from the National Health Interview Survey (NHIS) indicated that

approximately fifty percent of adults in the United States had at least one chronic
condition. Of those, roughly half identified as having multiple chronic conditions (Ward,
Schiller, & Goodman, 2014). As life-long conditions, patients with chronic diseases tend
to have multiple healthcare providers and higher consumption of health services (Centers
for Disease Control and Prevention [CDC], 2009).
This is especially true for gout, the most common type of inflammatory arthritis
which affects up to 6 million Americans (Lawrence et al., 2008). The risk of developing
gout increases with age. It is also associated with several common clinical (e.g. diuretics,
low dose aspirin, hypertension, cardiovascular disease) (Wallace et al., 2004) and
behavioral (e.g. consumption seafood and beef) (Choi, Liu, & Curhan, 2005) factors.
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Further complicating matters, gout treatment requires two different medication tacks, one
for the acute symptoms (anti-inflammatory drugs) that arise when the disease is not
properly managed and one for chronic disease management (urate-lowering
therapies[ULTs]) designed to prevent the deposition of monosodium urate crystals in joints
Schlesinger, Dalbeth, & Perez-Ruiz, 2009).
Despite being considered the best understood of the joint diseases and the only
chronic arthritis with the potential to be ‘curable’, gout still often goes undiagnosed and
sub-optimally treated (Doherty et al., 2012). There are myriad reasons for this, all of which
can be traced back to a lack of appropriate information needed for education. The complex
nature of gout requires self-management for optimal treatment which must include
medications and lifestyle changes. This makes identifying information values throughout
the care continuum critical to encourage patient engagement in self-care (Fields &
Batterman, 2018). However, this endeavor is often unsuccessful because there is no
established consensus among stakeholders as to the goals and means of patient education
in the various stages of care (Doherty et al., 2012).

1.2

Statement of Problem
With an initial promise of government financial incentives and technical assistance,

and the threat of fines and other penalties in the future, the U.S. healthcare system slowly
but surely began adopting electronic health records (EHRs) (Adler-Milstein & Jha, 2017).
However, the goal of the HITECH Act was never mere adoption of technologies. The
central tenet of the Act is the improvement of healthcare through the “meaningful use”
(MU) of certified EHRs. HITECH identifies multiple ways to improve the quality, safety,
and efficiency of healthcare (Blavin, Ramos, Shah, & Devers, 2013). One such way is
through patient engagement. In order to make well-informed decisions, patients must be
active participants in the management of their healthcare. Research has demonstrated that
failure to supply patients with adequate information can contribute to poor adherence to
treatment (Stevenson, Cox, Britten, & Dunder, 2004). To ameliorate this, the MU
component of the HITECH Act requires that EHRs include functionalities that allow
patients to easily access their personal health records (PHRs) (Ahern, Woods, Lightowler,
Finley, & Houston, 2011). PHRs can contain various types of information from multiple
2

sources. To facilitate access to these records, MU mandates that EHRs provide a patient
portal that is designed to support the communication of accurate information between
patients and healthcare providers. As the portal is linked directly to their electronic medical
record (EMR), from the perspective of the patient the information is provided
automatically and is more personalized than a generalized search for health information
through the Internet (Arnold et al., 2013).
Though results have been mixed, the general consensus is that patient portals
provide a secure means of accessing relevant health information that can lead to higher
patient involvement and engagement. The potential beneficial health outcomes include
increased adherence to treatment, knowledge and understanding, and patient satisfaction,
all of which can lead to better clinical outcomes (Kruse, Argueta, Lopez, & Nair, 2015).
Of course, patients must use the portal to reap these benefits. Unfortunately, much of the
initial research on patient engagement focused on deciding what patients could or should
do rather than factors involved in actively engaging patients in their care.
Such findings are particularly relevant to patients with rheumatic diseases. The
chronic, life-long nature of this disease group generates a multitude of information unique
to each patient that could aid in self-management of the disease and its symptoms.
However, there is a paucity of research specifically looking at the effects of health
information available via patient portals on treatment of rheumatic diseases. The specific
problem is that patients have access to an overwhelming amount of information without
the knowledge or guidance to sort through, manage, or otherwise utilize said information
to improve their health (Klerings, Weinhandl, &Thaler, 2015). A knowledge gap exists as
to what personal health information is required to optimize care.
Some publications offer generic educational interventions that might help increase
knowledge and understanding of gout and its treatment options. However, these studies
focus on one or two aspects of disease management and do not include PHRs, which
contain information personalized to the patient. In contrast, this study will look across the
entire care continuum.

3

1.3

Study Purpose
Arthritis, a broad term generally used to refer to conditions in the rheumatic disease

family, is considered to be one of the top ten chronic conditions. According to the
European League against rheumatism (EULAR) (n.d.), rheumatism includes more than
200 diseases which can affect the entire musculoskeletal system, making it the most
prevalent group of diseases in the industrialized world. Treatment of these diseases is
usually complex, involving medications and lifestyle changes to decrease pain and
preserve mobility. As such, patients with these diseases must actively engage in selfmanagement to alleviate symptoms. Consequently, there is a plethora of information that
patients must keep up with for effective self-care (Zhang et al., 2011). Much of this
information is accessible via a PHR tethered to an EHR, making this an ideal disease group
for cNLP research. On the other hand, each disease classed under this heading presents a
unique set of opportunities and challenges.
Gout is an inflammatory disease caused by high uric acid in the blood (Schlesinger,
2004). It is the most prevalent form of inflammatory arthritis and continues to increase
(Zhu, Pandya, & Choi, 2001). The most common symptom is gout flares which occur when
uric acid crystalizes into needle-like formations within the joints (Suresh, 2005).
Diagnostic codes have proven a poor source for flare identification in patients (Halpern,
Fuldeore, Mody, Patel, & Mikuls, 2009). Furthermore, there is no standard definition for
the symptom, leading researchers to search for better methods of identification using cNLP
(Taylor et al., 2009).
The purpose of this study was to use clinical natural language processing (cNLP)
techniques to determine the prioritization of patient health information and explore ways
that health information technologies can best be utilized to provide that information for
gout patients. The study included gout patients with available data in the University of
Kentucky Healthcare (UKHC) EHR system.
The issues presented in this chapter highlight a fundamental problem with PHRs.
In order to receive information, a user must first interact with the system. For various
reasons, patients are not sufficiently motivated to engage with PHRs. This study sought to
address this problem by performing a value chain analysis to identify the most relevant
information that could be obtained through a patient's PHR and then using natural language
4

processing techniques to automatically extract information that patients could use to guide
healthcare decisions. This is pertinent for several reasons.
First, tethered and integrated PHRs are populated with information from EHRs
which were designed to meet the needs of healthcare providers. The average patient neither
needs nor understands all of this information (Wilson, 2009). Furthermore, studies have
found that access to such an excess of information has the potential to cause information
overload (Wynia & Dunn, 2010).
Second, many studies focus on the effects of PHRs on health outcomes, with mixed
results. Yet, the reasons for PHRs failing to produce the promised potential benefits largely
remain a mystery (Giardina, Menon, Parrish, Sittig, & Singh, 2014). Health outcomes are
the ultimate result of a complex set of processes. The value chain affords us the opportunity
to view the entire continuum of care as a system to pinpoint where in the chain breakdowns
are occurring.
Finally, value chain analysis can show us where value is not being created and
evaluate if the gap can be addressed with the information available or if there is a patient
need that current functionalities of PHRs are not able to fulfill.

1.4

Study Importance
Patients have unprecedented access to their health records through patient portals.

Such access is beneficial and necessary if patients are to be able to appropriately control
their health care; however, the data is often offered without context or regard for individual
background knowledge. This creates barriers to interpretation and optimal usage. This is
especially troublesome for patients with chronic diseases who must deal with vast amounts
of information over their lifespan.
It is expected that gout patients might benefit the most from this study, as they will
have direct, tangible output to aid them in managing their health. By researching the
information necessary for patients to successfully deal with issues faced by gout patients,
potential solutions may be discovered for providing information currently lacking,
encouraging more patients to persist in the management of their health conditions. Several
other stakeholder groups may also benefit from the results of this study on automatically
extracting valuable information from patient records. Clinicians may leverage findings to
5

institute personalized education programs by adapting templated patient education
materials that typically lack information that is relevant to specific patients. This study
may also benefit healthcare organizations, adding tools for more effective patient care via
HIT because better information filtering can be provided for smoother workflow,
educational enrichment, increased productivity, higher satisfaction, and reduction of costs
and other resources (Clarke et al., 2013).
By understanding what information contributes to sustained engagement of patients
in their care, leaders will be better equipped to understand the changes that are needed to
further develop EHR systems. Lawmakers may also be encouraged to enact policy changes
that continue to enable patients to access relevant health information, providing a platform
for more efficient HIT tools and, in turn, paving the way for improved public health. These
insights may also be helpful for creating strategies to close the health care gap by providing
practical methods for incorporating information that can be used to minimize health
disparities and target specific areas of inequity for engagement. Over time, these changes
may impact an overall cultural change in the healthcare industry, providing an underlying
foundation for patients to be better prepared for involvement in healthcare decisionmaking. These findings may also equip gout patients with useful guidelines for topics of
discussion with healthcare providers. Patients educated according to study findings may
become social and community sources of information and support. Their perspectives may
offer guidance to others navigating an often-stigmatized disease while stemming the
perpetuation of misinformation that currently abounds.

1.5

Research Questions
Value chain research can identify where value is being or could potentially be

created. In reflection of this, the research questions for this study were:
RQ1: What are the major types of information required by gout patients according
to the care delivery value chain?
RQ2: What information can be identified by mapping online gout patient education
materials to the value chain?
RQ3: What gout information values can be identified from patient notes based on
the value chain using cNLP techniques?
6

As there is no conclusive research for why gout patients are not getting necessary
information, other research approaches may be too limiting. There are many layers and
dimensions as to why gout patient outcomes remain suboptimal. A value chain analysis
was used to try to uncover insights and develop a model for supplying gout patients with
the best information for disease management at the most beneficial time in the care cycle.

1.6

Research Design Overview
This study was conducted in multiple phases, each with distinct output that feds

into the next. In the first phase, a literature review using Porter’s care delivery value chain
(CVDC) as a framework was performed. A value chain is a holistic approach that allows
for looking at all stages of a process. As value is ultimately created and judged by patient
well-being in healthcare, the CVDC essentially allows us to perform a needs assessment
for patient information across the entire care continuum for gout. The information
identified and categorized according to the stages of healthcare delivery served as the
annotation guidelines for the second phase, where patient education materials were
evaluated for information considered valuable to gout patients for managing the disease in
each stage of care. Information chosen in this step was used to form our model for
information extraction from clinical documents. Phase 3 saw the design and comparison
of algorithms capable of identifying which factors included in this value chain were most
predictive of gout flares. As the most common and often the first sign that gout is being
poorly managed, information associated with and able to predict flares would be
considered important and valuable (Suresh, 2005). More specific details about the design
of the study are provided in chapter 3.

1.7

Summary
This study sought to understand what information helps gout patients engage in

long-term self-management, using value chain analysis. As most previous work on gout
patient information focuses on creating education and medication interventions for
treatment, there is a knowledge gap as to other types of information that might aid in
wellness goals, including what information is already available in EHRs that can be used
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for this purpose. The results of this study may serve multiple stakeholders such as
clinicians, healthcare policy makers, health IT developers, and most of all, gout patients.
Four more chapters follow. Chapter 2 is a review of the literature on the theoretical
framework and principal techniques used in this study. The primary topic discussed for the
next chapter is the gap in the literature related to a value chain model for patients to
optimally manage gout long-term and clarifies how this study will fill this gap. Chapter 3
further discusses the research design and specific details of how the study was conducted.
The remaining chapters focus on the output from the research conducted for this study.
Results are reported in Chapter 4, followed by discussion and interpretation of the findings
in Chapter 5.
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CHAPTER 2. LITERATURE REVIEW

2.1

Background
It is widely acknowledged that the United States spends over twice as much as other

developed nations on health care. From 2004-2006, roughly $1.8 trillion per year was spent
on health care, about $6,000 per capita (Anderson & Frogner, 2008). By 2008, that number
had risen to $7,681 per capita for a total of over $2.3 trillion and continues to rise. The rise
in health care costs has exceeded the rate of inflation while seemingly having a negative
correlation with the quality of U.S. health care (Kaiser Family Foundation, 2010). For all
the money spent, the United States has essentially the same life expectancy and mortality
rates as countries like Germany, Canada, and Japan, which spend far less (Murray & Frank,
2010). This disparity between expenditures and outcomes has led to widespread analysis
of the healthcare industry. These analyses have concluded that without some sort of major
structural overhaul to reform healthcare, costs will continue to rise to an unsustainable
degree (Council of Economic Advisors, 2009). This chapter will explore ways health
information technology can turn the tide on those costs and/or offer more value for the
money spent.
General consensus seems to be that, along with spending the most money, the
United States has the best research and development, the best professional training and
development, and a myriad of other superiorities in the healthcare field. Unfortunately,
these advantages do not add up to a superior health care system, at least when it comes to
things like population longevity and quality of life. Because healthcare systems exist
within societies having differing cultural expectations and values, quality indicators can
be rather subjective, making it difficult to compare economic value with other countries.
However, with the Institute of Medicine reporting almost 100,000 inpatient deaths and two
million ambulatory patient injuries due to errors, it would be irresponsible to discount the
experiences and opinions of patients and their families (Brailer, 2005).
While the majority of businesses embraced technology-based information systems
long ago, the medical field has been extremely reluctant to do so. This resistance continued
in the face of numerous potential benefits until the government passed the Health
9

Technology for Economic and Clinical Health (HITECH) Act in 2009 (Blavin, Ramos,
Shah, & Devers, 2013). This act provides monetary incentives to implement and use
electronic health records to improve health care (Romano & Stafford, 2011).
The National Academy of Science has long recognized that information technology
is essential to the dual goals of improving health care quality while cutting costs (Adams
& Corrigan, 2003). Despite the health care industries reluctance to adopt information
technology, much research has been done on ways clinical decision support systems can
be used to reduce cost at the individual patient level. There are a multitude of systems that
can help clinicians make the best choices for their patients and reduce errors through the
use of checks, reminders, and alerts. Electronic health records, specifically, further reduce
redundancy and errors by integrating patient data from multiple sources. These tools have
the power to eliminate duplicate or otherwise unneeded testing and treatments (Payne et
al., 2012).
Reducing expenses is only one side of the equation. If Americans were receiving
equivalently superior health care to match the highly superior costs, there would not be
such an issue. U.S health care needs to be safer, more patient-centered, more responsive,
and much more cohesive. Research has shown that organizations that successfully manage
costs do so through the use of information technology at the patient level and at the
structural level to facilitate a more team like approach. Healthcare organizations
accomplish this through technologies that allow patients to be more proactive in their care.
This allows health care to take place in the patient’s home or another lower cost location
when possible. Health information technologies also provide more efficient
communication allowing health care workers access to experts at any distance and the
ability to share data with such experts quickly for consultations (Payne et al., 2012). There
are multiple other ways technology can and does benefit health care such as maintaining
records and making billing easier. However, there are reasons the industry has not
embraced technology for health care purposes.
Cost reduction is the easiest way to prove a system's economic value. Dollar values
can be placed on expenses that will be reduced over time and used to offset the cost to
implement the new system. These numbers are based on estimates, which is risky, but is
done in the business world all the time. Many healthcare organizations do not have the
10

capital to invest in an expensive system and wait for a return that may never materialize.
The HITECH Act does mitigate this somewhat, but it only applies to certain systems.
It is much harder to put a monetary value on better health and, in actuality, better
patient health outcomes do not directly benefit a health care organization’s bottom line.
Nor is there a financial return on investment for technology that facilitates those outcomes.
Theoretically, better healthcare leads to repeat patronage and more patients. However, due
to the current fee for use system, when an organization looks at its revenue, all it sees is
less income from less testing and other services.
Information technology is essential to reducing health care costs while
simultaneously improving quality. However, their benefits are not guaranteed. An
organization must carefully choose system designs and functionality when adopting a new
system and then successfully implement with an eye toward improving workflow and
operations.
2.1.1

Personal Health Records

In 2003, the Institute of Medicine (IOM) issued a report identifying the key features
that an optimal electronic health records (EHR) system should have. Chief among them
were that it provides knowledge and decision support to enhance patient care. To that end,
the system should allow access of information to the proper users immediately. Two
component systems considered integral to optimization are the electronic medical record
(EMR) and the personal health record (PHR) (Tang, 2003). When PHRs are linked to an
EHR in this manner, they are considered “tethered,” as the information comes directly
from the patient's EMR. This connectedness has many potential benefits.
Due to frequent usage for health and disease management, the majority of PHR
research has focused on patients with chronic conditions (Bronwyn et al., 2018). In 2012,
results from the National Health Interview Survey (NHIS) indicated that approximately
fifty percent of adults in the United States had at least one chronic condition. Of those,
roughly half identified as having multiple chronic conditions (Ward, Schiller, & Goodman,
2014). As life-long conditions, patients with chronic diseases tend to have multiple
healthcare providers and higher consumption of health services (Centers for Disease
Control and Prevention [CDC], 2009). Because PHRs provide patient access to
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information along with tools for self-management and additional communication channels
to healthcare providers, they are ideally situated to help with this process (Tenforde, Jain,
& Hickner, 2011). However, PHRs are not a panacea and still have room for improvement.
Many patients are still reluctant to adopt PHRs. Current barriers to effective PHR usage
include low perceived value and usability, privacy and security concerns (Dontje, Corser,
& Holzmer, 2014), and low health and technology literacy, especially in elderly
populations (Lober et al., 2006). Prior research has made great strides, but these and other
complex issues still must be dealt with in order to optimize patient education and care,
particularly for those with chronic conditions.
2.1.2

Health Literacy

Advances in information and communication technologies (ICT) have made it
possible to store and access the large amounts of data necessary for PHRs. However, PHRs
demand that patients be able to adequately access, understand, and use the provided
information to make appropriate health decisions in order to reap these benefits, making
health literacy (HL) essential to improving healthcare (Bronwyn, Rollo, Georgiou,
Balandin, & Hill, 2018). This requires a diverse set of literacy skills (cumulatively referred
to as health literacy (HL)) that enable a patient to complete multiple tasks that involve
reading and calculation, such as reading prescription labels and measuring medication
dosages (Nielsen-Bohlman, Panzer, & Kindig, 2004). Lower HL is not only associated
with adverse health outcomes, but also, specifically, less active self-management (Dewalt,
et al., 2004).
In the case of musculoskeletal disorders, patients must have knowledge of their
specific disease for optimal management and self-care. However, previous studies have
demonstrated that many patients only know that they have arthritis and are unaware of any
subtype (e.g. rheumatoid arthritis, osteoarthritis). Furthermore, patients often inaccurately
self-report musculoskeletal diagnoses (e.g. gout, osteoporosis). While the diseases in this
category require significant participation on the part of the patient for self-management,
each has its own combination of medication and lifestyle intervention guidelines (Hill et
al., 2015). This, coupled with the fact that most adults do not have the HL skills to
accurately or consistently make use of health-related information, causes a disparity in the
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self-management tasks patients are able to do and those that are required for optimal health
outcomes (Kutner, et al., 2006). For gout patients specifically, health literacy is
particularly low for medications, often leading to non-adherence. Encouragingly, patients
seem to be aware of their knowledge gaps and want more information, especially about
the whys and wherefores of treatment regimens (van Onna et al., 2015).
2.1.3

cNLP Methods

The HITECH Act of 2009 caused an upsurge in the adoption of electronic health
records and researchers rapidly moved to take advantage of this data source (Blumenthal,
2010). Early studies largely focused on usability (Ellsworth, Dziadzko, O’Horo, Farrell,
Zhang, & Herasevich, 2017) or using structured data for risk prediction modeling
(Goldstein, Navar, Pencina, & Ioannidis, 2017). However, the data that is most useful for
documentation and communication is usually in an unstructured, free-text format (Jensen
et al., 2017). Yet, clinical natural language processing (cNLP) techniques for information
extraction (IE) remain underutilized for clinical and translational research (Wang et al.,
2018). Because the purpose of this study is to identify and examine the information
contained in clinical notes, cNLP techniques of IE are the most appropriate choice.
2.1.3.1 Pipelines/Algorithms

A natural language processing pipeline is simply a chain of processes to complete
a task where each subtask feeds into the next. In other words, the output from one process
becomes the input for the one directly following it. Different algorithms can be applied to
each component of the pipeline (Nadkarni, Ohno-Machado, & Chapman, 2011).
In order to deal with the complexities inherent to rheumatic diseases, researchers
have employed a variety of pipelines and algorithms sometimes within the same study. Lin
et al. (2013) first used the clinical Text Analysis and Knowledge Extraction System to
discover named entities with their accompanying concept unique identifier (CUI) from
UMLS, assertion status, and context. The output was then fed into a pipeline that was
designed to select optimal features using a three-step process comprising frequency cutoff,
chi-squared, and correlation-based feature selection (CFS) which utilized the genetic
algorithm. Erythrocyte sedimentation rate (ERS) and C-reactive protein (CRP) lab values
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were then added to this output to create a data set for algorithm development which process
utilized Weka to implement several classification algorithms: logistic regression, Naïve
Bayes, Multilayer perceptron, and multiple Support Vector Machines (SVMs). The
resulting models were then tested on a document set using 10-fold validation.
In contrast, Love et al. (2011) used a more simplified approach to feature selection
that is not detailed in the paper. The chosen predictor variables were extracted from clinical
notes using mySQL queries. The random forest method was then used to train three
algorithms for testing.
Most studies fall somewhere in between these two, though most NLP studies of
rheumatic diseases are fairly complex and detailed. While the paper only obliquely explains
that a dictionary-based method was used for NLP, it does explicitly state the several ML
algorithms that were tested: naïve Bayes, SVM, neural network, and decision tree (Zheng
et al., 2014).
As demonstrated by these example works, while there is variation in specific
pipelines and algorithms, rheumatology studies employing NLP tend to rely on dictionarybased methods for named entity recognition and supervised ML techniques. Likely due to
this, researchers also tend to use similar measurements for performance evaluation of
models. In contrast, our entity extraction pipeline included a sentence splitter, context
sensitive tokenizer, part-of-speech tagger, section identifier (patient history, family history,
etc.), a named entity recognition (ner) module created using the ML algorithms and
terminology/ontology mapping from UMLS.

2.2

Theoretical Framework
The concept of a value chain was first introduced by Michael Porter as the set of

activities that an industry specific firm uses to create value in the market. Value was
originally defined as the amount consumers are willing to pay for a product or service.
Thus, it would be measured by revenue generated. In order to encompass total value, the
framework employs a process view of organizations in which firms are conceptualized as
systems composed of subsystems, each with their own sets of inputs, transformation
processes, and outputs (Porter, 1985).
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2.3

Overview
Originally applied to a manufacturing context, Porter theorized the myriad activities

that organizations must perform in order to transform inputs into outputs as primary or
secondary activities. Primary activities are those considered essential for the creation of
value and competitive advantage. Secondary activities are those undertaken to support and
improve primary activities. Value activities are identified and classed according to
technologic and strategic distinction. Thus, Porter proposed that primary activities consist
of five generic components (inbound logistics, operations, outbound logistics, marketing
and sales, and service) with the idea that every discrete activity that a firm engages in can
be categorized for the purpose of identifying areas of competitive advantage. Support
activities can be similarly classified into four broad categories (procurement, infrastructure,
technological development, and human resources (HR) management) with the proposition
that increased efficiency in any of the four will lead to beneficial results in at least one of
the primary components. All activities contribute to a firm’s profit margin, which is
determined by the extent that value exceeds costs (Porter, 1985). This is considered the
traditional, physical value chain model.
2.3.1

Healthcare Applications

Porter (1985) originally posited that his generic value chain could be used to compare
and differentiate competing businesses. While the value added by each category may vary
by industry, each component was considered integral to some extent in distinguishing
competitive advantage. Therefore, though the model could be applied to any industry,
including services, it was only relevant at the business unit level. That is, value chain
analysis should be performed on competing firms within the same industry. However,
much work has been done to expand the model in the intervening decades, much of it by
Porter himself.
Porter’s (1985) original assertion that industry-level and sector-wide value chains
would be too broad to parse out sources of competitive advantage did not deter
researchers. Buttigieg, Schuetz, and Bezzina (2016) employed qualitative research
methods to create and compare value chains for public and private healthcare sectors in
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Malta. This analysis was used to evaluate the feasibility of recommendations for
maximizing the provision of healthcare services.
Porter (1985) similarly objected to applying the value chain to subsets of a
business. Segmenting and analyzing a firm according to lines such as products or
geography would not be useful. Due to the interrelated nature of an organization’s
subsets, it would not be possible to fully understand the value chain without the view
provided by the firm-level value chain. Nevertheless, researchers have continued to do
so, especially in the realm of health information. Frisse (1999) believed that the
framework provided a lens for evaluating the value of information technology (IT) for
various stakeholders. Through this lens, the study factored in the experiences of providers
and patients to identify the support activities made possible by IT. These activities were
then compared to analogous activities in other industries to demonstrate how
improvements accomplished using IT, such as “just-in-time” logistics, can be applied to
healthcare. Fetterolf (2006) adapted the value chain model to create a “disease
management” value chain. In this study, knowledge distribution was the ultimate goal
with the model demonstrating the flow of processes required to do so, starting with the
acquisition of raw data. This type of model could help demonstrate the value in creating
comprehensive disease management (or similar) programs throughout an organization.
Finally, Theyel (2017) presents a bit of a conundrum with a value chain for biomedical
products. The article advocates and proposes technologies to track products throughout
their lifespan in order to identify areas within the value chain for improvement and
innovation. Though specific to certain products, these products are not tied to any
particular firm. The complete value chain for biomedical products, such as drugs and
medical devices, can span multiple industries and encompass numerous organizations and
could potentially be considered a global value chain. Research in these areas continues
today with no clearly accepted value chain emerging.
The above examples highlight the complexities inherent in healthcare and
demonstrate potential applications of the value chain to identify ways to successfully
utilize information technologies to address that complexity. There is still much work to
be done, not the least of which is validating previously proposed models. The Wharton
School of business developed a value chain representative of a conventional approach to
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value chain analysis which involves mapping the activities involved in delivering a good
or service (Burns, 2010). From a patient perspective, however, lab tests by themselves
have no value, even though they still must pay for them. A tests value is in being able to
connect the patient to needed treatment. Even treatment itself is not the ultimate goal, but
patient well-being. Thus, to analyze value in healthcare delivery, the focus must shift
from products and services provided to outcomes achieved. In this manner, value for
health outcomes cannot be attributed to a specific intervention at one point in time but
must be redefined as the total outcomes achieved per costs over the total cycle of care.
According to Kim, Farmer, and Porter (2013), primary value is created by delivering care
for specific medical conditions and they created the care delivery value chain (CDVC),
which emphasizes the interrelated nature of healthcare and highlights the need for
integrated care.
Figure 2.1: Adapted Care Delivery Value Chain

Screening
medical history

Diagnosing
medical history

family history

tests

screening

data

test high risk
patients

expert/specialist
consulations

Preparing
choose care team

Intervening
drug therapy
educate about effects on
connect patient with
disease progression and
care team
potential side effects
connect patient with
other resources

intervention
preparation
limit co-morbidities
risk factors
management plan that affect disease
progression
improve disease
schedule follow up
ID high risk patients
progression and
visits
prognosis awareness
prevention
pre-treatment
modify behavioral
risk factors

assess medication
readiness
procedures
counseling therapy

Recovering
recovery

Monitoring
condition

fine-tune
therapy

ID important clinical
and lab values

manage
associated
illnesses
nutrition
modifications

manage acute attacks
therapy

maintain primary
care

manage treatment
side effects

discharge plans

initate second or third
line drug therapies
lifestyle modifications
provide additional
support
(community/social)

create treatment plan

promote risk
reduction strategies

The CDVC is divided into six categories of primary activities. The initial stage of
the value chain (preventing/monitoring) contains information pertinent to the prediagnosis phase including critical signs and symptoms and risk factors for the disease.
For gout, this stage is more accurately called screening. If such factors are present in a
patient, this phase is followed by Diagnosing, where diagnostics exams and tests are
performed. In the case of a confirmatory diagnosis, a patient moves into the preparing
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stage where they are given information for treatment options. The chosen treatment is
then administered in the intervening stage. For gout, there is no recovering/rehabbing
stage in the traditional sense. Instead, this phase is dedicated to fine-tuning therapies to
minimize side effects while keeping gout symptoms in remission. Monitoring and
managing acute gout attacks and other complications is continuous and constitutes the
final stage of the value chain. Figure 2.1 shows the adapted model that will be used as a
framework for this study.
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CHAPTER 3. METHODS

The purpose of this chapter is to introduce the research methodology for this
exploratory study regarding what information gout patients require to optimize selfmanagement.
This approach allowed for a deeper understanding of patient experiences treating
and managing gout and provided a way to develop a conceptual framework from the data
in order to understand what information is available to motivate patients to engage in longterm self-care.
The applicability of value chain analysis and natural language processing
techniques for this study are discussed in-depth in this chapter. The research plan, including
the methodology, study participants, procedures, and analysis methods are also primary
components of this chapter.
3.1.1

Research Questions

This study sought to build a model in order to answer the following questions:
RQ1: What are the major types of information required by gout patients according
to the care delivery value chain?
RQ2: What information can be identified by mapping online gout patient education
materials to the value chain?
RQ3: What gout information values can be identified from patient notes based on the
value chain using cNLP techniques?

3.2

Selected Methodology
This study was conducted using value chain analysis and cNLP techniques with a

broad aim to investigate whether the value chain is suitable for application to patient health
information, specifically as a tool to optimize gout management. This research study
sought to develop a model using ML techniques that could automatically extract pertinent
information from clinical notes. Using Porter’s care delivery value chain, emphasis was
placed on the stages at which information is most useful.
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Porter and Teisburg (2006) are adamant that value is a measure of health outcomes.
Gout flares are the most common outcome associated with poorly controlled gout and, as
such, are the best proxy for evaluating the value of the information provided by the
proposed model. Thus, this study will examine the relationship between the information
extracted by our model from clinical notes and adequacy of disease control.
Due to the reasons mentioned above, identifying gout flares presents a challenge that
retrospective claims analysis alone has not been able to meet. Because the goals of this
study include using NLP techniques to further improve this endeavor, algorithms from
previous studies that have been used with some success were adapted for defining clinical
surrogates for use in identifying gout flares using only structured claims codes for
comparison to our NLP model. Hence, gout flare episodes were identified and counted
using one of two criteria that utilize coded data available in the EHR. A gout diagnosis and
at least one of the following within seven days: a medication commonly prescribed for
acute gout attacks, a joint radiograph, magnetic resonance imaging of an extremity, joint
aspiration, joint fluid evaluation, or serum urate testing qualified as a gout flare (Halpern
et al., 2009). A diagnosis of joint pain accompanied by a prescription for colchicine within
seven days would also qualify (Wu et al., 2012). When used together, these two algorithms
have demonstrated high positive predictive value (PPV > 0.8) (Zheng et al., 2014).

3.3

Phase One Methods
3.3.1

Aim

Despite extensive research on patient education and counseling, there is relatively
little on the overall information requirements of healthcare consumers, especially
regarding gout. A preliminary search yielded no systematic reviews of the comprehensive
health information needs for those impacted by gout. Given the increasing availability of
health information and its sources, an extensive review of the current literature seemed
pertinent to identify relevant topics and key information for aiding in the management of
gout. Therefore, this review aimed to identify and examine the available research
concerning or related to the information needs of gout patients.
Therefore, a literature review was conducted using a scoping protocol. As the aim
was not to evaluate the quality of the available literature, but rather the span of the
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subject knowledge and the extent of specific topic focus for a field that had not been
widely reviewed, this seemed the ideal methodological approach (Khalil et al., 2016)
3.3.2

Inclusion Criteria

In accordance with previously published methods for scoping reviews (Peters et
al., 2015), the eligibility criteria for this review included any study where health
information was specifically or tangentially mentioned concerning patients seeking or
receiving information for the purpose of treating and managing gout. Due to gout being
rare in children, the minimum age for patient inclusion was 18 years. Studies that did not
clearly distinguish between patients and non-clinical health information consumers
seeking to aid patients, such as family members, were also included.
Only lay consumers of health information were of interest to the study. Thus,
studies that only investigated the role of professionals, such as healthcare or information
providers, in the use of gout information were excluded. Furthermore, studies
investigating non-health related information were excluded, even if such studies explored
or measured the health effects related to searching for, receiving, or otherwise utilizing
that information in the context of gout treatment and management. Only studies
published in the English language were included, however, there were no restrictions
based on geographic area or publication date.
3.3.3

Search Strategy

The scoping review was conducted by performing a comprehensive search for
relevant literature using online databases. The research team included a library and
information science expert that was involved in the development and refinement of the
search strategy. The strategy was designed to adhere closely to the previously mentioned
approach (Khalil et al., 2016). The resulting search strategy steps and the information
sources utilized are detailed below.
1. The initial search utilized only two databases believed to be able to provide the
broadest overview of results pertinent to the scoping review topic. PubMed was
chosen for its range of biomedical literature and CINAHL was included for
perspectives from the allied health professions. The results were used to modify
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the initial search terms for the purpose of expanding the range of relevant results.
Additional terms identified in this manner were used to create the final search
strategy: ("gout"[MeSH Terms] OR "gout"[All Fields]) AND ("patients"[MeSH
Terms] OR "patients"[All Fields] OR "patient"[All Fields]) AND ("Information
(Basel)"[Journal] OR "information"[All Fields]).
2. A targeted search was conducted on the basis of the expanded vocabulary using
five databases chosen to provide a complete picture of gout patient information
requirements. Boolean operators and controlled vocabulary terms were used
whenever possible. MeSH (Medical Subject Headings) terms found in PubMed
formed the base for controlled vocabulary equivalencies found in the other
electronic databases. CINAHL and their Major Headings (MH terms) were
included in this search, as well. In addition, ERIC was searched using Descriptors
(DE terms) for patient education research and PychINFO was searched using
Index Terms for psychology-related literature. Scopus, which does not provide a
controlled vocabulary search option, was included for a comprehensive review of
available research literature.
3. A gray literature search was conducted through WorldCat using the keywords and
phrases that had been mapped to the controlled vocabularies for the final search
strategy. Results were limited to the English language.
4. The reference lists of all literature that met the inclusion criteria were reviewed
for any additional studies related to the topic. In turn, the references of each
additional relevant article were reviewed until saturation was reached.
3.3.4

Study Selection

All search results were imported into EndNote, where duplicates were removed
before a two-step screening process was conducted to determine inclusion eligibility.
During the first stage of screening, only the titles and abstracts were read. Articles
determined to be relevant on the basis of this screening were then read in full to assess
their ultimate inclusion or exclusion. The diagram for this process is presented in figure
3.1 below.
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Figure 3.1: Flow chart of study selection process.

3.3.5

Data Extraction

The final included articles were examined according to scoping review protocol
(Khalil et al., 2016) and summarized in tabular format according to the stage of the care
cycle the information would be most relevant. Publication details (author surnames,
publication date), research objectives, methods, key findings, and conclusions drawn are
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summarized for each study. The information involved in each study was also categorized
according to patient need to provide additional context in aid of the aims of this review.
3.3.6

Data Synthesis

This study utilized both tabular and narrative approaches to integrate and
synthesize data. The great variation in research design, focus, and quality between the
included studies lent itself to the use of narrative integration for data synthesis. Thus,
while tables were used to summarize the extracted data, narratives were used to evaluate
the data and explain key findings.

3.4

Phase Two Methods
3.4.1

Gout Data Mart

Our research first identified potential gout cases by utilizing two distinct types of
EHR data. First, we searched the structured data from the EHR at the University of
Kentucky Healthcare Systems (UKHC). UKHC is a large academic tertiary referral center
which contains the detailed records of >1 million patients since 2004 stored in an electronic
data warehouse with a relational database structure readily available for research purposes.
We then screened the structured EHR data to create a highly sensitive dataset containing
all potential patients with gout. The gout data mart consists of all patients with ≥1 ICD-9/10 code for gout (274.9, M10.0, M10.2, M10.3, M10.4, M10.9). Patients aged <18 years
at the time of the first ICD-9/-10 code were excluded. Our preliminary search of UKHC’s
EHRs yielded 5590 potential patients. This study was approved by the University of
Kentucky Internal Review Board.
3.4.2

Potential Gout Features

Based on a preliminary literature reviewed, we created a comprehensive list of
variable types for the gout flare phenotyping algorithm classified by the six divisions of
the CDVC. Whenever possible, the list of terms was then converted to structured data
readily available from our EHRs. Along with diagnostic codes as forms of ICD-9 or ICD
10 claims codes, the codes include current procedural terminology codes (CPT) for
procedural claims, national drug codes (NDC) for electronic medication prescriptions, and
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Logical Observation Identifiers Names and Codes (LOINC) for laboratory tests. In
addition, encounter records further identified dates of outpatient visits and inpatient stays.
For unstructured EHR data, we obtained narrative data from all types of commonly
available clinical notes. These included outpatient notes, rheumatology notes, discharge
summaries, radiology, pathology reports, etc. For our purposes, a note is defined as any
type of healthcare narrative which contained more than 500 characters. Pre-processed
narrative data was analyzed with CLAMP cNLP software to extract clinical variables at
the patient level for patients with more than 2 notes (~4000) to ensure they have enough
documentation for classification.
The entity extraction pipeline included a sentence splitter, context sensitive
tokenizer, part-of-speech tagger, section identifier (patient history, family history, etc.), a
named entity recognition (NER) module created using ML algorithms (Brown clustering,
word embedding, etc.) and terminology/ontology mapping from UMLS. Thus, this pipeline
was able to provide us with all of the information needed to further classify extracted
concepts according to our value chain. For example, a condition extracted from the family
history section of a document and marked as screening could be easily identified and
included under the family history grouping of the screening/preventing stage of the value
chain.
3.4.3

Concept Collection

Text articles describing gout were identified from publicly available knowledge
sources (Wikipedia, Medscape (eMedicine), Mayo Clinic, MedlinePlus, the American
College of Rheumatology (ACR), WebMD, and Up-to-Date). Researchers then used the
gout value chain above as criteria for annotating the information deemed important for gout
patients contained in each article according to the stages of care delivery. The annotated
documents were used with the previously mentioned machine learning algorithms to create
a named entity recognition model; however, the low number of articles included in this
study (N=7) did not provide enough data to produce a model capable of reliably extracting
the desired information from future documents. Therefore, after applying the poor
performing model to the total set of articles, the extracted terms were used to develop a
keyword dictionary. The output from this model provided us with a list of 494 terms that
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could be used as a beta dictionary. The list was reviewed and revised to exclude overly
generic (e.g. symptoms, effects) and non-useful terms (e.g. and, no). The resulting 450
terms made up the final dictionary. This dictionary was then used in a pipeline as the named
entity recognition module and applied to the same seven text articles to label the keywords
founds. the resulting annotations were used with the same ML algorithms to create a much
better model (Table 3.1). Terms were not case sensitive, and stemming was used to ensure
variations of terms (such as different tenses or plurals) were included as much as possible.
Both models were created using 5-fold cross-validation.
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Table 3.1: Summarized results of 5-fold for gout value chain model.
Summarized results of n-fold:
correct

predict

gold

P

R

F1

semantic

72

84

85

0.857

0.847

0.852

Recovering

57

62

109

0.919

0.523

0.667

Screening

113

130

180

0.869

0.628

0.729

Diagnosing

194

214

248

0.907

0.782

0.84

Intervening

28

33

53

0.848

0.528

0.651

Preparing

206

237

322

0.869

0.64

0.737

Monitoring

3.4.4

Data Processing

The final ‘gout value chain’ model was used to process all of the available clinical
notes (310,519) for our gout cohort. Each mention of a concept per care phase was counted
at the patient level. Because terms and their associated CUIs could appear labeled as more
than one phase of the value chain, the CUIs for each extracted term were first aggregated
by CDVC phase before occurrences were counted for each patient using a Perl script. For
example, a symptom might be labeled diagnosing if it serves as diagnostic criteria for the
disease or intervening if it is a side effect of a medication used to treat the disease. It could
also be included in any of the other phases depending on the context in which it was used
in the clinical note. Therefore, multiple instances of the CUI in the screening phase are
aggregated and counted as ‘symptom CUI; screening’. The same concept appearing in
other phases would be similarly aggregated and counted according to the number of times
it appears for each patient with the associated phase’s label. These methods allowed for an
easier comparison of NLP concepts extracted from patient education materials versus
patient notes in terms of frequency, value chain stage, etc.

3.5

Phase Three Methods
3.5.1

Algorithm Training and Evaluation

This study utilized a modified version of the surrogate-assisted feature extraction
(SAFE) procedure outlined by Yu, et al. (2016). In order to train and evaluate algorithms
to predict gout flares, this study utilized an available R package (PheCAP) that allows the
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use of various classification methods. Using gout flares as the outcome variable, the
PheCAP algorithm allowed us to identify which of our candidate features are most closely
associated with flares at each stage of care delivery.
In addition to NLP concepts extracted from patient notes in the previous stage, we
included frequency of codified data readily extracted from structured EHR data using
MySQL as candidate features. These features include the phenotype for gout, competing
diagnoses (such as rheumatoid arthritis), and medications (allopurinol, colchicine,
febuxostat) that were determined by our clinical domain expert to be relevant to the target
phenotype. The identified terms and concepts were then mapped to their associated
diagnosis (ICD-9/10) and drug codes (NDC) and counted for each patient. We also counted
the total number of unique billing codes (ICD), the total number of healthcare visits, and
the total number of clinical documents per patient as potential measures of patient
healthcare utilization to round out our candidate feature set.
Gout flares were identified and counted using an adapted version of a previously
published algorithm (Zheng et al., 2014). Using a Perl script, patients in our cohort were
classified as having a flare if they had either a diagnosis code for gout in the system (ICD9: 274.xx; ICD-10: M10.0x, M10.1x, M10.2x , M10.3x, M10.4x, M10.9x) followed by at
least one code for any medication (colchicine, nonsteroidal anti-inflammatory drugs
(NSAIDs), corticosteroids) or procedure ( radiograph of a joint, magnetic resonance
imaging (mri) for any part of an extremity, joint aspiration, microscopic examination of
joint fluid, urate testing) commonly prescribed for gout flares within seven days or a
medical claim with a diagnosis code for joint pain (ICD-9:719.4x; ICD-10: M25.5x)
followed by a code for colchicine within seven days. Consistent with prior studies, care for
gout flares is expected to last for thirty days. Therefore, any codes indicating repeated flares
within that time frame were counted as one flare, with the date associated with the first
applicable diagnosis code being considered the flare start date.
PheCAP relies on surrogate variables to act as “silver standard labels”. These are
features that are believed to be highly predictive of textbook cases of a condition. For this
study, surrogate variables were chosen using concepts identified as priority in our gout
value chain. For instance, any concepts identified as specifying or ordering labs or tests
will be used as surrogate variables for the diagnosing stage. This applies to both the NLP
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concepts extracted from clinical documents and the structured codes identified as candidate
features. These features were then used as response variables to choose potential features
using penalized logistic regression for final algorithm training. In this manner, PheCAP
provides an automated method for reducing uninformative variables.
3.5.2

Metrics

The selected features were then used to train models for each care stage using adaptive
lasso penalized regression (ALASSO). The performance of each model was evaluated and
compared using the area under the receiver operator characteristic (ROC) curve (AUC)
along with false positive rate (FPR), true positive rate (TPR), positive predictive value
(PPV), negative predictive value (NPR), and F1 scores.
3.5.3

Summary

This study uses several novel approaches to answer the research questions. First, in
order to identify the types of information needed by gout patients, this is the first
application of the value chain to patient information and the first to apply the care delivery
value chain to gout. It is also the first to use a scoping review of previous research to
construct the value chain. Second, no previous studies using patient education materials to
create a named entity recognition model were found. Using the stages of the value chain as
named entities gives a framework for comparing the information found in patient education
materials and patient clinical notes. The use of an NLP pipeline featuring the created NER
model to identify information mapped to each stage of the care delivery chain allows for a
type of automated content analysis. Third, this is the first study to use PheCAP as a
prediction model for a health outcome rather than a disease. Whereas the value chain
enables the identification of medical concepts over the entire continuum of care, which
necessarily includes comorbidities and other risk factors which must be managed along
with gout for optimal care, PheCap was utilized in this manner to identify information in
clinical notes that could be considered more specifically associated with gout at each stage
of care. The innovations used in this study were designed to help determine the information
patients need and what they currently have access to.
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CHAPTER 4. RESULTS

This chapter contains the results of the value chain methodology study to answer the
research questions:
RQ1: What are the major types of information required by gout patients according
to the care delivery value chain?
RQ2: What information can be identified by mapping online gout patient education
materials to the value chain?
RQ3: What gout information values can be identified from patient notes based on the
value chain using cNLP techniques?
This chapter also includes discussion on how the analysis ties back to the research
questions. Additionally, this chapter includes sample demographics, using tables to
complement the summary. The process used to analyze the model is described in detail in
this chapter. Included in this chapter are tables and other graphic representations used to
present detailed theme data.

4.1

Phase One Results
4.1.1

Study Selection

Overall, 1100 records were retrieved using the outlined search strategy. More
specifically for each of the five databases, Scopus yielded the most results (n=487),
followed by PubMed (n=297), then CINAHL (n=122), with ERIC (n=1) and PsycINFO
(n=11) both producing far fewer results. WorldCat produced an additional 182 results.
4.1.2

Study Characteristics

All of the included studies were published during the 21st century, with the vast
majority having a publication date in the current decade. Much of the literature were
themselves literature reviews (n=13). The studies were predominately qualitative (n=17)
with many of the more quantitative studies also including and analyzing qualitative data.
One study did not discuss methodology.
Well over half of the included studies with a focus on information pertaining to
treatment, either alone or with other topics. Only the screening/preventing phase did not
contain any articles regarding gout treatment information. In this category, Doherty et al.
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(2012) and Richardson et al. (2015) both focused solely on information regarding
pathophysiology. Most of the studies included several types of information, with
information about treatment appearing the most often by itself in studies (n=9), especially
in articles classed in the intervening stage.
Included studies were subsequently divided into 6 groups according to the stage
of the care delivery cycle their research most closely pertained to: screening (n=2),
diagnosing (n=1), preparing (n=7), intervening (n=11), recovering (n=5), and monitoring
(n=13). A study could be included in more than one group if it contained separate
findings and conclusions relevant to more than one stage of care.
4.1.3

Screening

Although containing information pertinent to the pre-diagnosis phase of gout,
neither study categorized in this stage of care specifically focused on screening. Table 4.1
shows the results for this stage. Richardson et al. (2015) was a qualitative study of gout
knowledge in female gout patients, while Doherty et al. (2012) was a literature review
searching Medline with general gout terms along with more specific phrases relating to
the treatment and management of the disease.
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Table 4.1: Preventing/Screening literature results
Publication

Doherty, et al. (2012)

Richardson, et al.
(2015)

Objective

Methods

Findings

Identify and address
why a 'curable'
disease is so poorly
managed.

Literature review
searched the Medline
database for articles
published in English
language using the
search terms ‘gout’,
‘hyperuricaemia’,
‘hyperuricemia’,
‘tophi’ and
‘monosodium urate’
published after 1
January 1980,
searched keywords
'therapy',
'management', 'cure',
and 'treatment' alone
and with the previous
terms, other materials
judged relevant.

Perception of gout as
benign, humorous,
self-inflicted disease.

Semi-structured
interviews of female
gout patients using a
narrative approach

No knowledge of
gout before
diagnosis, inability to
find information
relevant to women.

Explore and better
understand the
experience women
with gout.

4.1.4

Information
Type

Conclusion

pathophysiology

Patients need to
understand the
genetic and other
risk factors of the
disease.

pathophysiology

Diagnosis is likely
to be missed due to
lack of knowledge
about gout in
women and its
perception as a
man's disease.

Diagnosing

The sole article concerned with information pertaining to gout diagnosis was
included in a journal supplement is displayed in table 4.2. Perez-Ruiz (2009) reads like
material for gout education that is mainly concerned with treating and curing gout and
contains no information about methodology. Any information related to other phases of
care is included as a means of providing understanding and support for the targeted
treatment recommendation.
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Table 4.2: Diagnosis stage literature review results
Publication

Objective

Perez-Ruiz (2009)

Review practices for
long-term gout
management
w/emphasis on MSU
crystals in
pathogenesis and
treating to target
SUA level.

Methods

Findings

No explicit
methodology.

Patients need to
understand the role of
MSU crystal
observation for
definitive diagnosis and
the need for long term
therapy to eradicate
these crystals.

4.1.5

Information
Type

Conclusion

labs,
pathophysiology
, treatment

Patients need to be
educated about
diagnosis, the
disease, and their
contribution in
long term
treatment,

Preparing

The studies featured in this group (n=7) displayed the greatest variety in topics
with all studies featuring <2 types of information as recorded in table 4.3. Lack of
information and knowledge relating to gout pathophysiology was highlighted in all
studies concerning patient education. Zhang et al. (2011) was the only quantitative study.
While the qualitative studies were designed to elicit feedback from patients through
interviews for the purpose of thematic analysis to aid understanding about gout
perceptions and knowledge, Zhang et al. (2011) aimed to create an instrument that could
evaluate such knowledge. Harrold et al. (2012) highlights that knowledge gaps are not
due to a lack of desire for information on the part of the patient and Chandratre et al.
(2015) specifies that patients want more of this type of information from their healthcare
providers. Patients also express a desire for more time with healthcare providers with
Khanna et al. (2012) specifying that patients want healthcare providers to spend more
time explaining the disease progression in particular. There is also a general lack of
knowledge concerning treatment options, especially urate-lowering therapies (ULTs).
Lindsay et al. (2011) found a general perception among men that gout is a disease the
must be simply endured. Similarly, Spencer et al. (2012) found that patients are unaware
of the existence of allopurinol, a urate-lowering drug (ULD) that can prevent acute gout
attacks. Moreover, according to Perez-Ruiz (2009) patients are unaware that ULTs
commonly cause gout flares upon treatment initiation and have no knowledge of
prophylactic therapy as an option to reduce this side effect.
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Table 4.3: Preparing stage literature review results
Publication

Objective

Lindsay, et al. (2011)

Explore the
experience and
attitudes of men
with gout,
especially those
affecting outcomes
w/emphasis on
barriers to uratelowering therapy.

Khanna, et al. (2012)

Identify conceptual
gaps for patients
that lead to poorly
controlled gout.

Methods

Findings

Qualitative
grounded theory
interviews of 11
men with gout.
Categorized by
themes using
NVivo.

Lack of understanding of
pain severity, disease
progression, disease
mechanisms and causes of
attacks (model of gout).
Lack of knowledge about
long term treatment.
Perception of gout as
something that must be
endured.

In-depth focus
groups.
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"1) Patients did not have a
clear understanding of the
natural history of gout; 2)
patients did not realize
that recurrent acute flares
resulted in chronic joint
damage; 3) there was lack
of knowledge regarding
treatment options and
duration of therapy for
acute and chronic gout; 4)
patients felt that
physicians did not spend
enough time explaining
the progression, i.e.
natural history of the
disease and its long-term
effects; 5) patients did not
grasp the need for chronic
ULT to avoid
complications and
disability; and 6) patients
were not aware of
treatment goals for
hyperuricemia, as evident
by adherence to their gout
medications."

Information
Type

Conclusion

disease
progression,
pathophysiology

Patients need a
"pathophysiologic
model of gout"
that aids
understanding and
destigmatization.

pathophysiology,
disease
progression,
treatment, labs

These are the key
variables that need
targeted in patient
education
resources.

Table 4.3 (continued)

Zhang, et al. (2011)

Design and test a
survey to evaluate
patient goutrelated knowledge
and identify targets
for patient
education.

Spencer, et al. (2012)

Explore patient
and provider
perceptions of gout
to improve
management
practices.

Perez-Ruiz (2009)

Review practices
for long-term gout
management
w/emphasis on
MSU crystals in
pathogenesis and
treating to target
SUA level.

Harrold, et al. (2010)

Chandratre, et al.
(2015)

Explore patient
and provider views
of ULDs for gout
management.

Explore patient
perspectives on
how gout impacts
HRQOL.

Survey of gout
knowledge in 3
hospitals.

Most patients know about
too much uric acid in the
blood but are unaware of
actual crystals in joints.
Poor knowledge of
optimum SUA levels and
duration of use for SUA
lowering drugs.

Semi-structured
interviews of gout
patients between
age 30 and 100
analyzed using a
grounded theory
approach.

Patients do not understand
that crystals continue to
accumulate while
symptom free. Unaware of
existence of allopurinol
which can prevent gout
attacks.

No explicit
methodology.

Explain to patients that
mobilization flares are
'price to pay' for cure and
risk can by reduced
through prophylactic
therapy

Qualitative indepth phone
interviews of gout
patients

Lack of details about what
causes gout. Perception of
gout as condition that
must be adapted to rather
than one that can be
controlled through
lifestyle and medication.

Thematic analysis
of focus group
interviews about
HRQOL.

Confusion concerning role
of diet in cause and
treatment, lack of 'trusted'
sources of information,
self-discovered sources
considered
overwhelming/frightening.
Gout not viewed as
disease.

4.1.6

pathophysiology,
disease
progression,
treatment, labs

Need to design
more effective
educational
materials similar
to those for
diabetes.

disease
progression,
treatment,
pathophysiology

"universal lack of
knowledge and
understanding
about
the cause and
consequence of
gout and the
importance of
making adequate
lifestyle changes
and adherence to
lifelong ULT"

pathophysiology,
treatment

pathophysiology,
treatment

Patients want
more information
and more time
from providers.

pathophysiology,
treatment

Patients concerned
about quality of
Internet sources
found and desire
more information
from healthcare
providers.

Intervening

Studies included in this group (n=11) understandably focused on information
related to disease treatment, specifically pharmacological interventions. Information
about these studies is included in table 4.4. This phase of care featured the most
quantitative studies and the only intervention studies. Rees et al. (2012) featured an
35

Patients need to
understand the
importance of
therapy adherence
to obtain sUA
targets and
eradicate crystals.

education intervention and tested SUA levels 12 months later. Two studies were followups to previous education interventions with Mikuls et al. (2017) being a randomized
evaluation of a pharmacist-led intervention, while Abishek et al. (2016) featured a five
year follow up questionnaire for a nurse-driven intervention. Serawate et al. (2006) was a
retrospective claims analysis using logistic regression. Each of these studies also used
SUA levels as outcome measures. There were two systematic literature reviews included
in this category. Galo et al. (2014) focused exclusively on treatment, while Reach (2011)
discussed disease progression along with treatment information as a means to understand
why side effects occur when commencing ULT. Dalbeth et al. (2011) similarly concluded
that patients with greater understanding of gout had higher adherence to ULTs. However,
Robinson and Schumacher (2013) found that this type of information was missing from
the majority of patient education materials that they analyzed. Beyond long term
pharmacological treatments, patients are only aware of very limited treatment options for
symptom relief during acute attacks (Lindsay et al., 2011). Likewise, only Singh (2014)
included information pertaining to lifestyle modifications, as diet was identified as a
concern for their target population of African Americans and women with gout.
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Table 4.4: Intervening stage literature review results
Publication

Objective

Methods

Findings

Lindsay, et al. (2011)

Explore the
experience and
attitudes of men
with gout,
especially those
affecting outcomes
w/emphasis on
barriers to uratelowering therapy.

Qualitative
grounded theory
interviews of 11
men with gout.
Categorized by
themes using
NVivo.

Patients learn
treatment methods
from other family
members with gout.
Lack of knowledge
about long term
treatment. Perception
of gout as something
that must be endured.

Explore the effects
of nurse-led
intervention on
ULT adherence.

Proof of concept
study: 5 year
follow up
questionnaire to
patients that had
participated in a
previous
intervention.

Very high proportion
of responders had
excellent ULT
adherence and
EULAR target SUA
level.

Abhishek, et al. (2016)

Mikuls, et al. (2017)

Examine the impact
of pharmacistdriven intervention
to optimize
allopurinol therapy.

Serawate, et al. (2006)

Determine
treatment patterns,
specifically for
allopurinol.

Galo, et al. (2014)

Identify and assess
medication
adherence
intervention studies
for rheumatic
diseases.

Randomized
evaluation of
pharmacist led
intervention via
telephone
Retrospective
claims analysis
using multivariable
logistic regression
for factors
associated with
adherence to
allopurinol therapy.
Systematic
literature review:
"searched Medline
(1946–June 2014),
Embase
(1974–June 2014)
and International
Pharmaceutical
Abstracts (1970–
June 2014). We
used Medical
Subject Headings
for concepts
underlying our
search,
‘medication
adherence’,
‘intervention’ and
‘inflammatory
arthritis’ and
applied keywords
for concepts
that did not map."
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Intervention patients
showed increased
adherence and met
SUA goals.

Previous diagnosis
was positively
associated with
treatment compliance,
while post index SUA
flares indicated less
compliance

All interventions that
had an effect on
adherence included an
education component
and were tailored to
the patient.

Information
Type

Conclusion

treatment

Patients only aware
of antiinflammatories and
diet and exercise as
symptom
management
options.

treatment

Personalized
interactive
education can have
long term effects on
ULT persistence.

treatment

Shows that simple
interventions can be
effective, but most
patients still failed
to reach the low
SUA levels
generally
recommended.

treatment

Newly diagnosed
and flare patients
may require more
education to
promote therapy
compliance.

treatment

Patients need
personalized
education about
therapies including
proper
administration and
risks/benefits and

Table 4.4 (continued)

Dalbeth, et al (2011)

Robinson &
Schumacher (2013)

Examine the
relationship
between illness
perceptions of gout
patients and disease
outcomes,
particularly
medication
adherence and
musculoskeletal
disability.

Examine
characteristics,
including
readability, content,
and construction, of
gout patient
education materials
from different
countries and
organizations.

Questionnaire for
patients with gout
for under 10 years.

Analysis of written
patient information
content.
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Patients with greater
understanding of gout
also reported a higher
need for, less concern
about, and stronger
adherence to ULT.

"treating serum uric
acid (SUA) to target
and prophylaxis
against acute flare
during urate-lowering
therapy
(ULT) initiation and
titration" were absent
in 60% of the studied
resources.

treatment

Interventions to
improve disease
understanding
may reduce
concerns about
ULT and increase
adherence.

treatment

Information
content coverage
is generally good,
but the most
commonly
missing
information is
important."
Failure to
understand that
SUA needs to be
below a certain
threshold (the
target) may
prevent patients
from returning to
their doctor for
assessment of
their SUA and
titration of
their ULT. Being
unaware of the
importance of
using antiinflammatory
prophylaxis
against acute
flares could
reduce adherence
during ULT
initiation and
titration. This
lack of such
prophylaxis
would allow
more flares and
cause patients to
stop ULT and/or
lose confidence
in their doctors.:

Table 4.4 (continued)

Rees, et al. (2012)

Test effectiveness
of nurse-led
intervention based
on 'best practices'
delivered in a
hospital-based gout
clinic setting.

Aung, et al. (2017)

Review and discuss
intervention
strategies to
improve ULT
adherence and gout
outcomes.

Reach (2011)

Discuss reasons for
gout treatment
strategies and
review literature on
adherence.

Singh (2014)

Assess barriers to
treatment.

Proof of concept
study: education
intervention
followed by
measurement of
sUA at 12 months.

Package of care’ that
includes
patient education,
individualized
lifestyle advice and
slow
upward titration of
ULT according to
serial SUA levels
achieved target levels
in over 90% of
patients.

pathophysiology
including cause of
gout, its risk
factors and
prognosis
(including the risk
of chronic joint
damage), and
available
treatment
strategies that
can eliminate the
crystals

Review of
treatment
interventions

Patients are concerned
about lack of
information and
understanding about
treatment strategy.

Pathogenesis,
treatment

Literature review

Patients often stop
taking medications
because they believe
they are not working
or bring on attacks
when attacks occur
early in therapy.

treatment, disease
progression

NGT study of
African Americans
and women with
gout diagnosis code
about gout
treatment.

Patient worries about
medication
interactions and side
effects. Not sure
which medications for
every day vs. during
attacks. All groups
indicated concerns
about dietary
modifications.

treatment, lifestyle

4.1.7

Given proper
education,
knowledge of
their therapeutic
target, and
regular contact
with a nurse
specialist,

Patients feel that
healthcare visit
time is too short
to provide
adequate
information and
discussion about
gout, leading
them to rely on
Internet sources.
Patients need to
be informed
about the reasons
for increased
attacks upon
treatment
initiation and
understand that
long term
adherence
decreases the risk
of attacks.
Patients need
provider advice
about diet.
Medication
concerns are
common for
chronic
conditions and
not specific to
gout.

Recovering

As a chronic disease, articles included in this group (n=5) pertain to topics related
to the fine-tuning of long-term therapies and continuous management of gout. All studies
in table 4.5 highlight a lack of understanding regarding short-term side effects, ultimate
goals, and expectations of treatments leading to poor adherence to long-term medications
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and treatment plans. Most of the studies focus on ULDs, while several specifically
mention allopurinol. Coburn et al. (2010) has the most specific target population,
focusing on a population of VA patients that have recently initiated allopurinol therapy.
While all studies contain information pertaining to treatment, Becker and Chohan (2008)
offer an editorial review that contains the most variety with information relevant to
pathophysiology, disease progression, and labs, as well. Doherty et al. (2012) is the only
literature review in this category and the only study that refers to lifestyle advice. The
two qualitative studies have only treatment information for this category; however,
Chandratre et al. (2015) explores gouts impact on quality of life (QOL), while Harrold et
al. (2010) is more concerned with general perspectives on ULDs.
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Table 4.5: Recovering/Rehabbing literature review results
Publication

Objective

Harrold, et al. (2010)

Explore patient and
provider views of
ULDs for gout
management.

Coburn, et al. (2016)

Examine patient
knowledge of gout,
especially SUA
goals including
factors associated
with that
knowledge and the
effects on health
outcomes.

Becker & Chohan
(2008)

Chandratre, et al.
(2015)

Identify and discuss
factors contributing
to suboptimal gout
management with
emphasis on
immediate
opportunities for
improvement.

Explore patient
perspectives on
how gout impacts
HRQOL.

Methods

Findings

Qualitative in-depth
phone interviews of
gout patients.

Patients understand use
of allopurinol for
reducing serum uric acid
and preventing gout
attacks, not clear on
planned duration of
therapy. Belief that
allopurinol triggers or
worsens gout, concerns
about side effects.

Information
Type

Conclusion

treatment

Patients
unaware of
potential for
flares upon
ULD
initiation as
short-term
side effect.

Survey of gout
knowledge for VA
patients over 19 that
had started
allopurinol in the
previous 6 months.

Correct knowledge was
high in patients for all
topics except SU goal.

treatment, labs

SU goal
knowledge
was
associated
with more SU
measurements
during the
first 2 years
following
ULT
initiation.

Editorial Review

Education about the
disease is key: "diagnosis
and course, the
distinctive therapeutic
modalities employed,
circumstances likely to
promote or mark
progression, the
significance of comorbid
associations, and means
to monitor therapy and
maximize adherence to
therapeutic
recommendations".

pathophysiology,
disease
progression,
treatment, labs

Patient
education is
key to
improving
clinical
outcomes.

Thematic analysis
of focus group
interviews about
HRQOL.

Lack of information
about acute attacks as
side effect of allopurinol,
interactions between
medications for comorbidities. Incorrect
advice to discontinue
treatment.

treatment

Lack of
knowledge
about ULT
benefits may
lead to poor
HRQOL.
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Table 4.5 (continued)

Doherty, et al. (2012)

Identify and
address why a
'curable' disease is
so poorly managed.

Literature review
searched the
Medline database
for articles
published in English
language using the
search terms ‘gout’,
‘hyperuricaemia’,
‘hyperuricemia’,
‘tophi’ and
‘monosodium urate’
published after 1
January 1980,
searched keywords
'therapy',
'management',
'cure', and
'treatment' alone and
with the previous
terms, other
materials judged
relevant.

4.1.8

Belief that gout refers to
the acute attacks.

Lifestyle,
treatment

Patients
underestimate
the
importance of
long-term
ULT.

Monitoring

As the largest group of articles (n=12), this phase reflects the long-term, slow build
up which results in sudden acute attacks and other complications. This care phase has the
most information concerning lifestyle modifications. As with all phases of care, an
overall lack of education and understanding is highlighted by table 4.6, with a particular
emphasis on non-pharmacological interventions and managing co-morbidities. In line
with Perez-Ruiz’s (2009) contention that knowledge of non-pharmacological approaches
and lifestyle modifications is essential to gout management, only Ogdie et al. (2012) does
not include lifestyle advice, instead focusing on the long-term monitoring of SUA levels.
The needs assessment conducted by Rifaat et al. (2016) indicates that this type of
information, specifically dietary guidelines, is the most sought after in this phase of care,
at least by highly educated patients. Interestingly, the patients involved in Harrold et al.
(2010) did recall being told to avoid certain foods, but the patients involved in Harrold et
al. (2012) were largely unaware of dietary triggers of gout attacks. In contrast, Vaccher et
al. (2016) found that most patients do know some personal triggers for acute attacks, but
do not recall receiving this information from their general practitioner and instead, sought
it out online. However, Johnston et al. (2015) found that all 30 of the patient education
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materials they reviewed contained lifestyle information, including diet, particularly foods
to avoid. Other types of information were not included as consistently and Jimenez-Liñan
et al. (2016), who analyzed similar resources, points to a distinct lack of emphasis on the
importance of ULTs. This category also features the British Society for Rheumatology’s
recommended guidelines for gout management (Hui et al, 2017) as it relates to health
information, as well as EULAR’s patient education recommendations for inflammatory
arthritis (Zangi et al., 2015). Both of these sources advocate for what Fields and
Batterman call a multifaceted approach to gout patient education and management.
Table 4.6: Monitoring/Managing literature review results

Publication

Objective

Methods

Findings

Information
Type

Conclusion

Roddy, Zhang, &
Doherty (2007)

Compare practices
for chronic gout
management in the
UK to EULAR
recommendations,
including lifestyle
advice and ULT
therapy.

Questionnaire mailed
to all patients over 30
in 2 general practices.
Self-reported gout or
acute arthritis attacks
invited for clinical
assessment.

Infrequent
lifestyle
modification
advice.

lifestyle advice
regarding weight
loss, alcohol
reduction, diet.

Advocates
dissemination of
EULAR
recommendations for
management.

lifestyle,
treatment

Patients want more
information about
natural remedies.

Lifestyle,
treatment

Provide oral and
written information
regarding short- and
long-term effects of
ULTs and dietary
factors throughout
care.

Harrold, et al. (2010)

Explore patient and
provider views of
ULDs for gout
management.

Harrold, et al. (2012)

Identify and
understand patient
gout knowledge,
beliefs, and barriers
to management.

Qualitative in-depth
phone interviews of
gout patients.

Questionnaire about
gout knowledge and
beliefs.
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Patients recall
being told to
reduce certain
foods, suggest
follow up after
initiating
treatment.
Lack of
knowledge
regarding dietary
triggers, ULT
dosing during
flares, risk of
causing flares
upon initiation.
Deficit greater in
those with active
gout.

Table 4.6 (continued)

Hui, et al. (2017)

Revise and update
recommendations
for gout
management in the
UK.

Ogdie, et al. (2010)

Describe key points
of intervention and
propose educational
improvements.

Perez-Ruiz (2009)

Review practices for
long-term gout
management
w/emphasis on
MSU crystals in
pathogenesis and
treating to target
SUA level.

The British Society
for
Rheumatology/Britis
h Health
Professionals in
Rheumatology
guideline for the
management of gout

Review-no details

No explicit
methodology.
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"All patients with
gout should be
given verbal and
written
information about
the following: the
causes and
consequences of
gout and
hyperuricaemia;
how to manage
acute attacks;
lifestyle advice
about diet,
alcohol
consumption and
obesity; and the
rationale, aims
and use of ULT
to target urate
levels.
Management
should be
individualized
and take into
account comorbidities and
concurrent
medications.
Illness
perceptions and
potential barriers
to care should be
discussed"
Patients need to
understand that
SUA levels under
6 mg/dl means
unlikely to have
gout and goal of
therapy should be
to maintain that
level.
The role of
lifestyle changes
and nonpharmacological
approaches to
gout management
is essential
information

treatment,
lifestyle

Updated
recommendation due
to better
understanding of
barriers to effective
care

labs

Patient education
may be most
effective method to
change physician
behavior. Campaign
with slogans to get
patients to check
their SUA levels.

lifestyle,
treatment

These types of
measures might only
have a modest effect
on sUA levels but are
very beneficial for
general health.

Table 4.6 (continued)

Johnston, et al. (2015)

Review
internationally
available gout
education resources
to investigate
content and ease of
reading.

Analysis of written
patient information
content in 30 gout
sources from several
countries.

Vaccher, et al. (2016)

Investigate gout
understanding and
explore barriers to
optimum care.

Inductive thematic
analysis of semistructured interviews
about understanding
of gout management.

Jimenez-Liñan, et al.
(2016)

Assess content,
readability, and
accuracy of free
online patient
education materials
as related to current
gout knowledge.

Review of 30 online
gout education
resources

Zangi, et al. (2015)

Develop patient
education
recommendations
for those with
inflammatory
arthritis and identify
areas for further
research.

Rifaat, et al. (2016)

Identify patient
knowledge gaps and
concerns for
inclusion in
education initiative.

An extensive
systematic literature
search in Medline,
Embase, PsycINFO,
Cochrane Library and
CINAHL from
January 2003 up to
September 2013 of
publications in
English, German,
French or Spanish
describing any kind
of PE activities, was
conducted
Needs assessment
given to highly
educated patients
being seen by
rheumatologists
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Lifestyle,
treatment,
pathophysiology

"informing patients
with gout of their
increased risk of
heart disease and
diabetes is important
for encouraging
screening as well as
modifying diet and
lifestyle factors to
manage risk.
Providing patients
with a target level for
SUA may also prove
important for
tracking progress and
maintaining
motivation to take
urate-lowering
therapy during
intercritical periods
of gout."

Pathophysiology,
lifestyle, disease
progression,
treatment

Most patients do not
recall receiving
information about
gout from their GP,
leading them to
research gout
themselves and
expressed a desire for
more informative
sources.

pathophysiology,
treatment

Not many web-based
sources provide
accurate and easy to
read information
about gout.

Trend toward
emphasis of
behavioral,
cognitive, and
emotional
processes in
patient education

lifestyle,
pathophysiology,
disease
progression

Eight
recommendations
with the overarching
principle that patient
education should
enable people to
manage their life and
optimize health and
well-being

Information of
most interest was
diet guidelines.

lifestyle

Major gaps in
knowledge essential
to self-management.

All sources noted
role of uric acid,
lifestyle factors
such as weight,
alcohol, and diet,
including foods to
avoid. Other
topics not
covered
consistently.

Most patients
have basic
knowledge of
gout and know
some personal
triggers of
attacks, but do
not understand
medications or
the earliest signs
of an attack.
education
resources often
contain no or
inaccurate
information about
pathogenesis and
fail to emphasize
the importance of
ULT.

Table 4.6 (continued)

Abhishek & Doherty
(2018)

Fields & Batterman
(2018)

Highlight common
knowledge gaps,
recommend core
knowledge for
education, and
review nonpharmacological
strategies for gout
management.

Explore literature on
gout patient
education suggest
future research
directions.

4.1.9

Systematic literature
review: searched
PubMed from
inception to 28
March 2017

Gout patients
have significant
knowledge gaps.
Lack of time to
provide
individualized
education is one
of the many
barriers to care of
gout.

pathophysiology,
disease
progression,
treatment,
lifestyle

"People with gout
should be educated
about the
pathogenesis,
associated comorbidities and
management of
gout, including both
pharmacological and
non-pharmacological
management."

Literature review

Key concepts
highlighted in the
literature include
genetic and
metabolic causes
of gout, the risk
of progressive
damage with
inadequate
treatment, goal
serum urate levels
and why they are
monitored,
rationale for
short- and longterm
management,
impact of
comorbidities,
and dietary
management.

pathophysiology,
disease
progression,
treatment,
lifestyle, labs

Optimal patient
education requires
multifaceted
approach.

Gout Information Value Chain

On the basis of these results, the gout information value chain (figure 4.1) was
created to define the types of information needed by gout patients throughout the
continuum of care. This value chain will be used throughout the remaining phases of the
study to identify important information that is available to gout patients in both patient
education materials and their own clinical notes.
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Figure 4.1 Gout Information Value Chain
Primary Care Cycle Screening

Diagnosing

Priority

Ordering/Adminis
Intervention Options
Specifying/Orderi
tering Drug
Therapy Fine Tuning:
Education: (Hui et
ng Labs/Tests:
Therapy: (Hui et
(Hui et al., 2017)
al., 2017)
al., 2017)

signs/symptoms:

painful joints (big
toe), redness,
synovial fluid
warmth, swelling
analysis (Sivera
(Ragab,
et al., 2014)
Elshahaly, &
Bardin, 2017)

Preparing

Intervening

side effects,
acute attacks
compliance, efficacy

ULT

Further Details

Medical History:
Comorbidities

Interpreting Test
Results: serum uric
acid levels,
imaging:ultrasoun
ds (Hui et al.,
2017; Ragab,
Elshahaly, &
Bardin, 2017)

Existing
Medications/
Comorbidities:
pregnancy, renal
insufficiency (Hui et
al., 2017)

efficacy, side
interactions/counter
effects,
effects
compliance

Risk Factors
(Khanna et al.,
2012; Hui et al.,
2017)

Choosing Care
Team: (Hui et al.,
2017)

behavioral causes:
Rheumatologist
alcohol (beer)
current
medications:
diuretics, low
dose aspirin,
immunosuppressa
nt
family history:
gout (Kuo et al.,
2015)
etiology:
hyperuricemia
(Hui et al., 2017)

ULT

Monitoring/Manag
ing to Avoid
Complications:

acute attacks (Hui
et al., 2017)

prophylaxis

Non-pharmacological
Treatment: (Hui et
Interventions: (Hui et
al., 2017)
al., 2017)

kidney disease,
Consulting with
cvd, obesity,
Experts: (Khanna
diabetes (Khanna
et al., 2012) ex.
et al., 2012)

PCP/GP

Recovering/Rehabbing Monitoring

rest

injection guidance topical ice

Complications:

kidney stones
(Kramer et al., 2003)

recurrent gout
flares (Hui et al.,
2017)

advanced gout:
encourage cherry/skim tophi, joint
milk powder intake
deformity (Khanna
et al., 2012)

rheumatologist/gout
specialist/PCP/NP

Determing
Treatment Plan:
Acute vs. Chronic
(Hui et al., 2017)

Performing
Procedures:

increase vitamin C/
omega-3 fatty acids

Monitoring Therapy
Compliance:

NSAIDS

joint aspiration
(hui et al., 2017)

Clinical Procedures:
bariatric surgery

ULT (Sivera et al.,
2014)
Life Style
Modifications:
(Khanna et al.,
2012; Hui et al.,
2017)

ULT (dosage)

genetics (Hui et
Medical History:
al., 2017; Ragab,
(Perez-Ruiz, 2009;
Elshahaly, &
Sivera et al., 2014)
Bardin, 2017)
confirmatory
signs/symptoms
(bony erosions,
tophi)
Confusing
Conditions:
psuedogout
(Ragab, Elshahaly,
& Bardin, 2017)

reduce alcohol/red
meat intake/soft
drinks
avoid low
temps/dehydration
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4.2

Phase Two Results
4.2.1

Data Collection

The NLP concepts extracted from patient notes and patient education materials
served as the primary source of research data. The demographics and medical claims data
served as supporting research data. At each step of the process, output was coded according
to the stages of the CDVC and reviewed for emerging themes. This method ensured that
value chain analysis was embedded throughout the data collection process. The original
PEM output used to create the keyword dictionary and the subsequent output from patient
clinical notes using the final model are provided in Appendix A and B.
4.2.2

Data Analysis

All collected concepts were divided into one of two categories: medication or
diagnosis and procedure related terms. The original dictionary and the final model output
were then compared and analyzed for categories or themes. The model successfully
retrieved 3892 terms and phrases that were able to be mapped to CUIs in the UMLS (512
medication terms and 3380 diagnosis/procedure terms). 105 of these terms matched both
CUIs and value chain phases in the keyword dictionary. An additional 51 terms matched
CUIs appearing in the dictionary but were labeled with different value chain phases. In line
with the proportions of all terms appearing in the PEMs, the most matching terms appear
in monitoring (figure 4.1). The medications that were also extracted from clinical notes for
this phase are all commonly prescribed for gout flares. Surprisingly, diagnosing has the
second most matches. Although screening, diagnosing, and intervening are close in
proportion, the diagnosing stage contains no medication terms in the keyword dictionary
and only one medication related term in the clinical note output. While screening has very
few keyword terms categorized as medication related (n=3), clinical notes produced 32
medication terms for the stage. The majority of keyword terms classified as medication
appear in intervening and this is the only stage with more medication related terms than
diagnosis/procedure terms. The terms also appearing in patient clinical notes are all
commonly associated with gout except ‘fenofibrate’, a cholesterol medication. The
matching terms in the screening stage largely consist of risk factors including behaviors
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(‘beer’) and medical history (‘family history of gout’, patient comorbidities, genetic
factors). For the diagnosis stage, terms matching the stage in the keywords and clinical
notes consist of procedure related terms for confirmatory diagnosis (‘synovial fluid
analysis’, ‘radiographic findings’, ‘urate crystals’), symptoms used for diagnosis (‘joint
damage’, ‘tophi’), and similar diseases that can be confused for and must be differentiated
from gout (‘calcium pyrophosphate disease’).
Figure 4.2: Percentage of Words Appearing for Each Stage in Keyword Dictionary.

The preparing and recovery stages have the lowest number of keywords. Preparing
had six medication related terms, however, three were considered generic. Interestingly,
two of the remaining three appeared in patient notes (‘blood thinners’ and ‘take NSAIDs’).
Recovering has exactly one less concept than preparing for both medication and
diagnosis/procedure terms. None of the medication related keywords were extracted from
the clinical notes by the model. One concept was considered generic and four concepts
were also found in the patient notes for each stage. The concepts common to the keywords
list and those extracted by the model were all possibly related to the kidneys or diet.
Although there were a high number of keywords that the model did not extract from
patient notes (table 4.7), many of these are combinations or longer versions of concepts
that appear separately in the NLP note output, such as ‘allopurinol and probenecid’. The
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medications that do appear by themselves in the keyword list that were not found in the
notes are not commonly associated with gout treatment and are often prescribed for
comorbidities. In fact, most of the concepts that the model did not identify in any clinical
notes are long phrases typical of the writing style found in PEMs. Thus, while we might
expect to find phrases like ‘under a microscope’ or ‘inject a corticosteroid directly into
your joint’ when explaining concepts to patients, they are not likely to appear in clinical
notes under the same context. Therefore, when similar concepts appear in the clinical notes,
they are assigned different CUIs. For example, the CUI for ‘after acute attacks’ was not
identified in any of the patient notes by the model. However, numerous variations of ‘acute’
and ‘attack’ were extracted and assigned the appropriate CUI.
Table 4.7: Keywords not Extracted from Patient Clinical Notes
under a microscope C0395796, dual energy computed tomography
C4055114, are most often affected C3808454, joint appears warm
C0575034, attacks often C1867940, chalky C3267206, monosodium urate
monohydrate C0037564, Monoarticular involvement C0427254, Posterior
Diagnosing
interosseous nerve syndrome C1696572, Location outside C2016008,
Ultrasonographic C1301497, crystals within the joint space and deposition
of crystals C1401835, too much uric acid in the blood C2029412, crystals in
the joint fluid C0200652, in one or more of your joints C0162296
or use other medicines C0678312, inject a corticosteroid directly into your
joint C2137753, blood levels of uric acid to normal C0855643, oral
corticosteroids plus colchicine C0775883, Lesinurad C3886073, prevent
Intervening
disease C0679698, deposition of urate crystals in the renal medulla or uric
acid crystals C0522574, Xanthine oxidase inhibitors C0302609,
benzbromarone C0005035, allopurinol or probenecid C2194181
meats and fish C0335766, deposit in the joints C0541866, Alcohol in excess
C0159070, Sugary drinks and foods C0453425, but because it can help
C3827771, uric acid levels in the blood may lead to deposits of urate
crystals C0522574, crystals can be found in uric acid C2022384, anakinra
C0245109, after acute attacks C3279118, inflammation are under
C0877470, when starting these C3166682, acid in the blood C1287384,
Monitoring
Secondary infections C0442886, Urate or uric acid C0851010, Increased
susceptibility to infection C0236171, Nerve or spinal cord impingement
C0751463, kidney stones or urate C2109382, increased overall likelihood of
C2015876, increased risk for any vascular event C2673803, medicines are
working and you are taking C3176475, high levels in the blood C1399735,
skim milk C0349375, call your doctor C3476384
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Table 4.7 (continued)
Treatment choices depend on C2069130, production of uric acid C3653539,
do not overproduce uric acid should take C3476381, inflammation in the
joints C0574941, uric acid to break down a chemical C0041980, crystals
Preparing
form and collect in your joints and cause gout C0809978, Uric acid buildup
also can lead to disfiguring lumps called tophi C3806613, crystals
accumulate in the urinary C0151579
on this medicine long term to prevent C2922112, eating foods that are rich
Recovering
C3898963, damage to joints C0269891, table salt C0206136, joint
destruction C0541875, Pembrolizumab C3658706
painful swelling in single joints C0311222, Esidrix C0700694, and its
complications occur more often C2073319, to run in some C3810163, run in
C3274438, more common in men C1867966, people become older
C3826770, Sickle cell anemia and other anemias C0029738, Leukemia and
Screening
other blood cancers C1516238, hydrochlorothiazide and other water pills
C3217109, Hypertriglyceridemia Hypercholesterolemia C0543517
metabolic abnormalities C4021768, base of the big toe C0224039, high
levels of uric acid C0948643, presenting as slight C4036274
On the surface, there is little variation in the types of concepts extracted from the
PEMs and the patient notes. The PEM output is more gout specific with the NLP output
featuring more terms related to comorbidities. The most frequent keywords also highlight
more technical terms, such as ‘hyperuricemia’,’ pseudogout’, and ‘urate crystals’ (figure
4.2).
Figure 4.3: Top 20 Terms Most Frequently Found in Gout PEMs.
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The NLP counts show a sharper decline among the most frequently extracted terms.
The top four terms appear in patient notes over a million times, while the remaining top 20
terms show up at least half as frequently. The top four terms are also in the top 20
keywords; however, they rank much lower in frequency except for ‘pain’, which is fourth
for both sets of output. The medications featured in the keywords output were all also
extracted from patient notes, however, ‘febuxostat’ did not make the top 20 list for clinical
notes (figure 4.3).
Figure 4.4: Top 20 Terms Most Frequently Found in Gout Patient Clinical Notes.

The model extracted exponentially more terms in both frequency and amount from
the patient notes. 14 terms were considered generic and not medically relevant. These terms
were excluded from further processing. Many other terms, while potentially medically
relevant, are not necessarily related to gout (‘history of adopted child’). Therefore, we set
a threshold wherein a concept needed to have been extracted from the notes of at least 4
patients to be included for final analysis. This was done to minimize noise and maximize
sample size in the final analyses. 2020 terms appeared for only one patient. A further 521
terms only appeared in two patient records. An additional 252 terms were removed for
appearing in only three patient records. The remaining 1094 terms were examined for
associations to gout flares in the next step of the project.
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4.3

Phase Three Results
4.3.1

Sample

Data for 3964 patients was included for this study. The demographics presented
represent patients that met the minimum requirements sought as described in Chapter 3.
71% of the population was male (n=2827) and 29% female (n=1137). All but 15 patients
had information about race available in the database. 83% of the sample was identified as
white (n=3276), 16% as black/African American (n=627), and 1% as Asian (n=40). There
were also two patients identified as Hawaiian/Pacific Islander and four patients as
American Indian/Alaskan. Additionally, 98% were designated non-Hispanic/Latino. The
median age for the study cohort is 59 with the majority of patients being between the ages
of 55 and 69.
4.3.2

PheCAP Analysis Results

High-throughput phenotyping using a common automated pipeline was conducted
using the chosen concepts combined with the structured EHR data for each patient. This
initial complete dataset included 3964 patients with 1206 variables. 2702 patients had been
identified with flares and 1262 patients were identified as not having had any gout flares.
Patients were divided into a training sample (n=2378) and a validation sample (n=1586).
As the purpose of this first analysis was to create an overall, general model for gout
flares, surrogates were selected to be specific to the target phenotype. Subsequently, ‘gout
flares’ was chosen for the NLP surrogate. As there is no diagnosis code for gout flares, we
used the ICD codes for gout as an ICD surrogate. The SAFE algorithm identified the CUI,
ICD-9 gout code 274.xx, and the ICD-10 codes M10.0, M10.2, and M10.9 for use as
outcome variables in the training algorithm. The algorithm chose only those identified by
SAFE to be used in the model. Though the ICD codes as a group had a strong association
with outcomes, when considered in combination with the gout flare CUI there was a weak,
negative association. When considered individually, only M10.0 and M10.9 had non-zero
beta coefficients. The training model had an AUC of .735 and the validation set AUC was
.733 (figure 4.5). When evaluating the model over 20 different threshold values for
determining gout flare designation, the PPV stayed high (>.85) but the NPV was fairly low
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(<.5). The FPR was low (<.2) but the TPR was relatively low (<.6), as well. The lowest
threshold cutoff (.698) had the highest F1 score (.671).
In the same manner, models were created separately for each stage of the value
chain along with a comprehensive model combining all stages to explore the differences in
information provided in patient notes between the care stages more thoroughly and
determine whether certain stages contain information that could be considered more
predictive of or closely associated with gout flares. Results for each model are similarly
presented below and statistics for all models at a fixed FPR are included in table 4.8.
Overall, the models have little negative predictive value and low sensitivity.
Figure 4.5: Area Under the Curve for Training and Validation Data Sets Featuring NLP
Variables From all stages of CDVC.
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Table 4.8: TPR, PPV, NPV, and F1 scores for all models at FPR of .2.
Model
TPR
PPV
NPV
F1
General
0.533
0.854 0.454
0.656
Screening
0.34
0.78 0.367
0.473
Diagnosing
0.357
0.788 0.374
0.492
Preparing
0.376
0.797 0.381
0.51
Intervening
0.519
0.844 0.444
0.643
Recovering
0.361
0.79 0.375
0.496
Monitoring
0.514
0.843 0.441
0.638
Comprehensive
0.669
0.875 0.537
0.758
4.3.3

Screening

For the screening stage, there were 329 potential variables. The priority information
for this stage was signs and symptoms. Therefore, ‘high fever’, ‘warm skin’, and ‘during
the night’ were chosen as NLP surrogates. There are ICD codes associated with joint pain
(719.4x, M25.5x). As one of the most common symptoms of gout, the general, unspecified
versions of those codes were used as surrogates, as well. The model developed using these
variables as surrogates did not perform well (training AUC=.632), although it did do
slightly better on the validation dataset (AUC=.646) (figure 4.6). None of the NLP CUIs
by themselves contributed to the model. As a group, the CUIs and ICD codes showed a
weak association (all beta coefficients < ±.1). This models .5 F1 score (.463) occurred at
the lowest cutoff (.743). PPV (.78) was lowest at this point. While all other metrics were
highest at this cutoff, all were <.5.
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Figure 4.6: AUC Plot for Training and Validation Data Sets Featuring NLP Variables
Labeled Screening.

4.3.4

Diagnosing

The model for the diagnosing stage was developed using the CUIs and CPT codes
used for lab tests involved in diagnosing gout. Specifically, ‘fluid analysis’ and ‘urate
crystals’ were used as NLP surrogates and the CPT code for serum urate testing was used
as the surrogate for coded data. In total, 238 variables were considered for diagnosing. This
model performed similarly to the screening model (training AUC=.637, validation
AUC=.65) (figure 4.7). However, the code for serum urate testing did demonstrate a fairly
strong association with the outcome variables with a beta coefficient >.65. Furthermore,
the NLP variables together had a beta coefficient >8.18.
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Figure 4.7: AUC Plot for Validation and Training Data Sets Using NLP Variables
Labeled Diagnosing.

4.3.5

Preparing

The preparing stage contained only eight NLP variables to choose from. The priority
information for this stage of the value chain include all terms related to education
concerning treatment options. Though this category can include information about side
effects, compliance, and efficacy, it is not limited to medication or drug interventions.
Thus, ‘red meat’, ‘taking NSAIDs’, and ‘kidney’ were chosen as NLP surrogates. Because
NSAIDs are likely to be the first line of treatment for gout flares that patients can take
while deciding on long-term treatment options, the NDC codes for a common over-thecounter treatment (ibuprofen) were also designated as surrogate variables. 121 possible
variables were considered for this model. The model performed similarly to the previous
stages (figure 4.8). Ibuprofen demonstrated the greatest effect on the model. ‘Red meat’
was the only NLP variable to have an individual effect on the model.
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Figure 4.8: AUC for Model Created Using NLP Variables Labeled as Preparing.

4.3.6

Intervening

For intervening, there were 297 total variables. Priority information for the
intervening stage of the care cycle consists of ordering and administering drug therapies.
The NLP concepts chosen as surrogates were all drugs commonly prescribed for gout
treatment, both acute attacks and long-term ULTs. The NDC codes for these drugs were
also included as surrogate outcome variables for a total of 46 surrogates for consideration
by SAFE. This model performed better (training AUC=.729) (figure 4.9). Sulfinpyrazone
showed a strong association in the model with a beta coefficient > 5.
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Figure 4.9: AUC Plot for Training and Validation Sets Using NLP Concepts Labeled
Intervening.

4.3.7

Recovering

The recovering stage only provide three NLP concepts for consideration. Priority
information relates to fine tuning therapies. Two concepts were selected as being related
to this designation (‘daily’ and ‘renal impairment’). ICD codes for renal disease were
included as surrogate representation from the structured data. The model was developed
using 111 variables. The performance metrics for this model were slightly lower than those
presented previously (validation AUC=.639) (figure 4.10). The main variables all
demonstrated small associations with gout flares, however, the NLP concept ‘renal
impairment’ alone showed a beta coefficient of -96.27.
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Figure 4.10: AUC Plot for Training and Validation Data Featuring NLP Variables from
Recovering.

4.3.8

Monitoring

The monitoring stage presented 647 variables with which to develop a model. The
priority for monitoring is to manage and avoid complications, especially acute attacks.
From a coded data perspective, avoidance is handled through the continued monitoring of
serum urate levels. Management once an acute attack occurs frequently consists of using
colchicine to alleviate symptoms. Therefore, the respective CPT and NDC codes were used
as surrogate variables. 19 NLP variables related to priority information for this stage were
also selected to act as surrogates. This model performed slightly lower than the intervening
model (training AUC=.719) (figure 4.11). The CUIs for ‘fluid intake’ and ‘fish oil’ stand
out as showing strong associations with gout flares.
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Figure 4.11: AUC Plot for Training and Validation Models Created from Variables
Included in Monitoring.

4.3.9

Comprehensive Model

As a final test, a model encompassing the entire value chain was developed. Whereas
the first model was meant to be a general model to look for associations between broadly
defined surrogates, this model was designed to look specifically at each stage of the value
chain as a whole. The NLP surrogates defined for use in all previous models were also
assigned as surrogate outcomes variables in this model. For medical codes, all codes used
in the algorithm used to count flares were included as surrogates. In total, 1207 variables
were considered for the development of this model, 112 of which were designated as
surrogates. The model created had improved performance metrics when compared to the
other models (figure 4.12).
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Figure 4.12: AUC for Training and Validation Model for Complete Value Chain.

AUC for training data was .812. At the lowest threshold value (.672), PPV was at
its lowest value of .875. All other statistics were at their highest, including an F1 score of
.758.

4.4

Conclusion
This chapter contains the results of the analyses, connects the analyses back to the

research questions, and demonstrates consistency of the analyses with value chain theory.
Data for 3964 patients was included in this value chain study. Structured and unstructured
medical data was used to understand what information is readily available in patient
education materials regarding the topic of gout and which concepts are associated with
patient gout flares. The majority of patients were white males in the 55-69 age range.
Consistent with value chain analysis, each piece of data in each step of the study was
placed in the care continuum according to the stages of the care delivery value chain where
it is believed to contribute value. Comparative analysis was conducted to discover
categories, themes, and relationships between and within the six value chains, leading to
the following key findings. The key findings resulting from this study summarize the
contributions of PEMs to the inefficacy of patient education: (a) Gout PEMs contain far
more terms related to diagnosis or procedures than medications, except for information
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related to the intervening stage (b) term usage varies markedly between PEMs and clinical
notes, (c) Information related to preparing and recovering are noticeably absent from gout
PEMs, (d) Gaps in PEM data were exacerbated in clinical note output, (e) The best
performing models utilized the most input data.
Neither demographic nor healthcare utilization variables contributed to any of our
models. Additional data on the similarities and differences discovered across the different
stages of the care delivery value chain, between PEM and clinical note NLP output, and
how variables relate to gout flares are also found in this chapter. While great strides have
been made in creating good patient education materials, it is evident from the research
results that there is variability in the information patients are given to learn about gout and
the individual health data patients must keep track of to manage their disease. Chapter 5
includes the summary of critical analysis and discussion of these findings.
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CHAPTER 5. DISCUSSION

The purpose of the value chain study was to identify factors associated with gout
flares, leading to a model for identification. This chapter includes a discussion of major
findings as related to the literature on gout patient education and gout patient information
requirements and what implications may be valuable for use by stakeholders. Also included
is a discussion on connections to this study and value chain theory and healthcare policies.
The chapter concludes with a discussion of the limitations of the study, areas for future
research, and a brief summary.
The information value chain created from a scoping review allowed us to identify
important information from popular gout patient education materials. The ability to use this
information to identify important information in the clinical notes of gout patients and
subsequently identify associations to gout flares was hindered by the following key
findings: (a) Gout PEMs contained far more terms related to diagnosis or procedures than
medications, except for information related to the intervening stage (b) term usage varied
markedly between PEMs and clinical notes, (c) Information related to preparing and
recovering was noticeably absent from gout PEMs, (d) Gaps in PEM data were exacerbated
in clinical note output, (e) The best performing models utilized the most input data. Some
issues relate primarily to PEMs, some to the clinical narratives, and some are a combination
of the contextual relationship between the two. These issues help contribute to lack of
understanding and self-management skills for gout patients.

5.1

Phase One Discussion and Conclusions
5.1.1

Discussion

The results of this scoping review indicate that treatment and other interventions
are the most popular topics for gout patient information related research. This is reflective
of the confusing and complicated nature of gout treatment as both a chronic and acute
condition. Moreover, several key findings highlight the interrelated nature of the various
information types necessary to successfully manage gout.
A heavy focus on treatment for a health problem is to be expected, especially for a
chronic painful condition like gout. However, the emphasis on treatment in research
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studies for a disease that has proven treatment protocols is indicative of a larger problem.
Several studies highlighted that adherence to long term therapies is lacking in gout
patients. Patients often indicated that this is due to a lack of understanding of when and
how to take both long- and short-term medications prescribed for gout. However, many
studies found that lack of knowledge about the causes and progression of the disease was
a contributing factor to misunderstandings regarding adherence to treatment strategies.
Furthermore, all of the limited research pertaining to the first two stages of care
(n=3) identified lack of education regarding the causes and consequences of gout. Prediagnosis, this lack of understanding of gout pathophysiology leads to underdiagnosis.
The research focus on this topic throughout the care cycle indicates that this issue is not
remediated in later stages and continues to create barriers to effective disease
management.
In addition, the variety of information types identified as being necessary for
optimal gout management is reflective of the multifaceted nature of gout. Several of the
articles highlighted multiple information types demonstrating that the categories work
together to enhance understanding and aid the behavioral, cognitive, and emotional
processes necessary for treatment compliance. Specifically, patients desire more
information regarding natural remedies and lifestyle advice.
5.1.2

Further Research

Despite the rich research findings provided by the relevant articles identified by
the scoping review, the majority were only tangentially related to our aim of identifying
the information required for improving the efficacy of treatment/management strategies.
The existing literature is largely focused on identifying gaps in patient knowledge with
conclusions drawn about needed information through inference from the results. More
research needs to be done to explicitly identify the information that is required for more
efficient education guidelines to avoid extraneous information that risks overwhelming
the patient.
Six studies analyzed education interventions with two being systematic literature
reviews. All studies found the interventions to be successful for increasing treatment
adherence, however, each study utilized different methods for implementing and
measuring the outcomes of the chosen intervention. Limited research is available for
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interventions outside of the treatment stage. The included studies indicate that patients
give up on medications and treatment options when side effects occur due to
misunderstandings, essentially leading them to skip the recovering/rehabbing phase in
favor of treating only the symptoms of acute attacks. Furthermore, studies have identified
that, just as gout therapies need to be fine-tuned for the individual, education is best
tailored and personalized to each patient. Future research could focus on exploration of
what to do for improvement, rather than what is not being done.
5.1.3

Strengths and Limitations

This is the first scoping review conducted for this particular topic. The broad
search strategy and inclusion criteria contributed to the breadth of evidence uncovered
and provided a comprehensive overview of available research. In addition, these factors
were essential to conducting a rigorous review in adherence with published scoping
review protocols at each step of the screening, selection, and evaluation processes.
Despite the meticulous and robust methods utilized, the review still has
limitations. First, in line with general scoping review protocol, the quality of the available
research was not evaluated. As such, this review only identifies the existence of key
findings and makes no judgement on the worth or potential benefits of said findings.
Second, only articles published in the English language were included, meaning that
articles relevant to the topic that could have further incites might have been excluded.
Last, it is possible that some relevant studies were not retrieved using our search strategy.
Though the search terms were chosen because they were believed to be sufficiently broad
so as to encompass the majority of relevant research, it is possible that some authors
expressed the concept of ‘gout patient information’ in an alternate way that would not be
retrieved by our search strategy.
5.1.4

Conclusion

This review highlights the limited attention that has been paid to the information
needs of gout patients. Though interest has grown in the last two decades, there is still an
explicit need to explore the essential information requirements for optimal care and
patient self-management. Specifically, there is a need to determine what information is
most beneficial at each stage of the value chain.
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5.1.5

Practice Implications

This scoping review is an initial attempt to grow the field of patient education
research through the application of value chain analysis to identify areas that need further
exploration by highlighting where value is currently being created and where gaps still
occur. Continuation of this type of research can aid in recognizing the extensive health
information needs of gout patients for the purpose of ensuring the receipt of adequate
amounts of information at the time it is most beneficial. Such research can further be used
to develop education interventions and other solutions to address issues in patient
education.

5.2

Interpretation of Findings
While individuals vary in their healthcare knowledge, skills, and experiences, each

of the key findings identify prominent factors in encouraging patient education throughout
the continuum of care. These issues are dynamic in nature, as what is important to each
patient changes over time. Each issue is examined in detail in the following sections.
5.2.1

Phase Two

At first glance, the lack of medication information in patient education materials
about a disease might not seem like an egregious issue, or, in fact, an issue at all. There are
PEMs available for specific gout and other drugs. However, when looking back over the
gout value chain, we see that while medication information may be more important in
certain stages, it is an important consideration in all phases of the care cycle. In the
screening phase, it should be known that some medications can increase the risk of
developing gout. Patients start the tests that help determine the treatment plan, including
medication dosages, in the diagnosing phase. Medication information is especially
important in the preparing and recovering stages where it is most absent. Patients should
be receiving information about all of their treatment options in the preparing phase to help
decide on the best course of treatment, taking into account interactions of medications
currently being taken for preexisting conditions. For the recovering phase, patients need to
know when to consult their healthcare provider about fine-tuning their medication dosages.
Research has shown that patients that do not know the expected medication outcomes or
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that dosage adjustments are part of the process are more likely to stop treatment (Hui et al.,
2017). This stays important throughout the monitoring phase, where patients must
constantly deal with new and existing comorbidities, along with their associated
medications. In contrast, the sheer number of extracted medication terms identified as
intervening suggests that gout PEMs contain a significant amount of information related to
gout drugs. This noted imbalance likely caused our ner model to assign most medication
concepts to either intervening or monitoring.
It is clear from the results that there is an overall lack of concepts extracted from
the PEMs, and consequently from the clinical notes, for the preparing and recovering
stages. This is indicative of a gap in the gout PEMs and gout patient education in general
(Becker & Chohan, 2008). Furthermore, the information that is offered for these stages
often overlaps with concepts from the intervening and/or monitoring phase. Such terms are
usually used in the context of intervening or monitoring much more frequently, especially
for medication related terms. This means that the ner model is more likely to identify the
term as one of those two phases.
The researchers attempted to identify all important information contained with the
patient education texts. Due to the writing style characteristic to our set of PEMs, this
sometimes resulted in the annotation of longer phrases and sometimes, whole sentences.
Clinical notes are not written with patients in mind and can be written as brief notes with a
lot of medical jargon or abbreviations, depending on the style of the healthcare provider.
Our ner model did fairly well at extracting medically related concepts from longer phrases
and picking up certain abbreviations, even though these were not included in the original
keyword list. Interestingly, in many instances, the ner model assigned a different value
chain stage than originally labeled in the keyword dictionary. This is potentially correct
and all of the cases I reviewed were accurately labeled based on context. Even so, this still
can cause issues beyond the fact that the model will not accurately distinguish between
stages 100% of the time. At times, the model did not assign a new value chain stage to a
concept in addition to the keyword label, it assigned it instead of. This suggests that the
concept is not used within the clinical notes in the same manner that it is used in the PEMs,
which could cause confusion for patients
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5.2.2

Phase Three

. With regard to developing models with an aim toward identifying gout flares and
associated concepts, this eliminated several potential features for some stages while
potentially adding potential features to others. In addition, whenever a concept is included
in more than one stage, its counts are split between the stages depending on the context in
which it appears in the note. This is exactly what we would want the ner to do. However,
when working with algorithms that rely on frequency counts, as does the pheCAP
algorithm, entities with split counts are less likely to show well in the developed model.
In terms of the pheCAP models developed for these stages of care, this meant that
there were very few terms to choose from. This was especially noticeable when trying to
select NLP surrogates for the recovering model. Only six terms were extracted for this
phase. After removing generic terms and those that did not meet the patient threshold, there
were only three terms to choose from (‘dairy products’, ‘daily’, and ‘renal damage’). All
concepts were included for consideration in the final model; however, per the
methodology, surrogate variables were required to be chosen that reflected information
designated as priority for the specific phase. In the case of recovering, priority information
was related to the fine tuning of therapy. Thus, ‘daily’ was chosen as it could be part of a
medication dosage change and ‘renal damage’ was selected because it could possibly be a
reason for fine tuning therapy. ‘Dairy products’ was not chosen because it was categorized
as a nonpharmacological intervention, which is within the purview of recovering, but not
priority information. This was the lowest performing model.
It is always possible that the terms simply do not appear in patient notes. This would
go back to the textual and contextual issues previously discussed wherein information
patients need is included in PEMs but is not of concern to clinicians. This would seem most
likely for nonpharmacological interventions. However, terms such as ‘red meat’, and
‘seafood’ appear under the label of alternative stages like monitoring. There are also
frequent mentions of vitamins and other supplements such as ‘fish oil’ identified in other
stages, as well.
The best performing model, in terms of both gout flare prediction and identifying
associations, was the comprehensive model that not only included concepts from all stages
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of the value chain, but also designated NLP concepts from every care stage as surrogate
variables. In addition, all ICD, NDC, and CPT codes traditionally associated with gout and
its treatment were included as surrogate outcome variables. The model for the monitoring
phase performed second best, and it had the most concepts of all the care phases.
Though the study was somewhat hindered by the fact that the initial model was based
on only seven PEMs, the disparity in concepts collected for certain stages suggests that
some types of information are missing or neglected in gout materials. While there are
certainly more PEMs that could be used to add to the model, the ones used for this study
are among the most popular and trusted on the web. Furthermore, the concepts are fairly
uniform among the various PEMs. Though there are some definite differences, such as
Wikipedia, adding more PEMs in the same vein could just lead to exponentiation of the
current concepts.
This issue is not limited to NLP concepts. Many of the CPT codes selected due to
previous usage in gout studies were not useful for this project because none of our patients
had that code anywhere in their data. This was true for some ICD codes and a few
medication codes, as well.

5.3

Implications for Theory and Research
Chapter 2 included descriptions of several value chain models. These models

included Porter’s care delivery value chain utilized for this study. How the models
developed in this study fit with this model is discussed in the following sections.
5.3.1

Phase One

The strategic framework for healthcare delivery put forth by Kim, Farmer, and
Porter (2013) includes the suggestion that in order to optimize healthcare for equitable
community and economic development, we must first understand the full set of activities
involved across the entire care cycle for all medical conditions. In this study, a value chain
for gout is presented from an information perspective. The results of this study align with
the primary activities of the care delivery value chain as those that generate information.
However, the secondary activities primarily deal with tasks related to managing
information, which in the case of an information value chain seems redundant. In this sense,
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the focus is not so much on the value of task, but the value of the information created by
or required for the task.
5.3.2

Phase Two

Gout is a unique disease with a unique patient population. The rate at which NLP
terms were extracted across multiple care stages in both PEMs and clinical notes confirm
that the current practice of viewing medical care as a series of isolated interventions for
symptoms is less than ideal. The number of concepts related to complications and
comorbidities found in our patient notes gives credence to the assertion that a medical
condition is not one disease (Kim, Farmer, & Porter, 2013). Our cohort, specifically, has a
high number of patients that also have diagnostic codes for lupus. This is reflected in the
NLP output where we see several lupus related terms, such as ‘lupus flares’ and ‘SLE’.
5.3.3 Phase Three

5.4

Implications for Practice
The care delivery value chain touts the importance of a systemic view in order for

patients to best evaluate information to guide care decisions. The results of this study show
that the stages of the value chain are fluid, with patients potentially moving back and forth
through the chain multiple times. For gout especially, it is difficult to tell which care stage
a patient is in or which stage information is most applicable to. This is reflected throughout
the value chain, the PEM and clinical note output, and the models created to identify gout
flares and associated concepts.
5.4.1

Phase One

The gout information value chain was developed using a collection of research
concerning the information requirements of gout patients and best practices for treatment
and self-management. For a variety of reasons, best practices are not always implemented
by healthcare providers. The repetition of topics throughout the value chain indicates that
information might be best given multiple times in the care cycle. It is likely that patients
might need slightly different information about the same topics depending on the care

71

stage. Yet, patients are usually given only one worksheet of basic gout information when
first diagnosed with the condition.
5.4.2

Phase Two

Much of the information identified in the gout value chain are not included in PEMs
or clinical notes, nor are they told the information by any of their healthcare team. The
British Society for Rheumatology Guideline for the Management of Gout specifically
advocates for the provision of written and verbal instructions for most of the information
included in our value chain (Hui et al., 2017). Research routinely shows that patients do
not recall receiving educational information (Vaccher, et al., 2016) and our study
demonstrates that many concepts related to the necessary information are not readily
available in PEMs or patient notes.
5.4.3

Phase Three

When using the concepts collected from patient notes to develop models for each
stage of the value chain, there was a noticeable lack of available data for several care
phases. This was discussed in our key findings, but the attempts to create models for each
stage of care cycle revealed possible implications for clinical practice
There were plenty of available NLP concepts for screening; however, when
searching for priority information to use as surrogate variables it was discovered that none
of the symptoms that are considered among the first signs gout (painful joints, redness,
swelling) were included in the screening data. These concepts did appear in the diagnosing
and monitoring data. The concepts were annotated as screening when creating the keyword
dictionary, however, the concepts were used far more often in the context of diagnosing or
monitoring within the PEMs. The NER model subsequently learned to label those signs
and symptoms as one of those stages. As a consequence, the screening NLP was
proliferated with and overabundance of terms related to family history and risk factors.
Similarly, the priority information for diagnosis is related to the ordering and administering
of lab tests used to diagnose gout. Synovial fluid analysis is considered the gold standard
for gout diagnosis (Hui et al., 2017). There was a concept close to this (fluid analysis)
which was used as a surrogate variable for this model, however, the diagnosing data had
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far more data related to possible signs and symptoms. This is in line with the research,
which states that clinicians generally use signs and symptoms for gout diagnosis and
screening mostly takes place outside of the healthcare cycle (Kim, Farmer, & Porter, 2013).
The lack of concepts found in the preparing stage and the abundance of terms labeled
intervening support research that highlights the focus on treatment in healthcare with the
preparing stage largely being skipped (Hui et al., 2017). Recovering similarly had a low
number of concepts and research strongly indicates that this stage is mostly ignored in gout
due to patients not realizing that ULTs can often set off flares as a side effect. This can be
remedied by adjusting the medication; however, many patients just stop treatment (Hui et
al., 2017). The preponderance of terms found for monitoring are likely similar to
intervening.

5.5

Limitations
While this study produced numerous interesting results, the utility of the data is

reduced due to several limitations. First, despite the relatively high number of patients and
documents included in the study, the data was relatively sparse for the methodology. Even
though codes and concepts might occur in the data sets, total counts could be low overall
or spread among very few patients. As a result, the pheCAP algorithm identified very few
associated terms for each model.
Second, our models can only be developed using information that exists. Missing or
rare information in PEMs and patient notes prevents a complete understanding of the
associations between terms and care stages and may result in inaccurate information. While
one of the goals of this study was to identify missing and misclassified information in gout
PEMs and to a lesser extent, patient clinical narratives, using PEMs to develop an NER
model to extract information based on a care delivery value chain is likely not the best
method.
Third, the researchers tasked with selecting information deemed important to patients
are not clinicians, nor do they have the perspective of gout patients. The participation of
either would have greatly benefited the study. Though each step in the study process was
guided by prior research, the perspective of a rheumatologist would have been invaluable
in variable selection, such as designating priority information for the stages of the value
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stage or choosing surrogate variables for the phenotyping models. Having information
about why healthcare providers sometimes do not follow best practice guideline could have
a profound impact on the output of this study. Similarly, having patient annotations for
PEMs would be immensely helpful in identifying valuable information. Though the
literature review included multiple studies featuring summaries and conclusions about
what information gout patients want and need, without personally experiencing gout,
researchers can only annotate with an eye toward what they think gout patients need or
what they would want to know as a patient.

5.6

Future Research
There are several opportunities for future research that could add to the findings of

this study. The NER model created to extract concepts from patient data performed well
according to standard metrics. It did identify concepts from PEMs and learned to identify
similar, new concepts according to the value chain in clinical notes. However, in some
cases it overlearned. For example, researchers identified multiple instances of family
history related concepts in the PEMs as screening. Possibly to the frequency of occurrence,
the model learned that ‘family history’ was important and extracted every term associated
with ‘family history’ from patient notes. Future research could be done to refine the NER
model. Similar methods could also be applied to other diseases. Gout is a complicated
disease as outlined throughout this study. Other medical conditions are certain to have their
own inherent complexities, however, the application of value chain analysis could offer
additional insights into new diseases, as well as cNLP methods. As stated in the limitations
section, input from clinicians and patients should be sought throughout the process as much
as possible. Additionally, there is the opportunity to go farther with the concept of value
and attempt to quantify the importance of patient information. A more quantitative study
could be developed to understand the contribution of information to improving patient
health outcomes.

5.7

Conclusion
Having necessary information is critical to gout patient self-management. Many

factors are involved in ensuring gout patients have the right information to make well74

informed decisions about their healthcare. This is the first study the researcher is aware of
that creates a value chain for gout. It is almost certainly the first study to use value chain
analysis to develop an NER model. Though the models created in this study demonstrated
only marginal success, the results highlighted several interesting findings: (a) Gout PEMs
contained far more terms related to diagnosis or procedures than medications, except for
information related to the intervening stage, (b) term usage varied markedly between
PEMs and clinical notes, (c) Information related to preparing and recovering was
noticeably absent from gout PEMs, (d) Gaps in PEM data were exacerbated in clinical note
output, (e) The best performing models utilized the most input data.
The implications of these findings may not be immediately clear. The value chain
developed for this study would need to be validated. The NER model performs well at
extracting concepts, but those concepts are not necessarily gout related. The phenotyping
algorithms identified mostly weak associations between concepts in the value chain and
flares. The results of this study validate the gaps in information perceived by patients and
gives us particular areas to start filling in. Deciding how to fill those gaps is another matter.
The results of this study indicate that patient data does not necessarily have the information,
either. The weak associations identified could be used to identify stronger connections to
gout flares and thus, more useful information. Hopefully, someday patients will be able to
access important information tailored to their needs to optimize their healthcare. Until then,
future studies could focus on identifying patient information needs throughout the care
continuum.
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APPENDIX 1. KEYWORD DICTIONARY
Dictionary Keywords divided into medication related and other terms for each stage of the
value chain. Terms in italics were considered too generic and removed from the final
dictionary. Bold items also appear in clinical note output in the same phase.
Medication
benzbromarone

Diagnosis/Procedures
C0005035 Intervening stomach or intestines C0017178 Intervening

colchicine (Colcrys

C2718494 Intervening

chance

C0237506 Intervening

colchicine (tablets or injection

C4048699 Intervening

joint

C0022417 Intervening

colchicine-induced

C3656515 Intervening

inflammation and
pain in joints

C0003864 Intervening

Colchicine/probenecid

C0717652 Intervening

nausea, vomiting,
diarrhea and

C0151791 Intervening

disease, or who take drugs that
interact

C3805130 Intervening

relieve pain

C0002766 Intervening

Febuxostat (Uloric

C2608992 Intervening

also

C0238664 Intervening

Given orally (by mouth) or by
injection

C0555966 Intervening

heart and kidney

C0155602 Intervening

nonsteroidal anti-inflammatory
drugs

C0003211 Intervening

diarrhea, nausea,
vomiting, and

C0151791 Intervening

NSAIDs can also cause kidney
problems in people taking
diuretics or certain other
medicines to

C2029949 Intervening

stomach upset

C0235309 Intervening

or low-dose

C1542589 Intervening

Vitamin C

C0003968 Intervening

Pegloticase (Krystexxa) is given
by injection
C2938134 Intervening

Renal

C0022646 Intervening
C0373739 Intervening
C0445550 Intervening

Probenecid

C0033209 Intervening

blood uric acid
levels

Colchicine

C0009262 Intervening

Low-dose

doctor may need to change the
doses of your medications or
monitor you
Fenofibrate
Nonsteroidal anti-inflammatory
drug
ranolazine (Ranexa

deposition of urate
crystals in the renal
medulla or uric acid
C3476743 Intervening
crystals
C0522574 Intervening
C0033228 Intervening

ulcers or bleeding in
the stomach
C0586374 Intervening

ulcers, and bleeding
– NSAIDs can cause
C0003211 Intervening
stomach
C0586374 Intervening
C1703958 Intervening
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prevent disease

C0679698 Intervening

allopurinol (Aloprim

C4058836 Intervening

blood levels of uric
acid to normal

C0855643 Intervening

Allopurinol is also sometimes
used to treat seizures, pain
caused by

C0274778 Intervening

stores

C1698986 Intervening

brand name drugs

C0590778 Intervening

such as

C1881351 Intervening

cause other side effects

C0013679 Intervening

rash; skin redness

C2126375 Intervening

Colchicine is not

C1851351 Intervening

attacks of gout

C2712871 Intervening

Colchicine may cause side effects C0868415 Intervening

relieve pain and
reduce

C2940249 Intervening

corticosteroids

vitamins, minerals, or
other dietary
C0001617 Intervening
supplements
C4036036 Intervening

Febuxostat

C0249529 Intervening

ibuprofen

C0020740 Intervening

indomethacin

C0021246 Intervening

Lesinurad (Zurampic

C4074452 Intervening

Nonsteroidal anti-inflammatory
drugs (NSAIDs

C0003211 Intervening

of your medications or monitor
you carefully for side effects

C0513367 Intervening

oral corticosteroids plus colchicine C0775883 Intervening
prednisone, methylprednisolone

C0338362 Intervening

Steroids – Steroids can reduce

C2315131 Intervening

sulfinpyrazone (Anturane

C1578263 Intervening

What side effects can this
medication

C3639329 Intervening

xanthine oxidase inhibitors

C0302609 Intervening

naproxen (Naprosyn

C1578052 Intervening

allopurinol or probenecid

C2194181 Intervening

Allopurinol

C0002144 Intervening

Allopurinol may cause

C0274778 Intervening

azathioprine

C0004482 Intervening

can be taken as pills or as

C3641844 Intervening

febuxostat (brand name: Uloric

C2608992 Intervening

indomethacin (Indocin

C0306458 Intervening

ingredients in colchicine

C0009262 Intervening

inject a corticosteroid directly into
your joint
C2137753 Intervening
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effects may be

C4229333 Intervening

lesinurad

C3886073 Intervening

no side effects

C3650791 Intervening

nonsteroidal anti-inflammatory
drug (NSAID

C0003211 Intervening

NSAIDs

C0003211 Intervening

NSAIDs (Nonsteroidal antiinflammatory drugs

C0003211 Intervening

Medication

Diagnosis/Procedures

200 mg: Initiate 1 tablet of
lesinurad 200
mg/allopurinol 200 mg
C4073461 Monitoring

meats and fish

C0335766 Monitoring

adverse effects of NSAIDs C0413722 Monitoring

Nausea/vomiting

C0027498 Monitoring

doses of short?acting
NSAIDs give the fastest
relief of

C1880956 Monitoring

inflammation of the mouth

C0038362 Monitoring

79nitial79lam (Lescol),
lovastatin (Mevacor),
pravastatin (Pravachol),
and simvastatin (Zocor

C3173335 Monitoring

allergic reactions

C0020517 Monitoring

ibuprofen (Advil, Motrin

C0306865 Monitoring

Alcohol in excess

C0159070 Monitoring

increase your dose

C1707810 Monitoring

fever, chills, and

C0085594 Monitoring

Drink alcohol

C0001948 Monitoring

leukopenia

C0023530 Monitoring

like aspirin and ibuprofen),
ice the inflamed area and
drink plenty of
C1424457 Monitoring
Stevens-Johnson
Syndrome, drug
tell your doctor if you are
taking

C1274933 Monitoring

C3476385 Monitoring hypersensitivity reactions C0020517 Monitoring

anti-inflammatory

C0003209 Monitoring

inflammation

C0021368 Monitoring

before taking your

C3476385 Monitoring

stomach cramping

C0344375 Monitoring

Colchicine is

C1851351 Monitoring

stones

C0006736 Monitoring

cyclophosphamide
(Cytoxan

C1605278 Monitoring

wrinkled skin

C0037301 Monitoring

Do not take

C3476381 Monitoring

rapid or irregular heartbeat

C0080203 Monitoring

nonsteroidal antiinflammatory drugs
(NSAID

C0003211 Monitoring familial Mediterranean fever C0031069 Monitoring

steroids

C0038317 Monitoring

seafood

C0206208 Monitoring

adverse drug reactions

C0041755 Monitoring

decrease fertility in

C0151639 Monitoring

aspirin) and increase the

C0357297 Monitoring

swelling of the salivary
glands

C0240925 Monitoring

atorvastatin (Lipitor

C0286650 Monitoring
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osteoarthritis or rheumatoid
arthritis
C0029408 Monitoring

brand names: Advil, Motrin)
and indomethacin (brand
name
C0699203 Monitoring
brand names: Advil,
Motrin), and naproxen
(brand name

Renal stones

C0022650 Monitoring

Mediterranean fever (FMF;
an inborn condition that
C0699203 Monitoring causes episodes of fever

C0031069 Monitoring

Celecoxib (Celebrex

C1593710 Monitoring

degenerative arthritis

C0029408 Monitoring

Colchicine

C0009262 Monitoring

swelling

C0038999 Monitoring

Colchicine (Colcrys

C2718494 Monitoring

ulceration

C0041582 Monitoring

Colchicine comes as a
tablet and solution

C1251364 Monitoring

hypomagnesemia

C0151723 Monitoring

Common adverse drug
reactions

C0414040 Monitoring

breath odor

C0018520 Monitoring

CrCl

C1846718 Monitoring

tophi

C0221248 Monitoring

Do not stop taking

C3476381 Monitoring

sensitivity to light

C0085636 Monitoring

Febuxostat

C0249529 Monitoring

failure, kidney disease

C0035078 Monitoring

fluconazole (Diflucan),
itraconazole

C1541189 Monitoring

Renal colic

C0152169 Monitoring

fosamprenavir (Lexiva

C1321662 Monitoring

irritation of the eyes

C0235266 Monitoring

gastrointestinal adverse
drug reactions

C0413956 Monitoring

heart attack

C0027051 Monitoring

higher doses of

C3639809 Monitoring

within 48 hours

C0150946 Monitoring

It is taken
lesinurad 200 mg

C1881371 Monitoring acute flares of gouty arthritis C0149896 Monitoring
C4074641 Monitoring

pseudogout

C0033802 Monitoring

medicines are working and
skin lesions, severe acne or
you are taking
C3176475 Monitoring
a skin rash, sores or
C0241096 Monitoring
mg: Initiate 1 tablet of
lesinurad 200
mg/allopurinol 300 mg

C4073461 Monitoring

minders and those for eye
drops, creams, patches,
and inhalers) are not child C0402660 Monitoring

pain in one or more joints

C0162296 Monitoring

stomach cramps

C0344375 Monitoring

nonsteroidal antiinflammatory drugs
(NSAIDs

C0003211 Monitoring

blood flow and thereby
decrease

C0232342 Monitoring

NSAID

C0003211 Monitoring

blurred vision

C0344232 Monitoring

NSAIDs

C0003211 Monitoring

dry mouth

C0043352 Monitoring

certain types of

C0007832 Monitoring

over-the-counter NSAID
with a prescribed NSAID or
take more than the
recommended dose of the C2054168 Monitoring

ritonavir (in Kaletra, Norvir),
and saquinavir
C1977397 Monitoring decreased interest in sexual C0011124 Monitoring
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take by mouth

C3472561 Monitoring

to aspirin, other NSAIDs,
sulfa drugs, or have nasal
polyps (linked to a greater
chance of NSAID allergy C0038757 Monitoring
warfarin (brand name:
Coumadin) or

painful or difficult urination

C0013428 Monitoring

chronic

C0205191 Monitoring

C3827680 Monitoring antiphospholipid antibodies C0162595 Monitoring

you are taking

C3176195 Monitoring

symptoms occur

C0232959 Monitoring

your doctor before taking

C3476385 Monitoring

kidney stones

C0022650 Monitoring

diltiazem (Cardizem

C1243267 Monitoring

Chronic gouty arthritis

C0268108 Monitoring

Neoral, Sandimmune

C0699603 Monitoring

fibrillation after cardiac

C0232197 Monitoring

prostaglandins

C0033554 Monitoring

Increased susceptibility to
infection

C0236171 Monitoring

lesinurad

C3886073 Monitoring

Long-term use of NSAIDs

C2911180 Monitoring

ecchymosis

C0013491 Monitoring

Nonsteroidal
81nitial81lammatory
drugs

C0003211 Monitoring

remedies

C0205202 Monitoring

numbness of the feet, hands,
and around the mouth
C0221730 Monitoring

Some NSAIDs need to be
taken more often during the
day than
C3843221 Monitoring tophi occur in advanced gout C0221248 Monitoring
acylglucuronide

C0299192 Monitoring

peripheral vascular
disease

C0085096 Monitoring

Anakinra

C0245109 Monitoring

decreased appetite

C0232462 Monitoring

dose is too high

C3163907 Monitoring

skim milk

C0349375 Monitoring

mg/kg/day

C3642190 Monitoring

scaly skin

C0423773 Monitoring

reactions to allopurinol

C0414017 Monitoring

skin reactions such as
maculopapular rash

C0423791 Monitoring

when starting these

and chronic abuse of ethanol
(especially beer and hard
C3166682 Monitoring
liquor
C0425331 Monitoring

81

infections

C0439663 Monitoring

deposits of crystals

C0442844 Monitoring

Secondary infections

C0442886 Monitoring

reactions

C0443286 Monitoring

low doses

C0445550 Monitoring

soft tissues of joints

C0447831 Monitoring

Sugary drinks and foods

C0453425 Monitoring

affected joint and apply ice
packs or cold compresses
(cloths soaked in ice

C0508503 Monitoring

is working properly

C0509404 Monitoring

measuring device) to
accurately measure the
correct amount of

C0512904 Monitoring

uric acid levels in the blood
may lead to deposits of urate
crystals
C0522574 Monitoring
deposit in the joints

C0541866 Monitoring

kidney or liver

C0545792 Monitoring

feeling of warmth

C0549386 Monitoring

limiting alcohol intake

C0560219 Monitoring

not be safe

C0581563 Monitoring

rashes, or other allergic
reactions

C0585186 Monitoring

increased/decreased

C0679128 Monitoring

Long-term exposure

C0683018 Monitoring

high levels of a substance
called uric acid in the blood C0740394 Monitoring
high levels of blood uric acid C0740394 Monitoring
High levels of uric acid in the
blood
C0740394 Monitoring
high fever

C0743973 Monitoring

reactions are idiosyncratic
reactions

C0745213 Monitoring

gradual weight loss

C0750418 Monitoring

Nerve or spinal cord
impingement

C0751463 Monitoring

role in preventing

C0814407 Monitoring

of the lips or mouth

C0841473 Monitoring

redness of the skin

C0848314 Monitoring

drinking too much

C0848500 Monitoring

crystals can attract white
blood cells, leading to
severe, painful gout attacks
and chronic arthritis
C0850874 Monitoring
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Urate or uric acid

C0851010 Monitoring

raise uric acid

C0857189 Monitoring

paleness or grayness of the
lips
C0877384 Monitoring
inflammation are under

C0877470 Monitoring

controlling weight

C0920298 Monitoring

in the stomach

C0940163 Monitoring

bloating from increased gas C0946092 Monitoring
decreased, lymphocyte
count decreased

C0948021 Monitoring

High levels of uric acid

C0948643 Monitoring

Cherry products such as
whole cherries or
unsweetened cherry juice

C0982074 Monitoring

runny nose

C1260880 Monitoring

losing weight

C1262477 Monitoring

weight decreased

C1262477 Monitoring

weight loss

C1262477 Monitoring

risks for any coronary
heart disease

C1277690 Monitoring

acid in the blood

C1287384 Monitoring

increased levels of anti

C1295614 Monitoring

Moderate-to-severe

C1299393 Monitoring

attacks are typically followed
by periods of no symptoms C1304680 Monitoring
cardiovascular events

C1320716 Monitoring

undiagnosed vascular
disease

C1385120 Monitoring

cardiovascular events like
heart attacks

C1385306 Monitoring

kidney disease and adverse
cardiovascular events
C1397469 Monitoring
high levels in the blood

C1399735 Monitoring

Renal impairment

C1565489 Monitoring

gout flare

C1619733 Monitoring

Gout flares

C1619733 Monitoring

crystals can form tophi, or
swollen growths

C1720757 Monitoring

safe to use

C1820984 Monitoring

temperature and away from
excess heat and moisture
(not in the bathroom
C1822194 Monitoring
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temperature, away from light,
and away from excess heat
and moisture (not in the
bathroom
C1822194 Monitoring
and urinary: Tubulointerstitial
nephritis
C1843273 Monitoring
After several months of

C1858431 Monitoring

such as

C1881351 Monitoring

increased overall likelihood
of
C2015876 Monitoring
crystals can be found in uric
acid
C2022384 Monitoring
swollen or painful glands

C2032740 Monitoring

swollen glands in the neck

C2039120 Monitoring

kidney stones or urate

C2109382 Monitoring

goes away

C2128638 Monitoring

lower back or side pain

C2129277 Monitoring

Cut back on

C2186619 Monitoring

under the skin

C2200110 Monitoring

Risk for vascular disease C2584745 Monitoring
Increase risk of renal events C2673803 Monitoring

84

increased risk for any
vascular event

C2673803 Monitoring

irritation of the
gastrointestinal (GI) tract

C2697368 Monitoring

gout attacks

C2712871 Monitoring

osteoarthritis, and others)
and

C2893964 Monitoring

irritation, upper respiratory
tract

C2939098 Monitoring

Urate nephropathy

C2955673 Monitoring

fructose (especially high
fructose corn syrup

C2981326 Monitoring

high-fructose corn syrup

C2981326 Monitoring

risk of heart attack, heart
failure

C3176375 Monitoring

can become

C3259831 Monitoring

after acute attacks

C3279118 Monitoring

call your doctor

C3476384 Monitoring

may be increased in patients
with decreased
C3552940 Monitoring
flushing or redness

C3641769 Monitoring

organ meats such as

C3687641 Monitoring

risk of kidney disease

C3697935 Monitoring

but because it can help

C3827771 Monitoring

Do not

C3840725 Monitoring

Drink at least eight glasses
of water or other fluids each
day
C3841851 Monitoring
attack or stroke

C3844825 Monitoring

containing drinks and foods C3880948 Monitoring
numbness or tingling in the
fingers or toes
C3898946 Monitoring
Eat too many foods rich

C3898963 Monitoring

eating foods that are rich

C3898963 Monitoring

If you are overweight, losing
weight can help
C4034888 Monitoring
few hours

C4036223 Monitoring

unexpected

C4055646 Monitoring

to treat gout in adults who
were not treated successfully
with or who are not able to
take
C4068173 Monitoring
last 3 months

C4086725 Monitoring

effects can be

C4229014 Monitoring

effects may be

C4229333 Monitoring

Medication

Other

tell your doctor and pharmacist
crystals accumulate in the
what
C4086247 Preparing
urinary
C0151579 Preparing
you are taking or plan to take

C4068173 Preparing

liver disease or heart
failure

C0085605 Preparing

ask your doctor or pharmacist if
uric acid to break down a
you have any questions
C3165542 Preparing
chemical
C0041980 Preparing
blood thinners

C0003280 Preparing

kidney

C0022646 Preparing

take NSAIDs

C2054168 Preparing

breaks down

C0443161 Preparing

or non-prescription medicines,
or you take any herbal
medicines, ask your doctor or
pharmacist
C1978499 Preparing

drinks like cola

C0452444 Preparing
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red meat

C0452848 Preparing

inflammation in the joints C0574941 Preparing
crystals form and collect in
your joints and cause gout C0809978 Preparing
dissolving

C1549535 Preparing

uric acid (hyperuricemia

C1559990 Preparing

Treatment choices
depend on

C2069130 Preparing

kidneys remove uric acid C2109383 Preparing
do not overproduce uric
acid should take

C3476381 Preparing

production of uric acid

C3653539 Preparing

Uric acid buildup also can
lead to disfiguring lumps
called tophi
C3806613 Preparing
too much
Medication
take blood thinners

C3843660 Preparing
Other

C2054133 Recovering

table salt

C0206136 Recovering

on this medicine long term to
prevent
C2922112 Recovering

daily

C0332173 Recovering

uric acid-lowering drug, your
doctor should slowly raise

tophi

C0221248 Recovering

dairy products

C0010947 Recovering

damage to joints

C0269891 Recovering

C0857189 Recovering

effects, especially diarrhea or
allergic reactions
C1546347 Recovering
Pembrolizumab

C3658706 Recovering

uric acid levels drop
below 6 mg/dL (normal C0151411 Recovering
levels

C0441889 Recovering

grapefruit or drink
grapefruit juice

C0452456 Recovering

on a regular basis

C0513554 Recovering

of tophi (deposits of uric
acid crystals
C0522574 Recovering
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joint destruction

C0541875 Recovering

Lose weight

C1262477 Recovering

renal damage

C1408258 Recovering

renal impairment

C1565489 Recovering

drinks, such as

C3641919 Recovering

eating foods that are
rich

C3898963 Recovering

Medication

Other

diuretics (water pills)
that help with high
blood pressure

C3843190 Screening

drink alcohol

C0001948 Screening

Esidrix

C0700694 Screening

Obesity

C0028754 Screening

skin rash

C0015230 Screening

hydrochlorothiazide and
other water pills
C3217109 Screening

blood pressure), hyperlipidemia
(high cholesterol and triglycerides C0242339 Screening
gout first attacks your big toe

C0221168 Screening

Sickle cell anemia and other
anemias

C0029738 Screening

hemochromatosis

C0018995 Screening

serious

C0205404 Screening

painful swelling in single joints

C0311222 Screening

for rheumatoid arthritis

C0260963 Screening

Gout rarely affects

C0003868 Screening

Diabetes

C0011847 Screening

painful urination

C0013428 Screening

osteoarthritis

C0029408 Screening

Kidney disease

C0022658 Screening

family history of gout

C0221613 Screening

high blood pressure),
hyperlipidemia (high cholesterol
and triglycerides
C0242339 Screening
pseudogout

C0033802 Screening

base of the big toe

C0224039 Screening

gastric bypass surgery

C0192398 Screening

the big toe or other part of the
foot) and/or bouts of arthritis

C0264134 Screening

blood uric acid levels

C0373739 Screening

of severe pain, most often the big
toe
C0410779 Screening
What should I do if I forget

C0423915 Screening

drink beer

C0425331 Screening

lips, mouth, tongue

C0497193 Screening

of redness, swelling, pain, and
heat in one or

C0513106 Screening

pain, redness, swelling, and heat C0513106 Screening
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uric acid (a normal waste
product) collects in the body, and
needle-like urate crystals deposit C0522574 Screening
swollen, red, hot

C0541781 Screening

Hypertriglyceridemia
Hypercholesterolemia

C0543517 Screening

Kidney disease or

C0543793 Screening

after menopause

C0587113 Screening

alcohol, especially beer

C0678384 Screening

high levels of uric acid in the
blood

C0740394 Screening

hyperuricemia

C0740394 Screening

high fever

C0743973 Screening

genetic factors

C0814299 Screening

uric acid (a normal waste
product) collects in the body, and
needle?like urate
C0851010 Screening
site may be red and warm

C0857810 Screening

high levels of uric acid

C0948643 Screening

Intensely painful

C1320357 Screening

Leukemia and other blood
cancers

C1516238 Screening

Diabetes or

C1534917 Screening

problems (such as bleeding,
ulcer, and stomach upset), kidney
problems, high blood pressure or
heart problems
C1535460 Screening
may also be affected

C1836053 Screening

last 3 to 10 days, but the first 36
hours
C1865336 Screening
Men outnumber women

C1867966 Screening

more common in men

C1867966 Screening

more often in men, women

C1867966 Screening

and its complications occur more
often
C2073319 Screening
in the feet, especially

C2127235 Screening

fainting, slurred speech, sudden
blurry vision, or sudden severe
headache
C2219960 Screening
Hypertension (high blood
pressure
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C2240377 Screening

ankles, heels, knees, wrists,
fingers, and elbows

C2677764 Screening

Attacks are

C2751362 Screening

may lead to

C3151638 Screening

people don’t have another one for C3175618 Screening
run in

C3274438 Screening

Pain control tends to occur

C3809908 Screening

run in some

C3810163 Screening

to run in some

C3810163 Screening

people become older

C3826770 Screening

more at risk if you’re overweight
and drink alcohol
C3842894 Screening
high blood pressure, high
cholesterol, diabetes, or

C3843079 Screening

high blood pressure, kidney
disease, or

C3843080 Screening

during the night

C3845370 Screening

metabolic abnormalities

C4021768 Screening

presenting as slight

C4036274 Screening

What other information should I
know

C4055149 Screening

Other
fever

C0015967 Diagnosing

tophi

C0221248 Diagnosing

redness

C0332575 Diagnosing

chronic (lasting) arthritis

C0263680 Diagnosing

X-rays

C0043309 Diagnosing

chronic gout

C0268108 Diagnosing

Podagra

C0221168 Diagnosing

monosodium urate monohydrate

C0037564 Diagnosing

gouty arthritis

C0003868 Diagnosing

Synovial fluid analysis

C0200648 Diagnosing

around the

C0151205 Diagnosing

tophus

C0221248 Diagnosing

inflammation via multiple mechanisms

C0021370 Diagnosing

blurred vision

C0344232 Diagnosing
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pseudogout

C0033802 Diagnosing

in one or more of your joints

C0162296 Diagnosing

instep

C0230472 Diagnosing

pain

C0030193 Diagnosing

crystal-induced arthropathies

C0152087 Diagnosing

Synovial biopsy

C0150887 Diagnosing

dual energy

C0085736 Diagnosing

Migratory polyarthritis

C0240344 Diagnosing

urate crystals

C0344392 Diagnosing

fever, sore throat

C0343487 Diagnosing

crystals in the joint fluid

C0200652 Diagnosing

Gout – chronic

C0268108 Diagnosing

uric acid production increases

C0041981 Diagnosing

uric acid can build up and form needle-like crystals

C0344392 Diagnosing

Uric acid can form sharp needle-like crystals

C0344392 Diagnosing

Uric acid – blood

C0373739 Diagnosing

Uric acid levels in the blood

C0373739 Diagnosing

under a microscope

C0395796 Diagnosing

health care providers to

C0420340 Diagnosing

Monoarticular involvement

C0427254 Diagnosing

Uric acid – urine

C0428286 Diagnosing

radiographic findings

C0436485 Diagnosing

redness and swelling

C0513348 Diagnosing

calcium pyrophosphate disease

C0553730 Diagnosing

joint damage

C0565874 Diagnosing

joint appears warm

C0575034 Diagnosing

calcium pyrophosphate crystals

C0729282 Diagnosing

Hyperuricemia

C0740394 Diagnosing

Tophaceous gout

C0744466 Diagnosing

of lips, eyes or mouth

C0841473 Diagnosing

Ultrasonographic

C1301497 Diagnosing

plain radiography

C1306645 Diagnosing

radiographs

C1306645 Diagnosing
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crystals within the joint space and deposition of crystals

C1401835 Diagnosing

gout crystals time to dissolve, and that will put a stop to the flares

C1619733 Diagnosing

Posterior interosseous nerve syndrome

C1696572 Diagnosing

attacks often

C1867940 Diagnosing

joints, and knee

C1969180 Diagnosing

Location outside

C2016008 Diagnosing

too much uric acid in the blood

C2029412 Diagnosing

too much uric acid in your blood

C2029412 Diagnosing

Swelling, warmth, erythema (sometimes resembling cellulitis), and

C2039039 Diagnosing

acute gout

C2062908 Diagnosing

Gout – acute

C2062908 Diagnosing

pain starts suddenly, often during

C2130139 Diagnosing

Tophi (multiple

C2144520 Diagnosing

knee, wrist, elbow, or ankle

C2677764 Diagnosing

This usually happens

C3263474 Diagnosing

chalky

C3267206 Diagnosing

pain or discomfort in right upper stomach

C3641896 Diagnosing

gouty joint

C3697115 Diagnosing

are most often affected

C3808454 Diagnosing

can be found in deposits (called tophi) that

C3841020 Diagnosing

toe, but you also can have gout in your knee, ankle, foot, hand, wrist, or C3898946 Diagnosing
dual energy computed tomography
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C4055114 Diagnosing

APPENDIX 2. COMPLETE NLP OUTPUT
NLP output from patient clinical notes divided into medication related and
diagnosis/procedure terms for each stage of the value chain.

Medication
C0332173 daily Recovering

Medication
C3225726 pain pill
Diagnosing

dairy products
renal
impairment
dairy
renal damage

Other
C0010947 Recovering
C1565489 Recovering
C0010948 Recovering
C1408258 Recovering

Other
pain
Ingrown hair
fever
red
chest discomfort
redness and
Hypogonadism
chronic gout
toenail
Acute bronchitis
otitis
blurred vision
podagra
calcium pyrophosphate
crystals
pain syndromes
red blood
Panniculitis
redness and swelling
aching
pain chest
Acute gout
gouty arthritis
actinic keratosis
livedo reticularis
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C0030193
C0263492
C0015967
C0332575
C0235710
C0017574
C0020619
C0268108
C0222007
C0149514
C0029877
C0344232
C0221168

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0729282
C0391976
C0086252
C0030326
C0513348
C0001044
C0008031
C2062908
C0003868
C0022602
C0085642

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

bone biopsy
around
Ingrown
painful arc
pain increases
Otitis externa
osteoarthritis
Txp
radiographic abnormality
painful skin
painful lump
Steatosis
Dysphonia
tophus
tophaceous gout
hernia repair
pain tightness
thymic
popping
myofascial
pain management
Urticaria
Externa
keloid
microhematuria
hernia site
Chronic gastritis
lichen
planus
pain mgmt
Epidermoid cyst
pain radiating
Microalbuminuria
painful urination
putty
Toenail onychomycosis
Neuropathic
parasitic
osteodystrophy
fever chills
pain muscle
93

C0005933
C0750503
C0027343
C0343214
C0456441
C0029878
C0029408
C1134470
C0436485
C0241136
C2126145
C0152254
C1527344
C0221248
C0744466
C0019328
C3647127
C0040113
C0439820
C0262941
C0002766
C0042109
C0152345
C0022548
C0239937
C4087315
C0085695
C0023643
C0023646
C0994210
C0014511
C0234254
C0730345
C0013428
C0263893
C1274470
C0003892
C0030498
C0264009
C0085594
C0231528

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

crusty
odynophagia
Dysthymia
hemarthrosis
urate crystals
axillary nerve palsy
Vascular calcifications
Disuse osteoporosis
Phantom
warmth
Orchitis
fell
arc
painful joints
radiographic
pain much
Red streaks
subtalar
onychomycosis
Testicular
Staphylococcal
flag
red cell anisopoikilocytosis
hallux valgus
pain swelling
cardiac amyloid
Toenail avulsion
Pulmonary Blastomycosis
red cabbage
Uric acid level
Acute
Spermatic cords
Tinea corporis
Labial abscess
sciatic nerve palsy
reflux esophagitis
Hypophonia
pyrophosphate crystal
arthritis
collagenous colitis
Axillary lymphadenitis
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C0555957
C0221150
C0013415
C0018924
C0344392
C2062709
C0342649
C0152256
C0282611
C0392197
C0029191
C1425660
C0001857
C0003862
C1306645
C4085212
C2169832
C0038593
C0040261
C0205070
C0038170
C1708067
C3806041
C0018536
C0745574
C4273093
C0851257
C0339964
C0453115
C0041981
C0205178
C0037855
C0040252
C0745601
C0751925
C0014869
C0521007

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C1388597 Diagnosing
C0238067 Diagnosing
C0919797 Diagnosing

prurigo nodularis
TMJ
pain do
insect bite
joint arthritis
red flag sx
pain the
Chronic conjunctivitis
Truncal
Homans sign
red macular
fever call
Tenosynovitis
Pilonidal cyst
Polyarticular gout
Acute gastritis
Migratory arthritis
Enthesopathy
Sciatic nerve
Leukocytoclastic vasculitis
breast biopsy
Urolithiasis
tan
Acute conjunctivitis
Tonsillitis
Chronic iritis
uveitis
Hemorrhoid thrombosis
Chronic polyarthritis
Mucinous adenocarcinoma
turbinates
red meats
Chronic bronchitis
Genital warts
hernia
lymphadenopathy
Phantom limb
Amaurosis fugax
Seborrheic keratosis
Proliferative
red rubber
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C0263353
C0039493
C1976730
C0021564
C0158026
C3646161
C0004604
C0155145
C0042275
C0231781
C2216370
C2051610
C0039520
C0031925
C0744464
C0149518
C0694577
C0242490
C0036394
C2973529
C0405352
C0451641
C0302595
C0155141
C0040421
C0008690
C0042164
C0235326
C1735378
C0007130
C1266928
C0452848
C0008677
C0009663
C0019270
C0497156
C0031315
C0149793
C0022603
C0334094
C1874753

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

majora
painful bruise
along
retina damage
red and warm
Actinic skin damage
meniscal tears
his
loose
red lesions
red flag signs
clipping
Vascular cognitive
gout
Pigmented
Kidney biopsy
testicular masses
catheterizable
multicystic
joint damage
Painful bladder spasm
Sicca syndrome
pain rectal
Subungal hematoma
tinea cruris
team providers
MCL
red warm
rasied
Aphthous ulcers
Fever blister
rosacea rosacea
meniscus
discomfort
red ring appeared
bull
concha
bullosa
mouth ulcers
ragged
Staphylococcal bacteremia
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C0227760
C0301928
C0205154
C0235272
C0857810
C1879546
C0238218
C0019602
C0205407
C0241115
C4076444
C0175722
C3805043
C0018099
C0031911
C0194073
C0241353
C0261558
C0032460
C0565874
C0423735
C0086981
C0034886
C0474975
C1384589
C2224485
C0026691
C0200512
C1417207
C0038363
C0019345
C0035854
C0224498
C2364135
C2322198
C0007452
C0229316
C0014527
C0149745
C1414304
C0152965

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

fluid analysis
much
painful mucosal
red plaques
incision site
Lateral femorotibial
scabs
Moyamoya disease
around both
resolution
Tubulovillous adenoma
sacroiliitis
Acute hepatitis
Locates
painful neuropathy
Bronchopulmonary
Aspergillosis
Schatzki ring
Alport syndrome
axillary swelling
Pneum
Road
red blotches
Subclinical
tuberculous meningitis
cryptorchidism
exit
team
Endomyocardial biopsy
Testicular hypofunction
Graves disease
concha bullosa
suspicious
cubital tunnel
bilat
paraesthesias
Nephrogenic
around joints
per your blood
Calcium pyrophosphate
arthropathy
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C0200648
C0205393
C0858804
C2126304
C0449681
C0447797
C0205204
C0026654
C2016899
C0300132
C0334307
C0574960
C0267797
C0450429
C1850383

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C2350530
C0267081
C1567741
C0741354
C0032285
C0442650
C0857199
C0205211
C0041318
C0010417
C0337094
C0871489
C0189785
C0271622
C0018213
C0339821
C0233519
C0230376
C0155516
C0030554
C0391869
C0394854
C0267596

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0856830 Diagnosing

eyebrow
Seronegative rheumatoid
arthritis
excisional biopsy
toenail infection
synovial hypertrophy
posterior tibiotalar joint
midfoot osteoarthritis
vascular abnormalities
Myoglobinuria
red vaginal
Exogenous
Sclerodactyly
osteitis
around site
hairy leukoplakia
Red River
redness or
pansystolic murmur
red papules
Chronic anxiety
tophi elbow
burden
detrusor instability
insuf
red stool
Atrophic
redness swelling
Pain scale
toenail injury
Systemic lupus
erythematosus
peat
numbness
Mole
around the facet
ileitis
lines along
satellite lesions
calcinosis
Hemorrhoid
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C0015420 Diagnosing
C0409652
C0184921
C0749565
C0410574
C2182275
C3840160
C0241657
C0027080
C0241635
C0205228
C0150988
C0029400
C0509447
C0206186
C0328125
C0327344
C0232258
C0859044
C0581386
C3862729
C2828008
C1261562
C0029626
C0278012
C0333641
C2109113
C1504479
C0347575

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0024141
C0030739
C0028643
C0027960
C0394850
C0020877
C2138577
C0445304
C0006663
C0019112

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

painful dysphagia
the epiglottis
Sjogren
redness later
Munchausen syndrome
double vision
99nitial arthritis
pain syn
callus
painful muscle spasms
red tinge
energy
aortitis
fever osteomyelitis
Red macules
staples
vision
Osteitis pubis
Migratory polyarthritis
Seizure gout alcoholism
acromioclavicular joint
arthritis
Acute asthma
bowel biopsy
hernia recurrence
Red raised patch
pain chronically
healed
Epigastic
around the vagus
radiocarpal joint
pain cramping
Axillary nerve
red brown
red blood inhis stool
or warm
Ehrlichiosis
Fever Antibody
Asplenia
fever hepatitis
orthopnea
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C2183443
C1396772
C1527336
C2127376
C0026785
C0012569
C3829814
C0016053
C0376154
C4023104
C3266636
C0424589
C0003509
C1443896
C2089446
C0185012
C0042789
C0221010
C0240344
C0586323

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C1998181
C0582415
C0192611
C0281961
C2674296
C0150055
C0043240
C3130255
C0842552
C0043265
C0458254
C0228885
C0381431
C0018932
C0509768
C0085399
C0373883
C0600031
C0424776
C0085619

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

Meniscal
vestibular nerve damage
labial biopsy
around the vulva
lichen sclerosis
painful vulvar
Around the ears
pseudotumor cerebri
painful mass
cadaveric
Dieulafoy lesion
Infective otitis externa
clonal
painful hemorrhoids
hyperresonant
red cell anisocytosis
red mass
pain hip
acute cystitis
redness increases
pain neck
her
punch biopsy
fever or any
chronic
otitis media
painful burning
these
spondyloarthropathy
Polymyalgia rheumatica
acute appendicitis
radiculopathy
Acromegaly
bacilli
Hepatopulmonary syndrome
osteogenesis imperfecta
red site
cheat
around lesion
flat
red hot
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C1504554
C0235928
C0399303
C3670692
C0023652
C0241718
C2053145
C0033845
C1709448
C0304209
C0341217
C0021355
C1704387
C0744805
C0231882
C0221278
C0086899
C0019559
C0149523
C1512696
C0007859
C0446375
C0184924
C0041466
C0205191
C0029882
C0234230
C0039828
C0949691
C0032533
C0085693
C0700594
C0001206
C0004587
C0600452
C0029434
C1504570
C0683305
C2168390
C0205324
C0541781

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

synovial biopsy
shave biopsy
under
interphalangeal joint
synovitis
pain intensity
pain tenderness
pain laterality
ophthalmoplegia
Prolapsed internal
hemorrhoids
chronic thrombocytopenia
Latent tuberculosis
around outside
Toxoplasmosis
around base
colloid
Red skin
Red Dye
osteomyelitic
Molluscum contagiosum
navel
Xerosis cutis
polyarthritis
Inclusion cyst
Acute otitis
sob
Bartholin cyst
Painful supination
fever break
fibrofatty
symphyseal
damage
pulsatile
desmoid tumor
pain diary
polish
strauss
redness accompanying
Footdrop
Migratory
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C0150887 Diagnosing
C0184923 Diagnosing
C0542339 Diagnosing
C0730096
C1320357
C0234233
C0740543
C0029089

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0265037
C0749393
C1609538
C3642088
C0040558
C1314395
C0009361
C0041834
C1509471
C0158381
C0026393
C0041638
C0263465
C0162323
C0259770
C0149510
C0010399
C0004767
C1998080
C0011311
C0225350
C0034015
C0010957
C0439606
C0079218
C0451366
C0220896
C0008728
C2029700
C0085684
C0232901

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

hypoadrenal
cardiac cachexia
Pigmented gallstones
red blanching
Acute gout wrist
any blood
Cardiac
debris
polyarteritis nodosa
tegmen tympani
Painful orthopedic
snoring
around incision
hallux malleus
Submucosal
Prostate biopsy
vascular
sarcoid
painful bone
detrusor weakness
Vascular anomaly
Enterovirus
fever sweats
red blood cell morphology
spread
Quadriparesis
fever cough
warts
Acute bronchiolitis
Nonalcoholic steatohepatitis
quadrantanopsia
ILD
thymic hyperplasia
inflammation
arsenic
pain jaw
DMI
red mucosa
within the
pain AC joint arthritis
red discoloration
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C0001623
C0562491
C3278865
C2126289
C0750439
C0373612
C0018787
C0440266
C0031036
C0927520
C1393396
C0037384
C2055676
C2355596
C1515025
C0194804
C0042382
C0036202
C0151825
C0235091
C0158570
C0014383
C0038992
C0200655
C0332261
C0270790
C1277295
C0347390
C0001311
C3241937
C0544680
C0206062
C0040115
C0021368
C0104238
C0236000
C0011685
C3277147
C0425538
C4256999
C2054394

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

more
chemosis
carpal arthritis
Mt
joint discomfort
gouty joint
Myelofibrosis
around the ulcers
bloating
hardware
pain leg
porphyria cutanea tarda
Mosquito bites
NM
instep
degenerative
spondylolisthesis
Sacrococcygeal
Red nasal
painful site
hyoid bone
infrapatellar
midline
margins
Broca dysphasia
painful red
kinetic
Chronic hypokalemia
hallux
tingling
Polydypsia
Antiphospholipid antibody
syndrome
Cryptococcal Meningitis
redness erythema
Streptococcal
Pulmonary cryptococcus
IBD
chondrosarcoma
mutation analysis
arachnoiditis chronic
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C0205172
C0271298
C0741990
C0036525
C3544124
C3697115
C0026987
C0857313
C1291077
C1523994
C0023222
C0162566
C0417744
C0203634
C0230472

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0264184
C1550300
C2071372
C1718183
C0020417
C0224829
C0549183
C0205284
C0003550
C0853395
C0022702
C0268016
C0018534
C2242996
C0085602

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0085278
C0085436
C0497364
C0038402
C0748116
C0021390
C0008479
C0796357
C0238005

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

toenail bruise
chronic hematoma
Coccygeal
toenail abnormalities
radiographic compression
interphalangeal joint
arthroplasty
Spigelian hernia repair
Spigelian
pulmonary biopsy
Axillary abscess
Acute psychosis
painful lesion
adb
utd
orthopedic screws
orthopedic hardware
painful within the bone
issues
urticaria pigmentosa
cores
Pyoderma gangrenosum
solitary
Dual energy
Staghorn calculus
BPPV
red cell aplasia
Waldenstrom
macroglobulinemia
MDD
Gastric antral biopsy
arrythmias
Wegeners granulomatosis
Rectocele repair
Acute Esophagitis
Takayasu
around transplanted
Phthisis bulbi
Gliomatosis cerebri
panus
Phrenic nerve palsy
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C0274239
C0749095
C1550233
C1968817
C0180058

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0187577
C0198555
C0392508
C3806336
C0263115
C0281774
C0241091
C0236504
C3845665
C3826642
C1961571
C2219991
C0033213
C0042111
C0444669
C0085652
C0205171
C0085736
C0333014
C0155502
C0034902

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C0024419
C0262218
C0586699
C0003811
C3495801
C0677487
C0149882
C0039263
C2220728
C0271007
C0334576
C1093286
C1442879

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

pain postoperatively
glans
Pilonidal disease
red erythematous
pancreatis
pain hematuria
Pulmonary embolus
Solar damage
Chronic joint discomfort
just
pain discomfort
sinusitis
CF
red spot
pain knee
pain stimulator
CMC
red blood scan
around suprascapular
tophi finger
Menometrorrhagia
hue
acute arthritis
Tinnitus
chord
PTLD
painful pop
hallux interphalangeal
diagnostic biopsy
Eisenmenger syndrome
Streptococcal bacteremia
psych
radiocapitellar
Kaposi sarcoma
patellofemoral compartment
osteoarthritis
chondrocalcinosis
painful arthritis
pessary
Aseptic meningitis
painful bleed
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C0030201
C1550261
C2317114
C3845932
C0227579
C0473234
C0034065
C0850866
C0232491
C0442728
C0237277
C0037199
C0010674
C0376341
C0231749
C1709449
C0065772
C0948706
C0842558
C2088173
C0232943
C0678581
C0263678
C0040264
C0344749
C0432487
C4038661
C0447828
C0401747
C0013743
C0152964
C0229992
C1403299
C0036220

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

C1542808
C0553730
C0718667
C0031246
C0025290
C1533092

Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing
Diagnosing

Pagets disease
blood flow

C0028156
C0591139
C0699142
C0876060
C0749139
C0700899
C0243237
C3516158
C0209368
C1995848
C1692318
C0728963
C0286677
C2945755
C0678143
C0585361
C0038317
C0161672
C0022957
C0060926
C1636686
C3224278
C0085240
C0875967
C0003232
C0085758
C0002598
C2683919

Medication
NITROFURANTOIN
Bactrim
Tylenol
keppra
sulfa

C1368019 Diagnosing
C0232338 Diagnosing

Other

Screening
obese
Screening
diabetes
Screening
Kidney Disease
Screening
drink
Screening Family history of Cancer
Family history of
Benadryl
Screening
Cardiomyopathy
Docusate sodium
Screening
hyperuricemia
Kidney Medicine
Screening
Lupus
Mycophenolate mofetil Screening
hypoparathyroidism
Flunisolide nostril
inhaler
Screening
diabetic neuropathy
Docusate
Screening
Hypoxemia
lovenox
Screening
osteoarthritis
Family history of
Flonase
Screening
Tuberculosis
Flonase spray
Screening
Family history of
Zithromax
Screening
Breast cancer
Family history of
bid
Screening
Hypercholesterolemia
Family history of
steroid
Screening
Hypertension
Family history of
Yellow fever vaccine Screening
Emphysema
Family history of Heart
Lactulose
Screening
Disease
Gabapentin
Screening
Sinusitis
Byetta
Screening
tuberculosis
Family history of Lung
Benadryl pill
Screening
Cancer
Lupus anticoagulant Screening
rhinorrhea
Avandia
Screening
Groin discomfort
Antibiotics
Screening
Sad
family history of breast
Tca
Screening
cancer
amiodarone
Screening Family history of asthma
Family history of
Byetta pen
Screening
rheumatoid arthritis
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C0028754
C0011847
C0022658
C0684271
C0260515

Screening
Screening
Screening
Screening
Screening

C1272241
C0740394
C0024131
C0020626

Screening
Screening
Screening
Screening

C0011882 Screening
C0700292 Screening
C0029408 Screening
C0455351 Screening
C0015584 Screening
C0006142 Screening
C2732832 Screening
C0455405 Screening
C2315858 Screening
C2186266 Screening
C0037199 Screening
C0041296 Screening
C0728711
C1260880
C1096590
C0085159

Screening
Screening
Screening
Screening

C0559119 Screening
C1261327 Screening
C0221614 Screening

C0016365

fluoxetine

C1319409

diabetic medicines

C3214596

flecainide pill

C3230437

diabetes pill

Screening

Prostate cancer
Family history of Alcohol
Screening
Abuse
Family history of
Screening
Depression
Family history of thyroid
Screening
disease
Family history of
Osteoarthritis
PRN
hemochromatosis
hemochromatosis gene
during the night
Family history of
polycystic
warm
drinking alcohol
Kidney
family history of kidney
cancer
Fibromyalgia
Family history of
hyperlipidemia
Dyspepsia
Family history of Gout
family history of prostate
cancer
gout
Family history of
Arthritis
Family history of prostate
cancer nephrolithiasis
Hypertensive
cecal
history of Hemodialysis
Family history of Alcohol
addiction
Osteoarthritis of
glenohumeral
Quant
family history of renal
disease
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C0376358 Screening
C0476560 Screening
C0455383 Screening
C0850707 Screening
C0455444
C0558288
C0018995
C1384665
C3845370

Screening
Screening
Screening
Screening
Screening

C0455422
C0687712
C0001948
C0022646

Screening
Screening
Screening
Screening

C0700102 Screening
C0016053 Screening
C4040131 Screening
C0013395 Screening
C0221613 Screening
C1532320 Screening
C0018099 Screening
C0221565 Screening
C1563033
C0020538
C0007531
C4047993

Screening
Screening
Screening
Screening

C3541869 Screening
C0409939 Screening
C0695050 Screening
C2316874 Screening

Family history of
Multiple Sclerosis
Family history of Colon
Cancer
Family history
Kidney Surgery
diabetes management
denies
diabetes complications
drink some juice
after transplant
diabetes disease
Diabetes History
intertrochanteric femur
fracture
hypogammaglobulinemia
family history of
dementia
history of cerebrovascular
accident
Family history of
cataracts
Family history of Brain
Cancer
family history of urologic
diabetic exam
diabetic gastroparesis
history of CABG
Family history of Liver
Cancer
Unspecified
hyperthyroidism
Family history of
Alcoholism
family history of
aneurysm
CAMPYLOBACTER
diabetes insipidus
numbness big toe
genetic factors
Family history of Anxiety
Anxiety disorder
kidney cancer
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C0455388 Screening
C0730200
C0241889
C0194053
C0150544
C0332319
C0342257
C2136335
C3896643
C0085207
C0455678

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0162385 Screening
C0086438 Screening
C2315857 Screening
C0559159 Screening
C0455398 Screening
C1997137
C0455360
C3162295
C0267176
C1842251

Screening
Screening
Screening
Screening
Screening

C1998287 Screening
C0205370 Screening
C0020550 Screening
C0559555 Screening
C1271046
C0006813
C0011848
C0587056
C0814299
C4061647
C0003469
C0740457

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

YERSINIA
Family history of HIV
Sickle cell disease
Sickle cell trait
Debility
Hypoalbuminemia
etoh
Family history of
Cerebral Palsy
after surgery
Diabetic ulcer of toe
diabetic socks
diabetic enteropathy
Diabetes check
dysuria
Skin warm
Family history of
Leukemia
diabetic retinopathy
family history of liver
disease
too
Family history of anemia
history of Brain tumor
Family history of cardiac
Gluteal
serious
neoplasm uncertain
behavior
lightheadedness
Mold
Osteoarthritis of knee
diabetic nephropathy
Axillary
Hypophosphatemia
Cytomegalovirus viremia
cytomegalovirus disease
Diabetic polyneuropathy
polyneuropathy
diabetic autonomic
Diabetic Hypoglycemia
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C0043405
C2584882
C0002895
C0037054
C3714552
C0239981
C0001962

Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0455391
C0241311
C2183144
C3876752
C0400875
C1655734
C0013428
C0235218

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0260512 Screening
C0011884 Screening
C0455417
C0067954
C0260528
C1997047
C3669347
C1550262
C0205404

Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0154129
C0220870
C0369241
C0409959
C0011881
C0004454
C0085682
C0877635
C0010823
C0271680
C0152025
C0271686
C0865166

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

Family history of
Hepatitis
Family history of
Pulmonary Disease
Diabetic peripheral
neuropathy
history of Pneumonia
diabetic eye
Kidney injury
Acetone
Family history of
Glaucoma
history of Diphtheria
Gastric bypass surgery
obesity history
Family history of kidney
disease
Hiccups
tingling
sarcoid
Stump
Family history of Bladder
Cancer
campylobacter ab
Campylobacter Jejuni
odynophagia
Neoplasm
Family history of
Cervical Cancer
Diabetic foot
Family history of
Coronary Arteriosclerosis
Kidney lesion
history of Heart problem
Family history of Hernia
kidney disease requiring
Hydrocele repair
diabetes post
Family history of
Alzheimer Disease
Kidney calculi
Orthopedic surgery
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C0559141 Screening
C3887084 Screening
C0740447
C0455542
C0342245
C0160420
C0001002

Screening
Screening
Screening
Screening
Screening

C0455397
C1446286
C0192398
C0455493

Screening
Screening
Screening
Screening

C0260532
C0019521
C2242996
C0036202
C0002690

Screening
Screening
Screening
Screening
Screening

C2316064
C0945898
C0006819
C0221150
C0027651

Screening
Screening
Screening
Screening
Screening

C1997259 Screening
C0206172 Screening
C2317524
C1402288
C0559157
C3887151
C1719537
C0558336
C1504532

Screening
Screening
Screening
Screening
Screening
Screening
Screening

C1271045 Screening
C0022650 Screening
C0162439 Screening

drink water
Family history of
Cirrhosis
Murder
Constipation
Family history of
Gallbladder Disease
Family history of Skin
Cancer
Family history of macular
degeneration
Hypocalcemia
family history of blood
after menopause
Family history of
Hypercalcemia
Family history of
Hyperparathyroidism
diabetic shoes
Discitis
Family history of
malignant neoplasm
Menieres disease
Appendicitis
hyperventilation
kidney disease or
scarlet fever
Neurogenic bladder
radiculopathy
Labial abscess
Family history of Throat
cancer
Family history of
migraine
Family history of celiac
Diabetic ulcer
history of Deceased
drink water to
axillary lymphadenopathy
drink liquor
Family history of
Hypothyroidism
base of the
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C0599638 Screening
C3887082 Screening
C0086660 Screening
C0009806 Screening
C0559142 Screening
C1997275 Screening
C0520726
C0020598
C0455376
C0587113

Screening
Screening
Screening
Screening

C0342637 Screening
C3887070 Screening
C0499344 Screening
C0012624 Screening
C1261378
C0025281
C0003615
C0020578
C0543793
C0036285
C0005697
C0700594
C0745601

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C3887008 Screening
C0455393
C2316251
C0743150
C2229976
C0522749
C0578735
C0425331

Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0577643 Screening
C0225810 Screening

Diabetic foot ulcer
again
at night
Dry cough
osteoarthritis of the hip
Family history of
Hyperthyroidism
Accidental Drowning
soda
diabetic ketoacidosis
Family history of
Ischemic stroke
Family history of
Pulmonary Embolism
Dry mouth
granulomatosis disease
Osteoarthritis bilateral
Umbilical
history of Gunshot
Wound
history of Hysterectomy
Apathetic
Osteopetrosis
Family history of
Parkinson Disease
Family history of Thyroid
Cancer
after working
Vitiligo
Family history of
Essential
Hypertriglyceridemia
Family history of
Osteoporosis
Diabetes type
hypoglycemia
Family history of obesity
habitus
Family history of
Pulmonary Fibrosis
Colorectal cancer staging
after urination
Incontinence
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C0406526
C0723612
C0240526
C0850149
C0029410

Screening
Screening
Screening
Screening
Screening

C2317124
C0867949
C0683086
C0011880

Screening
Screening
Screening
Screening

C0260518 Screening
C2317597
C0043352
C0024307
C4081953
C0041638

Screening
Screening
Screening
Screening
Screening

C2169624
C0438065
C0085632
C0029454

Screening
Screening
Screening
Screening

C0574092 Screening
C2316063 Screening
C0425088 Screening
C0042900 Screening

C0559122 Screening
C2911643
C1320657
C0020615
C0455373
C0013170

Screening
Screening
Screening
Screening
Screening

C1800706
C0677947
C1821649
C0021167

Screening
Screening
Screening
Screening

Lymphedema of leg
family history of early
drink sugar
Family history of
Multiple Myeloma
Family history of Simple
Goiter
persistent fever
family history of
autoimmune disease
history of Metastatic
Cancer
history of Bradycardia
nights sweats
hemoptysis
Family history of
Hydrocephalus
Fungus
after fall
diabetic on
diabetic peripheral
SLE
bursitis
diabetes hypertension
neuropathic pains
Metabolic bone disease
Family history of
Polycythemia Vera
Family history of
Migraine Headache
nephrosclerosis
made
fibroids
Nonalcoholic
Steatohepatitis
Family history of
bleeding
atherosclerosis
bipolar disease
ataxia
history of Adopted child
Diabetic macular
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C1275454 Screening
C0455427 Screening
C0452443 Screening
C2317109 Screening
C2186265 Screening
C0476474 Screening
C0577642 Screening
C2170476
C4038788
C0028081
C0019079

Screening
Screening
Screening
Screening

C4038808
C0016832
C2135413
C0421248
C0011871
C0024141
C0006444
C0543574
C3714625
C0005944

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C1264016 Screening
C2367596
C0027719
C0425087
C0023267

Screening
Screening
Screening
Screening

C3241937 Screening
C2186261
C0004153
C0005587
C0004134
C2367303
C0730285

Screening
Screening
Screening
Screening
Screening
Screening

AAA
Recurrent UTI
history of Dialysis
family history of
colorectal cancers
diabetic injury
Family history of
Supranuclear palsy
family history of sleep
drink much
history of Arteritis
Dyslipidemia
microalbuminuria
Family history of
Pancreatic
Family history of Allergy
Family history of
Paranoid Schizophrenia
Diabetic diet
infraclavicular
lymphadenopathy
Migraine headache
nutritionist
high fever
gastroesophageal reflux
disease
history of
Adenocarcinoma
blood clots in
Family history of
Congenital abnormality
diabetes other
Family history of bipolar
amyloidosis
Family history of kidney
approximately
Family history of
Melanoma
Acne vulgaris
Family history of Gastric
Ulcer
Attacks are
coryza
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C0162871 Screening
C0262655 Screening
C0455667 Screening
C3266797 Screening
C3875503 Screening
C2931887
C2315516
C0848500
C3532493
C0242339
C0730345

Screening
Screening
Screening
Screening
Screening
Screening

C1997382 Screening
C0455453 Screening
C0455382 Screening
C0011878 Screening
C1264066
C0149931
C0237083
C0743973

Screening
Screening
Screening
Screening

C0017168 Screening
C1997170 Screening
C0423010 Screening
C0496711
C0011870
C0455384
C0002726
C1397162
C0332232

Screening
Screening
Screening
Screening
Screening
Screening

C1996990 Screening
C0001144 Screening
C0559140 Screening
C2751362 Screening
C0086066 Screening

sarcoid disease
Lupus nephritis
nephritis
Lymphedema of arm
Family history of Peptic
Ulcer
Family history of Hearing
history of macular
Kidney transplant
Family history of Smoker
waist
kidney atrophy
Neuropathic
diabetic amyotrophy
Strabismus Surgery
drink alcohol occasionally
Aneuric
Family history of Mental
Family history of Thyroid
Family history of
Epilepsy
arthropathy
trended
any fevers
Ureteral
intense
nonobstructing
Headaches
hemoperitoneum
family history of
headache
history of Tachycardia
Family history of
Esophageal Reflux
Acne
diabetic dietary
family history of
endocrine disease
Kidney mass
Family history of Breast
Cyst
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C0340432
C0024143
C0027697
C0730207

Screening
Screening
Screening
Screening

C0455415
C0260538
C3839192
C0022671
C1542099
C0230097
C0341698
C0003892
C0271685
C0197981
C0556298
C0049161
C1397167
C0455366

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0455392
C0022408
C1521798
C0041466
C0041959
C0522510
C0264787
C0018681
C0019065

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C2316204 Screening
C3887026 Screening
C3494804 Screening
C0702166 Screening
C0562216 Screening
C0455365 Screening
C0262613 Screening
C2315879 Screening

bruising or other
abnormalities
Osteoarthritis hands
Celiac Crisis
history of Aplastic
Anemia
diabetic clinic
hypertensive
nephrosclerosis
Osteoarthritis of ankle
Family history of
Atherosclerosis
perforated diverticulitis
wound healing
salmonella enteritis
Meningioma
Family history of
Psoriasis
Txp
umbilical hernia repair
diabetic neuropathic
kidney disease III
Prediabetes
Cellulitis
hepatocellular disease
Bronchitis
Family history of
Rheumatic Fever
CRC
diabetes in
obesity complicates
Pituitary adenoma
Family history of
Essential
Hypercholesterolemia
Family history of Oxygen
deficit
Chromhidrosis
Family history of
Psoriatic
keratoconus
after
Dysplastic nevus
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C0679314 Screening
C0263746 Screening
C1300681 Screening
C1997103 Screening
C3839636 Screening
C0264657 Screening
C0409931 Screening
C0455407
C0544794
C0043240
C0036114
C0025286

Screening
Screening
Screening
Screening
Screening

C0455439
C1134470
C0019333
C0343178
C1868148
C0362046
C0007642
C0023895
C0006277

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C2315907
C0170127
C0032969
C3647716
C0032000

Screening
Screening
Screening
Screening
Screening

C0020445 Screening
C2316880 Screening
C0263473 Screening
C2315905
C0022578
C0231290
C0205748

Screening
Screening
Screening
Screening

Family history of
Accidental death
Family history of Ulcer
Kidney tumor
obesity nutrition
Alzheimer disease
kidney disease stage
Family history of
Malignant Lymphoma
sickle cell
diabetic agents
chest discomfort
lupus arthritis
perirectal abscess
Family history of
Cerebral
nephrocalcinosis
barrier laser
Gastroenteritis
diabetic control
Dyspnea
bm
Family history of Blood
infection
MELAS
family history of
parathyroid
hyponatremia
kidney hydronephrosis
Gallstone pancreatitis
airway disease
occasional
Hypocalcemia and
hypophosphatemia
radiofrequency
adhesions
fever
278
Family history of
systemic lupus
much
MRSA
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C0425043
C0574097
C0022665
C1408387
C0002395
C0022661

Screening
Screening
Screening
Screening
Screening
Screening

C2315022
C0221283
C0935929
C0235710
C0541786
C0267566

Screening
Screening
Screening
Screening
Screening
Screening

C2584725
C0027709
C0302718
C0017160
C0421257
C0013404
C0011135

Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0554872 Screening
C0162671 Screening
C1840403
C0020625
C1385560
C0521614
C0699949
C0521114

Screening
Screening
Screening
Screening
Screening
Screening

C0475815
C2347883
C0001511
C0015967
C0075763

Screening
Screening
Screening
Screening
Screening

C3887087 Screening
C0205393 Screening
C1265292 Screening

Family history of
Hyperlipoproteinemia
Family history of colonic
polyps
Old age
obese weight
Saturday night
better
Family history of
deafness
Family history of
Parkinsonism
Toxic
Breast discomfort
osteoarthritis in multiple
become
history of testicular
NASH
Cirrhosis
posttraumatic
hernia repair
diabetes poorly
Family history of
Hodgkin Disease
tophaceous
ketoacidosis
history of Opioid abuse
speech
Family history of
Backache
genetic abnormalities
Kidney transplant
complication
Chlamydia DNA PCR
during night
Meningitis
regimen
history of Current Smoker
history of Abdominal
hernia
family history of other
smoldering
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C0700623 Screening
C2911243
C1999167
C0740216
C0270796
C0332272

Screening
Screening
Screening
Screening
Screening

C1442747 Screening
C2939151
C0600688
C0877338
C0559096
C0429569
C1960622
C1092184
C0023890
C0152086
C0019328
C0554876

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C2316879
C0744466
C0220982
C3266352
C0037817

Screening
Screening
Screening
Screening
Screening

C2316195 Screening
C0262496 Screening
C1261281
C1315245
C0231912
C0025285
C0040808
C3241966

Screening
Screening
Screening
Screening
Screening
Screening

C0455548 Screening
C0260535 Screening
C0002894 Screening

Overweight
Calcitonin
callouses
Family history of
Osteopenia
Acute myopericarditis
Yersinia antibodies
ehrlichiosis
after lunch
Cryptogenic cirrhosis
twisting
diabetic cheiroarthropathy
Drinks alcohol on rare
Family history of Seizure
Kidney damage
hematuria
history of Seasonal
allergies
Lupus cerebritis
lupus erythematous
Family history of Airway
Gall
hepatocellular cancer
rheumatoid arthritis
Kidney hematoma
Mucositis
myeloma
lupus erythematosus
morbid
HLD
Family history of CAD
parotitis
Family history of Bone
dental abnormalities
hyperplasia of breast
IBD
Hernia surgery
Family history of autism
family history of
disorders
COPD
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C0497406 Screening
C0006668 Screening
C3841385 Screening
C2315253
C0265132
C0523287
C0085399
C1879668
C0267809
C0231467
C0406685
C0425316
C3267207
C1408258
C0018965

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C2106658
C0393968
C0155180
C3887086
C2700230
C0345904
C0003873
C0475022
C0333355
C0026764
C0409974
C0026538
C0020473
C0329472
C0030583
C1997149
C0262444
C0542028
C0021390
C3826215
C1445919

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0559550 Screening
C0024117 Screening

Family history of
Diverticulitis
Meniscus repair
Family history of Alcohol
dependence
Kidney cyst
Rheumatoid arteritis
Campylobacter enteritis
subj
Family history of
myocardial infarction
history of hypoglycemia
abnormalities are
sinusitis disease
uveitis
Cornea clear
vomit
Family history of Tongue
Neoplasm
beam radiation
overuse
dizzyness
history of Mesothelioma
Family history of Colitis
Family history of
Megaloblastic Anemia
Diabetic toe
kidney disease in
neuropthy
Neoplasm of fibula
angioedema
over
history of Primary
hyperparathyroidism
390
drink more
staph
Family history of suicide
Campylobacter in stool
hernia repair mesh repair
for rheumatoid arthritis
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C2315926 Screening
C0407887 Screening
C2911218
C3887499
C0264993
C0275982
C3889670

Screening
Screening
Screening
Screening
Screening

C0455406
C4039056
C3277173
C0015029
C0042164
C1849214
C0042963

Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0573984
C3846444
C0035127
C0012833
C1997977
C0455416

Screening
Screening
Screening
Screening
Screening
Screening

C1306856
C0476266
C3824723
C0155302
C0347341
C0002994
C0020505

Screening
Screening
Screening
Screening
Screening
Screening
Screening

C4040208
C0054370
C3842894
C0038160
C0455386
C2020393
C0519122
C0260963

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

Family history of
Ichthyosis
history of
gastroesophageal reflux
vasculitis
Kidney initial
family history gastric
cancer
Osteoarthritis of foot
Diverticulosis
drink second bottle
bursa
Diarrhea much
Thrombocytopenia
worse
BOOP
organizing pneumonia
history of retinal
detachment
neurogenic claudication
granulomatous
lymphadenitis
Gluteal cellulitis
Ampullary adenoma
COPD bronchitis
diabetic
glomerulosclerosis
gastroparesis
hypochloremia
history of Adrenal
Family history of
Hypolipidemia
history of Morbid
Strabismus
snoring
Family history of Bowel
cancer
Family history of
Peripheral neuropathy
Schizoaffective disorder
history of
Hypernephroma
diaphragmatic
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C4012361 Screening
C4039982 Screening
C0042384 Screening
C2839534 Screening
C1708349
C0586735
C1510475
C2193544
C0006441
C4084784
C0040034
C0332271
C0242770
C0264383

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0455516 Screening
C0580173 Screening
C1960596
C0263158
C1332244
C0742809

Screening
Screening
Screening
Screening

C0017667
C0152020
C0085680
C4039586

Screening
Screening
Screening
Screening

C1857970
C3510286
C0038379
C0037384

Screening
Screening
Screening
Screening

C0559117 Screening
C2316926 Screening
C0036337 Screening
C4047637 Screening
C0011980 Screening

Family history of alpha
family history as
Shigella
his
Drinking warm
lymphomatous
Healthy adult
Flaring
Family history of
Bronchiectasis
Gastric cancer
workup
history of Polymyalgia
rheumatica
history of Amblyopia
umbilical hernias
diabetic lotion
Fibrocystic breast
cherry juice
Diabetes type II
MT second toe
diabetes are
diabetes as
neoplasm of bone
lupus membranous
Paget disease of bone
diabetes monitoring
family history of tremor
base of the thumb
Falls frequently
avid
Necrotizing
history of Hemorrhage
Calcaneus fracture
transplant recipient
osteoporosis
may also
Osteoarthritis of lumbar
spine
lipo
base of the second toe
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C4038806
C0514034
C0036953
C0019602
C1737350
C0024299
C0686750
C1517205

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C4231142 Screening
C0024623 Screening
C0741889 Screening
C3532608
C1272091
C0019322
C1169242
C0016034
C0982074
C0011860
C0085686
C3829804
C0375127
C0005967
C0268758
C0029401
C0422587
C2317094
C2016583
C0850703
C1510996
C0027540
C0475171
C0281926
C0376387
C0029456
C2678291

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C1442869 Screening
C1333906 Screening
C0224049 Screening

Sad affect
orthotic shoes
Mouth droop
diabetes under
Family history of cardiac
disorder
cornea cornea
wheezing worse at night
discoid lupus
half
Pseudoxanthoma
elasticum
Scleredema
Alport
Bilateral breast cancer
Seronegative rheumatoid
arthritis
Quadriplegia
Obesity hypoventilation
syndrome
psychosis
Hypoglycemia rarely
Family history of
Polycythemia
family history of
cardiovascular disease
history of Vulva cancer
Axillary abscess
incisions well healed
Headaches are occipital
Yersinia enterocolitica
Amyloid
Bronchiolitis
obliterans
Narcotic addiction
base of the ulcer
Dermatolysis
nasal drainage
Pericarditis
diabetic strips
Functional Murmur
Diabetes per
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C2219477
C3688926
C2237286
C2062378

Screening
Screening
Screening
Screening

C0559128
C0010031
C2203206
C0024138
C2825407

Screening
Screening
Screening
Screening
Screening

C0033847
C0036413
C1567741
C0281267

Screening
Screening
Screening
Screening

C0409652 Screening
C0034372 Screening
C0031880 Screening
C0033975 Screening
C4227725 Screening
C3887075 Screening
C0455404
C1997152
C0263115
C2116737
C0231613
C0043406
C0002716
C0006271
C0040021
C1527402
C2171457
C0010495
C0746759
C0031046
C0462900
C0232255
C3171765

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

Solitary
Hodgkin disease
Family history of
congestive
Family history of
hypertrophic
GvHD
working
diabetic dilated retinal
after removal
neoplasm of prostate
Necrotizing pancreatitis
drink fluids
history of appendicitis
gastric bypass
Family history of Urinary
problem
Family history of Black
lung
osteoarthritis history
Kidney problems
family history of atopy
inguinal hernia repair
smoker
diabetes test
diabetes uncontrolled
Family history of Breast
Neoplasm
diabetes to
after sex
endorses
Phrenic nerve palsy
lymphedema
lemonade
Intracerebral bleed
possible
guides
history of Heat stroke
hepatocellular carcinoma
intense pain
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C0205171 Screening
C0019829 Screening
C2315232 Screening
C0949658
C0018133
C0043227
C1314526
C0372646
C0154009
C0267941
C0426597
C0455547
C0017125

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0424960 Screening
C0574101
C0455572
C0812426
C0455457
C0021446
C0337664
C0438272
C2349362

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0455356
C0730232
C2126184
C0680918
C1442879
C0024236
C0452446
C2937358
C0332149
C0181090
C3887136
C2239176
C1320357

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

Family history of
Congenital
Malformations
Meningitis booster
Carcinoid tumor
drink coke
Blastomycosis
Diabetic Arthropathy
Family history of
Sarcoidosis
hyperhomocysteinemia
Paronychia of toe
disease deceased
Sinusitis acute
Family history of
Duodenal
history of Accidental fall
Hypervolemia
diabetic dermopathy
history of some
pulmonary sarcoid
quiet
will also be
reports
Uremia
Midline incision
Kaposi sarcoma
malaise
night shift
hypodensities
Moyamoya disease
Family history of
Nephropathy
Miracle
cites

Medication
take
C2054168
NSAIDS Preparing

C1261329
C3839177
C0007095
C0452444
C0005716
C0494909

Screening
Screening
Screening
Screening
Screening
Screening

C2317266
C0598608
C0311211
C0747268
C0149512

Screening
Screening
Screening
Screening
Screening

C0559139
C2242910
C0546817
C0406682
C3645919
C0340199
C0439654
C0425262
C0700287
C0041948
C0456276
C0036220
C0231218
C1660631
C0742093
C0026654

Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening
Screening

C0403443 Screening
C0996776 Screening
C1264695 Screening

Other
Kidney
DISSOLVE
red meat
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C0022646
C1549535
C0452848

Preparing
Preparing
Preparing

red blisters
blood
thinners
txp
red
break down
came
down
disfunction
red streaks
incidentalom
a
trx
blood
take down
do
dissection
sauce
damge
red violet
shut down
went
kidney dis
kidney down
insufficency
kidney diseas

C0038317
C0009262
C0030049
C0728755
C0445550
C0002645
C0003211
C0012373
C0027415
C3889572
C0728963
C1261311

Medication
steroids
Colchicine
Oxycodone
Dilaudid
low doses
Amoxicillin
NSAID
Diltiazem
narcotics
10mg dose
Lovenox
steroid injection

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
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C2126355

Preparing

C0003280
C1134470
C0332575
C0443161
C0960273
C0205104
C0005887
C2169832

Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing

C2609247
C1336690
C0005767
C0189301
C1512020
C0012737
C0453357
C0525773
C0763107
C1547200
C0796199
C0022658
C0194182
C0349073
C0431705

Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing
Preparing

Other
infection
C0439663
swelling
C0038999
serous effusion
C0302149
inflammation
C0021368
Chronic
C0205191
kidney injury
C0160420
weight gain
C0043094
Urinary tract infection
C0042029
weight loss
C1262477
Bowel sounds
C0232693
ulceration
C0041582
Pulmonary fibrosis
C0034069

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0700926

Ancef
Monitoring
ENTEROCOCCAL
C0851881
INFECTIONS
Monitoring
C0007561
Ceftriaxone
Monitoring
C0699129

coumadin

Monitoring

C0542867
C0360714
C0876068
C1962522
C0585077

60mg
statin
lidoderm
Amlodipine as
steroid dose

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0699177
C0700899
C0332173

Monitoring
Monitoring
Monitoring

C3656735
C0004259
C0719198
C0014563
C0242402
C0376196
C1851351
C0305814
C0002598

Plaquenil
Benadryl
qd
Amlodipine
induced
Atropine
Celebrex
Epinephrine
opioid
opiate
Colchicine not
debrox drops
amiodarone

C0022860
C0366521
C0701009
C0149783
C0875968
C2064827
C1547581
C1098080
C0006625
C3667576
C3663261

labetalol
labetalol dose
bumex
steroid therapy
Avelox
steroid topical
as needed
Crestor
cachexia
steroid spray
steroid ointment

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0040610

tramadol

Monitoring

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
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chronic obstructive
pulmonary
hypersensitivity
pneumonitis
Peripheral vascular disease
Staphylococcus Aureus
Infection
Increased risk for
pancreatitis
Chronic alcohol
CHRONIC CHEST
heart disease
delayed recall
Escherichia coli urinary
tract infection
immunosuppressive
Ibs
chronic infection
Wound infection
stone
encouraging weight
Chronic back
Renal stones
unintentional weight loss
chronic renal
gout flares
chronic pulmonary
embolism
gout attack
Abnormal weight loss
Nonpitting edema
Allergic rhinitis
respiratory infections
Chronic migraine
hemisensory loss
chronic cough
weight
cold intolerance
chronic were kidney
disease

C0024117 Monitoring
C0002390 Monitoring
C0085096 Monitoring
C1318973 Monitoring
C1842408
C0001973
C1740831
C0018799
C0561757

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0577708 Monitoring
C0021079 Monitoring
C0022104 Monitoring
C0151317
C0043241
C0006736
C2958424
C0457949
C0022650
C2363736
C0022661
C1619733

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0856722
C2712871
C0936227
C1265804
C2607914
C0035243
C1960870
C0234216
C0010201
C0043100
C0009269

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1561643 Monitoring

C2723026
C0051696
C0085826
C4257295
C0014025
C0394853
C0147814
C0020933
C0981221
C1619735
C0036557
C1652084
C0585361
C0020740
C0591139
C0807726
C0876060
C0586794

steroid topical
creams
Amlodipine
antiplatelet agents
fluticasone nasal
spray
Enalapril
steroid inj
Unasyn
imipenem
atropine drops
decreasing dose
sedatives
Flunisolide nasal
spray
bid
Ibuprofen
bactrim
refills
Keppra
steroids not

C0699992
lasix
C0366596 oxycodone dosing
C1702177
Januvia
C2985380
steroid creams
C0593507
advil
C1880956 such high doses
C2065041 steroid inhalers
C2925914 began after taking
C0700798
Indocin
C0366345 amiodarone doses
C0633854
Fioricet
C0376414
Paxil
C0015399
eyedrops
C0584668
stopped taking
C0250482
Zosyn
C0939412
novolog
NSAIDs while
C2054168
taking
C0040341
Tobramycin
C0663448
viagra

Monitoring
Monitoring
Monitoring

Chronic anemia
Chronic rhinitis
gout

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

count
risk for infection
heart attack
chronic anticoagulation
seafood
thrush
Candida under the breast
unexplained weight loss

C0750480
C0582147
C0027051
C0694554
C0206208
C0006849
C0741706
C1828173

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2116737
C0086769
C0024141
C0227759
C0041667
C0563556
C2126067

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Incision well healed
panic attacks
systemic lupus
labia
Low weight
Not doing weight bearing
recent weight loss
pneumothorax or
pulmonary
immune liver disease
infection of skin
pulmonary infections
bearing weight
chronic knee
chronic disease
renal cysts
pseudogout
allergic reaction
Umbilical hernia repair
Kidney or Liver
chronic pancreatitis
caffeine intake
Breast
BCC

C0810019
C0021053
C0162627
C0876973
C0085086
C0451820
C0008679
C0268800
C0033802
C0020517
C0019333
C0545792
C0149521
C4062719
C0006141
C0152320

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Monitoring
Monitoring
Monitoring

Vaccine reaction
obstructing stones
prostate cancer
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C0581384 Monitoring
C0008711 Monitoring
C0018099 Monitoring

C0565653 Monitoring
C0940751 Monitoring
C0376358 Monitoring

C0716467
C0054836
C0032825
C0570232
C1707810
C0366557
C0569293
C0719509
C0977190
C3663260
C0366686
C0521900
C0032143
C2054130
C3653411
C0058829
C1879367
C0308399
C2054177
C1427310
C1570232
C1439877
C3206494
C2029949
C0342269
C0701042
C0452115
C0663241
C0536495
C1822607
C1709043
C0074332
C0718612
C2702169
C0733815
C4081659
C0216784

2mg versed
carvedilol
KCL
steroid inj skin
reaction
increased dose
metoprolol dosing
Amiodarone
pulmonary toxicity
Coreg
3mg
steroid drops
warfarin dose
Amoxicillin as
tPa
chronic antibiotics
opiods
Dyazide
flexor
Bacitracin ointment
steroid to take
steroids for
Lyrica
after 129nitial dose

Monitoring
Monitoring
Monitoring

chronic histoplasmosis
low levels
fungal infection

C0854428 Monitoring
C0151723 Monitoring
C0026946 Monitoring

Monitoring
Monitoring
Monitoring

significant weight
Mycoplasma
Renal neoplasm

C3897172 Monitoring
C0026934 Monitoring
C0022665 Monitoring

Monitoring
simple cysts
Monitoring
Applauded
Monitoring
Chronic atrial
Monitoring
lucencies
Monitoring weight gain or weight loss
Monitoring
incision
Monitoring
opportunistic infections
Monitoring
scleral icterus
Monitoring
or edema
Monitoring
purified
Monitoring peripheral artery disease
Monitoring
Chronic hepatitis
Monitoring
kidney disease
Monitoring
advanced liver disease
Monitoring
PRN
Monitoring serosanguineous drainage
supraclavicular
amiodarone pills Monitoring
lymphadenopathy
NSAID related
Monitoring
do as
steroid induced
Monitoring
chronic cholecystitis
incarcerated incisional
cipro
Monitoring
hernia
infection or vaccine Monitoring
goes away
Linezolid
Monitoring
dry weight
chronic upper respiratory
moxifloxacin
Monitoring
infections
takes inhalers as Monitoring
urination
missing any doses Monitoring RLE full weight bearing
senna
Monitoring
Vascular calcifications
apatate
Monitoring
adverse reaction
Stelara
Monitoring
healing wounds
Levophed
Monitoring
blood in stool
Not taking if
Monitoring
paraesophageal hernia
Valsartan
Monitoring
chronic skin
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C0037157
C0662157
C0694539
C0743894
C2964349
C0184898
C0029118
C0240962
C0474434
C1998793
C1306889
C0019189
C0022658
C0860197
C0558288
C1112519

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0749155 Monitoring
C3899344 Monitoring
C0085694 Monitoring
C0311271 Monitoring
C2128638 Monitoring
C1439839 Monitoring
C2074970
C0042036
C2149803
C0342649
C0559546
C0043240
C0018932
C0267725
C0157738

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2054160
C4075962
C0556984
C2936530
C0568678
C3464355

taking otc
low dose chest
tid
opioid therapy
Atropine without
further event
Dymista nasal
spray

Monitoring
Monitoring
Monitoring
Monitoring

Honking systolic murmur
under the skin
cognitive deficit
Chronic obstructive

Monitoring

Chronic serous otitis

Monitoring Clostridium difficile colitis
Clostridium difficile
C1174739
Velcade
Monitoring
infection
C0245561
duloxetine
Monitoring
coffee ground emesis
Gastroesophageal reflux
C0038757
sulfa allergy
Monitoring
disease
C0746949 NSAID allergy
Monitoring
blood loss
C3209937 colchicine pills
Monitoring
blood clots
C0750389 chronic warfarin Monitoring
Carcinoid tumor
C0085542
pravastatin
Monitoring
single gastric polyp
C0393080 VORICONAZOLE Monitoring
Gastric polyp
C0001617
corticosteroid
Monitoring
anaphylactic reaction
C0304586 Antibiotics for skin Monitoring Postmenopausal bleeding
C0557004
when taking
Monitoring
blood loss anemia
C0416166 events while taking Monitoring
low blood
C1707813
dose pak
Monitoring
recent weight gain
C0124498
kayexalate
Monitoring
ventral hernia
C0740157
Carafate
Monitoring
lumbar hernia
C3642173
Renal dose
Monitoring
thromboembolic events
NSAID drug
C1542525
reaction
Monitoring
chronic infarcts
C0939400
Nexium
Monitoring
limiting sodium intake
NSAIDs and opioid
C0358845
analgesics
Monitoring
swelling of these joints
C0022209
inh
Monitoring
cigarette smoker
Staphylococcus aureus skin
C2363722 steroid psychosis Monitoring
infection
C0690666
150mg
Monitoring
pilonidal cyst
C0721444
low dose asa
Monitoring
inguinal hernia repair
C0025084
taking meds
Monitoring
rectal masses
C0026078
midodrine
Monitoring
Noninsulin dependent
adverse reaction to
C0570424
amiodarone
Monitoring
adenopathy
C1518010 low radiation dose Monitoring
arises
C0973749
160mg dose
Monitoring
dental caries
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C2046973
C2200110
C0009241
C0333166

Monitoring
Monitoring
Monitoring
Monitoring

C0155421 Monitoring
C0238106 Monitoring
C0343386 Monitoring
C1510416 Monitoring
C0017168
C0019080
C0302148
C0007095
C0940274
C0236048
C0002792
C0032776
C0154286
C1658984
C2367670
C0019326
C0401119
C0040038

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0548844 Monitoring
C1821817 Monitoring
C0152031 Monitoring
C0337667 Monitoring
C1739131
C0031925
C0021446
C0240873
C0011860

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0497156 Monitoring
C4019053 Monitoring
C0011334 Monitoring

C3251097
C0878554
C0589598
C0790952
C0810782
C0858726
C1736183
C0282638
C1319853
C0936433
C2054156
C0366482
C0950902
C0444956
C0001645
C0003015
C0059865
C1515187
C0980743
C0978129
C0715695
C0078839
C0406479
C4053796
C4036053
C0043031
C0359826
C0853383
C1555542
C0178602
C1706103
C0746307

ACE inhibitor beta
blocker
chronic opioid
intake
second dose
Azelastine spray
inhaler as
Steroid induced
osteoporosis
NSAID
prophylaxis
antibiotic
prophylaxis
NSAID induced
oxycodone tablets
taking weight loss
pills
Flecainide dose
Integrilin
high doses
beta blocker
ace inhibitor
etodolac
takes night dose
tobramycin drops
500mg
300mg
zolpidem
steroid acne
NSAID
nephropathy
or missed doses
warfarin
anticoagulation
Betadine skin
Low dose
epinephrine
Dosing weight
dose
dose as
hydralazine
induced skin lupus

Monitoring

C0019270 Monitoring

Monitoring
Monitoring
Monitoring
Monitoring

hernia
Advised continued weight
loss
loose
Perianal
chronic sinusitis

Monitoring

Chronic diarrhea

C0401151 Monitoring

Monitoring

stomach ulcers

C0038358 Monitoring

Monitoring
Monitoring
Monitoring

under local anesthesia
Periapical abscess
yeast infections

C1720162 Monitoring
C0031024 Monitoring
C0750466 Monitoring

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0555962
C0205407
C0442158
C0149516

Monitoring
Monitoring
Monitoring
Monitoring

bloating
Chronic otitis
sensorineural hearing loss
serositis
drainage or infection
microscopic colitis
inframammary skin
latent infections
helminth infections
hepatic cysts
low back
Degenerative lumbar spinal
Monitoring
stenosis
Monitoring
HIV infection

C1291077
C0747083
C0018784
C0036749
C3513343
C0400821
C0459398
C0872054
C0018889
C0267834
C0024031

Monitoring
Monitoring

chronic HIV infection
Internal Hernia

C0853112 Monitoring
C0178282 Monitoring

Monitoring
Monitoring

breast abscess
bone loss

C0151463 Monitoring
C0029453 Monitoring

Monitoring
Monitoring
Monitoring
Monitoring

infection is
TOOTH ABSCESS
or chest discomfort
Homans signs

Monitoring

Chronic systolic heart
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Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0410636 Monitoring
C0019693 Monitoring

C2010716
C0518988
C0008031
C0231781

Monitoring
Monitoring
Monitoring
Monitoring

C1135194 Monitoring

C4075005
C1273095
C0749009
C3207189
C0003360
C0684237
C0876226
C0499146
C0002771
C3249878
C1134651
C2370736
C2136360
C0857243
C3528809
C3837102
C0749012
C0196394
C0270994

does not take
single dose
steroid allergy
caffeine pills
antihistamines
Narcan
zyvox
Administer subcu
as single dose
analgesics
Steroid infections
beta glucan
dose zolpidem
Verbalizes taking
dose as
NSAIDs cause
mouth ulcers
80mg dose
steroid nasal
steroid dependent
steroid spinal
epidural injection
steroid myopathy

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

incision infection
Kidney working
keloid
BK virus infection
degenerative disk
Rectal
histoplasmosis skin

C0038941
C3176738
C0022548
C1096691
C2717759
C1527425
C0199757

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0238909
C0006109
C3489393
C0452242
C0231807

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Monitoring

Cat scratch
chronic damage
Hiatus hernia
drink milk
DOE
pneumothorax or pleural
effusion

Monitoring
Monitoring
Monitoring
Monitoring

friends
serous otitis media
bowel adhesions
umbilical hernia

C0079382
C0155415
C0267778
C0019322

Monitoring
Monitoring
Monitoring
Monitoring

Monitoring
Monitoring

Incarcerated hernia
Chronic venous stasis
degenerative arthritis
Hyperplastic polyps
Rectal polyp
bilateral knee
superficial skin infection
high levels
Scrotal abscess
Escherichia coli
Polymyalgia rheumatica
biliary colic
Heat intolerance
Escherichia coli bacteremia
Chronic neck
ulcerations no skin
ulcerations or lesions
stopped working
anxiety attacks
LBP

C0740406
C0750169
C0029408
C0333983
C0034887
C0230434
C0342985
C0151714
C0238418
C0014834
C0032533
C0151824
C0231274
C1096262
C0746815
C0437804
C0275990
C0425082
C0700031
C0020649

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
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C0947889 Monitoring

breast lump
inflammation process
inflammation or infectious
Chronic ischemic heart
disease
Abnormal weight
much weight loss
hemorrhagic cysts
Perianal Abscess
chronic insomnia
intentional weight loss
Nonobstructive coronary
artery disease
Nonocclusive coronary
GI blood loss
Renal osteodystrophy
scleroderma renal crisis
infection not
renovascular disease
sodium intake
toenail fungal infection
aortic vascular
systemic infection
skipping
black stools
invasive ductal
Breast cancer
chronic hip
clostridium difficile
enterocolitis
breath or chest
kidney cyst
ulcer disease
underlying
weight change
Infective otitis externa
tendinitis
HCV infection
Externa
Chronic viral hepatitis
wound
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C0024103 Monitoring
C1155266 Monitoring
C1400391 Monitoring
C0264694
C0578026
C4084777
C0333145
C0031019
C0751249
C1563041

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2007633
C4020724
C0041909
C0035086
C1262147
C0580334
C1442904
C0489645
C0749566
C0182556
C0243026
C0560435
C0025222
C1134719
C0006142
C0744939

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1400528
C0423729
C3887499
C0030920
C0749769
C0005911
C0021355
C0039503
C3871345
C0152345
C0276623
C0043250

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

chronic allograft
MRSA wound infection
skin rashes
Reflux Esophagitis
high levels of
chronic foot
Chronic memory loss
increasing sweats
scaling skin
nail abscess
chronic cardiovascular
disease
wound skin
coronary atherosclerosis
nonobstructing
inflammation or infection
Colovesical fistula
bronchogenic cysts
Rectal bleeding
biliary ductal dilatation
Gastric residuals
chronic chest wall
constipation
chest infections
Thyroid neoplasm
submental nodes
chronic dysphagia
Best
bowel gas
weight gain weight loss
hemarthrosis
bone contusion
Prostate
neuroendocrine tumor
may be
neoplasm of skin
supraumbilical hernia
abdominal distension
inguinal hernia
10lb
kidney
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C0403592
C1504508
C0015230
C0014869
C0564512
C0410418
C0746484
C0700590
C0237849
C1404693

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1290380
C0564444
C0010054
C0264787
C0679333
C0268842
C0006281
C0267596
C0842860
C3665864
C0742356
C0009806
C0149725
C0040136
C0229723
C0743317
C1522427
C3670913
C3175831
C0018924
C1390461
C0033572
C0206754
C1278418
C0007114
C0749174
C0000731
C0019294
C3364555
C0022646

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Infusion Reaction
Postherpetic neuralgia
Ulceration healed
Stump
Dental Infection
Recurrent urinary tract
infection
Chronic Abdominal
parenchymal liver
Mycoplasma pneumoniae
stream
infection blood
ureteral calculi
Melanosis in the colon
GI losses
who
Abscess Drainage
gluteal abscess
pelvic abscess
chronic thickening
reflux nephropathy
Dependent edema
Giardia cysts
source of infection
compression or cord
chronic neuropathic
Refused rectal exam
chronic glomerulonephritis
Pfannenstiel skin incision
bowel disease
intrarenal
fish oil
stone likely urate stone
Kidney infection
Noncardiac chest
Dry cough
infectious hepatitis
ganglion cysts
chronic constipation
attack stroke
intestinal infections
135

C2368034
C0032768
C0333293
C0002690
C0877046

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0262655
C0232491
C0745745
C0032302
C0442540
C0474659
C1456865
C0221391
C0473916
C0043237
C0344096
C0263118
C0030785
C2074894
C3495566
C0235437
C3662519
C0449426
C0037926
C1864996
C0741701
C0152451
C0457819
C0021831
C0226712
C0016157
C0798105
C0021313
C0476281
C0850149
C0019159
C1258666
C0401149
C3844825
C0178238

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

effusions
Chronic thrombocytopenia
chronic edema
as a sinus infection
Cerebral vascular disease
chronic wound
chronic lumbar
hardware
colonic polyps
flares
will become
do
tapers
chronic vascular
inconclusive
hydronephrosis
adenomatous polyps
dysuria
Night sweats
bowel obstruction
radiculopathy
low blood sugars
peritonsillar abscess
Cyst of skin
beer intake
or unusual
hypophonia
Hair loss
chronic thrombosis
Chronic elbow
chronic degenerative
chronic dvt
incisional hernia repair
chronic allergic rhinitis
senile macular retinal
sob
chronic vertigo
chronic arthritis
Abnormal weight gain
Rectal skin tag
chronic synovitis
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C0013687
C0749393
C0333241
C0940933
C1410784
C3494660
C0410414
C1523994
C0009376
C1517205
C0548520
C1512020
C0441640
C0559030
C0205258
C0020295
C0206677
C0013428
C0028081
C0021843
C0700594
C0020615
C0031157
C0191335
C0559430
C3166232
C0521007
C0002170
C2728999
C0564826
C0393583
C2728996
C0342971
C0748410
C0242383
C0010399
C0750248
C0263680
C0332544
C0345890
C0877521

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

MDS
cardiac dilatation
hilar adenopathy
Chronic gastrointestinal
bleed
chronic liver
zoonotic infections
Vanc
asthma attack
Monckeberg vascular
calcifications
deposition of amyloid
chronic pleural effusion
ascites
fluid intake
Adenomatous polyp of
colon
rectal abscesses
histoplasmosis infection
chest discomfort
cardiac events
weight loss goals
or cardiovascular disease
Pruritic rash
Lumbar radiculopathy
gall stones
do think
fluctuating weight
Upper respiratory infection
fevers chills
gained some weight
wound dehiscence
chronic deformities
inside wound
hematemesis
scarlet fever
Stage IV kidney disease
Reactive airway disease
chronic prostatitis
infections requiring
renal abscess
137

C0265219 Monitoring
C0264732 Monitoring
C0149711 Monitoring
C0266808
C0156189
C0043528
C1430966
C0347950

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0887866
C0011560
C0747636
C0003962
C0429791

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0850572
C0149770
C0019655
C0235710
C0741923
C0515789
C0007222
C0033771
C1263855
C0242216
C3259568
C0241729
C0041912
C0085594
C4014806
C0259768
C0744536
C0160524
C0018926
C0036285
C1561641
C3714497
C0085696
C3483787
C0151465

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Neuropathic
Cauda equina spinal cord
injury
obstructive uropathy
stone event
Buttock wound
infection like
esophageal varices
or reflux
Chronic membranous
glomerulonephritis
non weight bearing
bone erosions
Perianal skin
under anesthesia
hemophilia
DVT
kidney stones or
renal masses
chronic bone
ulcer on the skin
encouraged water intake
Cardiac ascites
catheter site infections
skin infections
Endorses
bowel perforation
reaction as
infected implants
after taking
sinusitis
Postnasal drip
friends who drink
Not taking
Gastric varices
not taking any
Extensive vascular
dark stool
for weight loss
much better
swelling as
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C0003892 Monitoring
C0854395
C0178879
C0418022
C0741846
C0745245
C0014867
C1535588

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0854414
C0445100
C0587240
C1704244
C1720436
C0684275
C0149871
C0744261
C0262613
C1385418
C0437803
C0204697
C0341525
C1112210
C0037278
C0680918
C0021845
C0865403
C0588128
C2129215
C0037199
C0032781
C0556322
C0426599
C0017145
C3844558
C0155094
C0474585
C0547548
C3841449
C0424810

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

DOS
chronic otitis externa
radiation pneumonitis
hemoptysis
she
chronic cystitis
memory loss
soa
infected knee
loose stools
chronic heel
prostate infection
saddle embolus
ureteral cysts
itching
pulmonary emboli
chronic shoulder
hepatojugular reflux
Central chest
unintended
Chronic hoarseness
chronic diastolic heart
coughing up sputum
beefy red open wound
sweats or weight
Chronic utis
chronic dyspepsia
loose bowel movements
Gastric lymphoma
Nabothian cysts
Fibroid uterus
symptoms or weight loss
neoplasm of colon
mucinous neoplasm
or rest
gallbladder stones
cat scratch disease
stones passing
thrill in the
smoking cigarettes
infection or fevers
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C0719635
C0151217
C0206063
C0019079
C1822717
C0221763
C0751295
C1898571
C1400580
C2129214
C0744717
C0240811
C0023370
C1696112
C0033774
C0034065
C0264042
C0239949
C0423634
C1283932
C0745015
C2711480
C0239134
C3645725
C4048703
C0262421
C0743312
C0011991
C0349532
C0027269
C0042133
C1542746
C0007102
C1334811
C0682643
C0947622
C0007361
C0848621
C2115906
C0700219
C1400815

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Salivary glands
indwelling stent
renal parenchymal disease
sharp pains
fructose corn syrup
purulent drainage
Staph infection
Incisional hernia
chronic colitis
hacking cough
further weight loss
long term
Increased pulmonary
vascular
Bee sting reaction
Hyperpigmentation of skin
epididymal cysts
Omega fish oil
swelling thumb
risk of cardiovascular
disease
frothy
lacunar infarctions
MAC
history of kidney stone
Lyme disease
breast tenderness
renal vascular disease
Simple
sliding hiatal hernia
chronic conditions
Chronic leg edema
chronic process
discomfort
hallux valgus
edema or infectious
corneal edema
corneal
corneal decompensation
pancreatic neoplasm
Breast cyst
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C0036098
C4270259
C1841992
C0455270
C2981326
C0517630
C0038160
C0267716
C0267375
C0239133
C0150869
C0443252

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1867423
C0438638
C0162834
C0037859
C1572282
C0575899

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C3176371
C4069284
C0333559
C0009545
C1998388
C0024198
C0262397
C0268790
C0205352
C0376710
C0399432
C1739409
C1827411
C2364135
C0018536
C1400819
C0010037
C0010031
C0948284
C0030297
C0006144

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Diaphragmatic hernia
kid
obvious
stone disease
fungal skin infection
stone each
infected mesh
ovarian cysts
burn scar
hyperplasia
head aches
sanguinous drainage
Ulcer debridement
leg wound
after recent viral infection
chronic reflux
rectal neuroendocrine
tumor
stitches in the skin
hilar lymphadenopathy
environmental allergies
ankylosing spondylitis
Monilia genital infection
CMV infection
infection of the
ureteral stones
chronic stone
FHx prostate cancer
chronic iritis
it is
chronic epigastric
chronic functional
constipation
today
GI infections
rectal prolapse
reflux
osteoarthritic
Mucinous carcinoma of
skin
mucinous adenocarcinoma
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C0019284
C0680063
C0557880
C0947660
C0011630
C1535790
C1321093
C0029927
C0036280
C0020507
C0018681
C0333271
C0730126
C1408542
C2919453
C0743582

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1335678
C1540362
C0456973
C0282504
C0038013
C0006840
C0010823
C0555971
C0041952
C0267885
C0260515
C0008690
C3174772
C0743541

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C4060572
C0310367
C4082764
C0034888
C0232483
C1834973

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0346020 Monitoring
C0007130 Monitoring

urination or pelvic
infection in the
Chronic polyarthritis
or colon
symptomatic aortic stenosis
breast skin rash
chronic leg
hoarseness of voice
degenerative disc disease
bright red
abdominal tract hematoma
scrotal edema
relapsing lung
Streptococcal infection
pulmonary vascular
chronic headaches
colostomy site
risk for cardiac event
Spinal epidural abscess
fungus
not put weight
chronic incontinence
chronic bronchitis
interstitial thickening
recent weight change
chronic residual
current infection
collagen vascular disease
psoas abscess
went
incision line
gastroparesis
Chronic osteomyelitis
dysarthria
endobronchial
venous stasis
Chronic venous
Bone Neoplasm
chronic microangiopathy
Bone neoplasm uncertain
behavior
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C3539896
C0854706
C1735378
C0555952
C0741183
C0741755
C0263560
C0019825
C0158266
C1272329
C0473120
C0151609
C0855002
C0038395
C0456261
C0151293
C0546255
C1443393
C0238434
C0016832
C0231246
C0749938
C0008677
C2750120
C2127346
C0270408
C0588457
C0262428
C0085222
C0796199
C0197081
C0152020
C0008707
C0013362
C0444471
C0277919
C0042485
C0005967
C3808622

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0346546 Monitoring

certain types of food
cerebellar ataxia
Treating as
infection per
chronic active hepatitis
Inflammatory bowel
disease
Chronic liver disease
within the
symptomatic
xanthine stones
stone or foreign
staghorn stone
atrial pacing
peripheral neuropathy
Psoriatic arthritis
inflammation and skin
Chronic angina
versus stasis disease
ventral incisional hernia
Adenovirus infection
Chronic nasal
Nasal polyps
atherosclerotic vascular
disease
high dose fish oil
abscess
dry itchy skin
renal vascular
stasis dermatitis
Calf tenderness
Anemia of kidney disease
log
in the cyst
Skin abscess
Infected sebaceous cyst
Chronic stasis skin
scaly skin
offsets
chronic proctitis
Infected graft
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C0566312
C0007758
C0516188
C2346550
C0241910

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0021390
C0341439
C0425538
C0231220
C1848431
C3879015
C0438018
C0199647
C0031117
C0003872
C0011603
C0340288
C0018133
C0750175
C0001486
C0746757
C0027430

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0004153
C0452295
C0000833
C3830437
C0227622
C0011620
C0238883
C1561828
C0228228
C1394327
C0149777
C0345989
C0748828
C0423773
C1711330
C0860176
C0349725

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

infected hip
Reducible umbilical hernia
chronic anal fistula
Herbal weight loss
in skin integrity
heart valve infection
cognitive impairment
pulmonary edema
inflammation related to
your gallbladder
chronic interstitial
interstitial lung disease
these
rectal fistula
water intake
definite epidural abscess
chronic pelvic
remember
GI bleed
chronic hearing loss
low dose lung
sexual behavior
chronic nerve
Nevus
tonsil stones
limiting alcohol intake
Chronic laryngitis
chronic volvulus
radicular
Bochdalek hernia
carotid bruits
femoral bruits
tears
nasal drainage
chronic childhood
respiratory disease
thrush infection
FHx of kidney disease
numbness
or wound infection
discomfort around
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C0744926
C0577704
C0740978
C1572271
C0946387
C0014121
C0338656
C0034063

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0008325
C0221236
C0206062
C0039828
C0034884
C0013123
C0237049
C0149960
C0034770
C0017181
C0744663
C4067633
C0036864
C4229567
C0027960
C0272388
C0560219
C0155836
C0267195
C0034543
C0265700
C0007280
C0558799
C0039409
C0746759

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1398939
C3646468
C0260532
C0028643
C3844442
C0858893

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

chronic asthma
emphysema or airway
chronic abscess
prostate abscess
after 48 hours
chronic prostate toe rectal
pains
epidermoid cysts
Norovirus infection
spinal stenosis
do become
Chronic ischemic colitis
axillary adenopathy
Metabolic bone disease
either
Low cardiac output
as food always
infections or upper
respiratory infections
voice loss
low fever
granulomatous disease
infection becomes
sleep disturbance
Ulcerative colitis
crypt abscess
Rectal ulcerative colitis
atrophy
infection up
stool
infections to
infected hematoma
Chronic allergic
caused neurotoxicity
chronic oral
pulmonary effusions
atypical pulmonary
infection
pannus
microscopic hematuria
chronic subdural hematoma
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C0877430
C1403214
C0333398
C0156290
C3897190

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0742666
C0014511
C2712971
C0037944
C0510415
C0267413
C0578735
C0005944
C3844638
C0007166
C3900013

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1536805
C0003564
C0239574
C0740451
C1864807
C0037317
C0009324
C0333374
C3509262
C0333641
C0158421
C0015733
C0157749
C0948087
C0029543
C0546131
C0747051
C1608981

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0392054
C0333350
C0239937
C0749095

Monitoring
Monitoring
Monitoring
Monitoring

do you
Perirectal small cutaneous
abscess
thyroid disease
Weight trending
Wound drainage
acute diverticulitis
Watchers weight
Surgical wound
chronic epididymitis
chest wound
incision dehiscence
heart murmur
carb intake
sarcoid pulmonary
anorexia or weight loss
Metastatic breast cancer
relief
urination or bloody
uloric
hernia repairs
risk for GI bleed
chronic productive cough
Chronic osteoarthritis
GI cancers
do not drink
of acute infection
low calcium levels in the
blood
food intake
gallstones or pancreatitis
infection bacterial infection
scapular
in the chest
MRSA pneumonia
Renal colic
obs
wound complications
Coughing up phlegm
check weight
chronic bronchiectasis
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C3259020 Monitoring
C0267566
C0040128
C0424655
C0694702
C0518989
C2067212
C0332803
C0238110
C0742361
C0038940
C0018808
C4255294
C0340199
C1971623
C0278488
C0564405
C0473237
C2683462
C0019328
C3251812
C0742859
C0263778
C0685938
C4087012
C0155392

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0020598
C0013470
C0521614
C0004623
C0223628
C1253943
C1142536
C0152169
C2986870
C1096106
C1536391
C2712830
C0741793

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

chronic fevers
ulceration or erosions
MRSA skin infection
or damage
Cecal polyps
disc disease
infection the skin
cecal volvulus
Calcified coronary artery
abscess cavity
hepatic abscess
Suicidal intent
effusion or pericardial
effusion
Chronic gouty arthritis
inflammation prostate
infected tunneled
choledocholithiasis or
acute obstruction
chronic in
chronically ill appearing
groin abscess
after weight loss
Incarcerated ventral hernia
Diverticulosis without
acute diverticulitis
prostate hyperplasia
chronic medical
vascular disease
inflammation around
varicella zoster infection
chronic depressive
vascular stenosis
subdural empyema
bone flap
Retention cysts
chronic musculoskeletal
chronic recurrent
Colloid cyst
Chronic sequela
vascular malformation
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C0743971
C4055054
C0343401
C1301684
C1112566
C0012619
C1142269
C0238047
C0742825
C0333372
C0023885
C0582496

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0031039
C0268108
C0033581
C3161243

Monitoring
Monitoring
Monitoring
Monitoring

C3649781
C0153912
C2051413
C0263109
C2129177
C0311269

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0149653
C2937421
C0425066
C0042373
C0031099
C0586989
C0581391
C0679403
C0038539
C1266913
C0035281
C0746683
C0410422
C0333157
C2198003
C0158570

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

colon perforation
Chronic rib
Chronic cardiopulmonary
disease
Allergic
Chronic head
Chronic hepatitis C virus
infection
volume blood loss
Chronic anxiety
fluid weight
around his wounds
dry mouth
inflammation/abscess
intermittent cough
blurry vision
risk of kidney disease
Chronic foot ulcer
chronic muscle cramping
acute flare
thyroid cysts
Coarse vascular
calcifications
infection but
vitamin K intake
seasonal allergic rhinitis
obstructing hernia
chronic fungal
swelling of legs
chronic ankle
Chronic hand
dysphonia
Chronic wrist
Colocutaneous fistula
recent wound infection
BONE INFECTION
drink juice
Septic pulmonary emboli
stump healed
Chronic pulmonary fibrosis
ischemic vascular
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C0347646 Monitoring
C0844663 Monitoring
C0238074 Monitoring
C0700624 Monitoring
C0558154 Monitoring
C0524910
C4265180
C0581386
C3484207
C2129888
C0043352
C3513855
C2077828
C0344232
C3697935
C0744178
C0746672
C4042866
C0162299

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1268677
C2749557
C2317598
C0018621
C0156140
C0396046
C0581394
C0410419
C0264045
C1527344
C0564827
C0341377
C2169571
C2242472
C2136335
C0333222
C1398427
C0340126
C0235490

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

head trauma
tingling in the hand
chronic iron deficiency
anemia
pancreatic pseudocyst
bright
urethral stricture disease
biliary sludge
hematuria or
adenocarcinoma of the
prostate
LVAD
ulcers or skin
drastic
arsenic levels
infection damage
chronic inflammatory
bowel
infectious colitis
as much as
nonocclusive
Purposeful
blastic pelvic
cervical spinal cord lesion
chronic pains
chronic dyspnea
intestinal metaplasia
Acute blood loss anemia
Chronic mesenteric
ischemia
hepatocellular disease
steatosis
chronic active ileitis
infection or hernia
chronic psychosis
increased weight gain
swelling and
inflammation of the liver
Chronic dermatitis
insignificant
brawny edema
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C0018674 Monitoring
C4084744 Monitoring
C0740989
C0030299
C0423899
C0041974
C0282074
C0475537

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0007112
C0181598
C0455787
C0743236
C0373548
C1411542

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0267374
C0277524
C1879743
C0266061
C1285529
C2021201
C0730136
C0150055
C1388883
C0334037
C0154298

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0311262
C0023895
C0152254
C0745221
C4049327
C0221764
C0000765
C0455933
C0019158
C0262975
C3898757
C0333248

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Papillary thyroid cancer
Xerosis of skin
gonococcal infection
chronic hypernatremia
Metastatic prostate cancer
infected coronary
prosthetic infection
truncal ataxia
GI: liver disease
invasive pneumococcal
disease
not drink
gouty
Thyroid
urinary leakage
chronic moderate
UK
weight loss after gastric
Integumentary: skin lesion
A fib
scarring to the flanks
Staphylococcus aureus
bacteremia
High cardiac output
Alopecia areata
kidney transplant
salivary stones
neoplasm of the lung
or erosions
infection prophylaxis
Not eating
alcohol intake
chronic uveitis
Psoriatic plaques
chronic hemolytic anemia
murmur as child
possibly
osteoarthritis flare
toenail infection
Seronegative rheumatoid
arthritis
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C0238463
C0263465
C0018081
C0268012
C0936223
C2049798
C0349726
C0427190
C0017183

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1320214
C0564343
C0003868
C0040132
C3897214
C0267386
C0077769
C2126001
C0191447
C0004238
C2037960

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1142423
C0085128
C0002171
C0022671
C0036091
C0024121
C1540849
C0877629
C0418837
C0001948
C1510449
C0920235
C0271904
C0746654
C0332149
C3544322
C0749565

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0409652 Monitoring

infections or stomatitis
Worse after
attacks
risk of heart disease
cyst rupture
myeloid leukemia
ulcerations or rashes
inflammation without any
intestinal
aneurysm dissection
Chronic daily headache
visual
msk
panic
abd
metaplasia
glycogen storage disease
ovarian simple cyst
Periumbilical hernia
chronic Hep
not be safe
Paresthesia of skin
heat as
chronically draining wound
yellow sputum
chest or abdominal
nails
Black lung
clavicular fracture
splenic granulomas
Chronic kidney disease
mineral bone disease
increased fluid intake
infected mastoid
away
viral infection
diverticular disease
added
symptomatic urinary tract
infection
degenerative changes
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C1398444
C0241739
C0004063
C1277690
C0333140
C0023470
C0744159

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C3889047
C0002949
C0752147
C0234621
C1420279
C0030318
C0449202
C0025568
C0017919
C0237010
C0747528
C0524909
C0581563
C0235046
C1820546
C0750432
C0457096
C0846687
C0027342
C0003165
C0159658
C1535984

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C4076240
C0426596
C1096736
C0425139
C0042769
C1510475
C0002395

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0749968 Monitoring
C0011164 Monitoring

helped
Gastric erosions
gastric
erosions
liver biopsy
pneumoperitoneum
sickle cell
sickle cell disease
Beta Thalassemia
sickle beta thalassemia
Cod Liver Oil OIL
under the nails
enterovirus types
under
Perforated appendicitis
omental adhesions
Alcoholic liver disease
squamous cell carcinoma
stage liver disease
inherited renal disease
promote weight loss
started as
weight loss surgery
chronic jaw
burgdorferi antibodies
chronic ear infections
or signs of infection
Bone marrow edema
localized infections
retrobulbar hemorrhage
gum infection
diverticulosis or
diverticulitis
salt intake
skin tears
Chronic intermittent
diarrhea
gastric reflux
vascular damage
chronic stage IV
Incision site
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C1269765
C0341177
C1704242
C0333307
C0193388
C0032320
C0221283
C0002895
C0005283
C0221019
C0009213
C0474374
C0376325
C0542339
C0854119
C0267781
C0023896
C0149782
C0745744
C0403547
C2584720
C0474365
C1456587
C0266964
C0368786
C0743359
C2191772
C0948162
C0016397
C0302497
C0744403

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0679411 Monitoring
C0489767 Monitoring
C0877377 Monitoring
C0743174
C0558176
C1389629
C0854804
C0449681

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

looks
bone fractures
renal as
Necrotic pancreatitis
chronic hydronephrosis
chronic hypocalcemia
foods
Squamous cell skin cancer
loss was
inflammation of duodenum
stones or masses
trigeminal neuralgia
arteriosclerotic vascular
disease
ureteral stent
chronic myeloid
inflammation no skin
gastric hyperplastic polyp
suture in the skin
Atrophic vaginal
Urticaria
chronic lumbar back
tingling in the arm
Metastatic renal cell
carcinoma
incision made
chronic drainage
wound open
thrombus
rectal cancer
radiation cystitis
Radiation proctitis
Mitral valve endocarditis
pacer
superficial wound infection
central line infection
risk of vascular disease
infection if
HBV Infection
synovial cysts
Heberden nodes
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C0233426
C0016658
C0403448
C0267941
C1405879
C0033806
C0016452
C0553723
C2018719
C0013298
C1714971
C0040997

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0003850
C0183518
C0023473
C3873446
C0878649
C0191408
C0221392
C0042109
C0741393
C2116338

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0278678
C2034895
C0748721
C0332798
C0087086
C0007113
C0156270
C0400827
C0746604
C3890506
C0406104
C1096243
C2584745
C2051616
C3854623
C0085648
C0018862

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

chronic sacroiliac
Short term memory loss
scrotal infections
crusting of healed skin
scrotal skin
Splenic laceration
infected inguinal
enterocutaneous fistula
hernia mesh repair
infection of the sacrum
rectal perforation
glottic gap
chronic respiratory
lupus flares
SLE flare
fluid thrill no ascites
chronic dental caries
Scrotal
heart attack or
cold sores
drink extra
necrosis
Abdominal Adhesions
Protracted upper
respiratory infection
chronic rash
asthmatic bronchitis
Degenerative
spondylolisthesis
falls or any
stone like
hernia as
or myalgias
RLE toe touch weight
bearing
Refused weight loss
attempting weight loss
Chronic anal fissure
nicotine
rashes or
importance of weight
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C0948612
C0701811
C1299539
C2231982
C0222198
C0347636
C0919796
C0341318
C0519122
C0410371
C0341402
C2138972
C0264220
C4054590
C1735608
C0437004
C0266852
C0036471
C2926099
C0019345
C1170830
C0027540
C0549357

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2133965 Monitoring
C3806538 Monitoring
C1319018 Monitoring
C0264184
C2707943
C1823135
C0267713
C0410002

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2149821
C2169617
C2046395
C0349071
C0028040
C0011974
C1705104

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Malignant neoplasm
chronic infiltrates
Thyrotoxicosis without
thyroid storm
or fevers
backup
chronic erythema
over
Antrochoanal polyp
fluid collection
scarring or old
such an
aspiration pneumonia
meningeal cysts
Pituitary Neoplasm
Chronic nausea
Over weight
chronic severe
uncal herniation
in weight gain
pulmonary vascular disease
likelihood
recheck
Acute pulmonary edema
intra
Perianal fistula
tics
chronic Q fever
psoas muscle
spine infections
Pancreatic cysts
Central
incision drainage
kidney stones and weight
Regaining
Anaplastic astrocytoma
Nonmelanoma skin
or sexual
reaction units
heat
erythematosus
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C0006826 Monitoring
C0021376 Monitoring
C2873871
C0275976
C1552560
C1265577
C0020505
C0008298
C0394552
C0404534
C1548400
C0032290
C0347534
C0032019
C0746779
C0497406
C0267387
C0393985
C1398625
C0020542
C0033204
C0745623
C0155919
C0347985
C0267561
C0040188
C1443892
C0085221
C0748912
C0030283
C0205099
C0152277
C2109384
C0730881
C0334579
C0699893
C1527307
C1975995
C0018837
C0409974

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Ulcerations are drying
Chronic pulmonary edema
lifts weight
T levels
hepatitis infection
dysphagia and weight loss
rectal colon polyp
holes or tears
incision skin
fiber intake
eating fish
prostate or urothelial
incision wounds
narcotic dependence
polyp in the sigmoid
chronic sacral
Blood
coccygeal decubitus ulcer
infected sacral
sacral decubitus
chronic pancreatitis as
Infected cyst
pelvic fluid collections
erythema of the skin
hernia or reflux
nasal bleeds
chronic pyelonephritis
Postmenopausal bone loss
not always
chronic mucosal
Chronic resp
pleural thickening
within 48 hours
chronic strain
airway obstruction
Rectourethral Fistula
above
oxalate stones
fevers or skin rashes
infection signs of infection
infection after dog bite
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C0747964
C0264518
C0043095
C1278066
C1112211
C3277224
C0742670
C1883270
C0191279
C1821272
C3671189
C1514430
C0000925
C1527402
C0742699
C2919335
C0005767
C2728301
C3648743
C0558159
C0940977
C1142249
C1697454
C0241365
C1268942
C0014591
C0085697
C0029458
C2749261
C1290074
C0421217
C0264545
C0150946
C2063696
C0001883
C0268875
C1282910
C0428457
C0847014
C2225262
C0850850

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

nephrolithiasis
after starting
profile
his
chronic inf
rust colored sputum
pus drainage
red meat intake
Blanching
lose consciousness
choking
barrier laser barrier laser
stone extraction
chronic allergies
chronic blood disorder
symptomatic infections
Renal arterial thrombosis
cold or heat intolerance
much
chronic ruq
Calcitonin
electrolyte abnormalities
paraumbilical hernia
Mediastinal
lymphadenopathy
septic arthritis
increased weight or edema
low
during this
swelling in the knee
chronic thromboembolic
discuss weight loss
under chin
hallux
as blood loss
stone surgeries
Cryptogenic organizing
pneumonia
simple liver cyst
yellow fever
anaphylactic reaction to
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C0392525
C1552564
C1721540
C0019602
C0155397
C0748946
C0748194
C0556202
C0948786
C2057717
C0008301
C0302718
C0883371
C0740905
C1275398
C0864665
C0340608
C0424798
C0205393
C0262419
C0006668
C0151613
C0019311

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0520743
C0003869
C0743393
C0205251
C3827541
C0240130
C2363973
C1535374
C0448809
C0018534
C0516480
C0401239

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0242770
C2887948
C0043395
C0344159

Monitoring
Monitoring
Monitoring
Monitoring

Monocryl
allergic conjunctivitis
hyperplasia of tongue
biliary obstruction
NUT ALLERGY
to the flanks
chronic basilar fibrosis
chronic lung fibrosis
leukemoid reaction
Tornwaldt cyst
nasal bone fractures
Chronic nasal bone
Not checking blood sugars
night
groin nodes
vulvar cancer
chronic mental
came
Anomalous pulmonary
venous drainage
Pseudomonas infection
nervous system infection
Hepatitis diagnostic
do not see any
muscle spasms
potassium in the blood
spondylitic
Midline abd hernia
GI
orthopnea
Chronic Lymphoma
infected bursa
he
Chronic Pansinusitis
infection because
infected intra
Drainage of abdominal
abscess
Recurrent hernia
no signs of infection
Deg
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C0381197
C0009766
C0024421
C0400979
C0577620
C2032306
C0334133
C0264526
C0023501
C0264294
C0339848
C1290184
C2136219
C0240526
C0857362
C0375071
C0683405
C0960273

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0265916
C0033817
C0007684
C0770872
C3639726
C0037763
C0020461
C0263853
C0750176
C0521362
C0085619
C2063391
C1290161
C1418983
C0155827
C0034386
C0270179

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0405771
C0281961
C3693702
C2348088

Monitoring
Monitoring
Monitoring
Monitoring

Acne scarring
ruptured aneurysms
invasive pulmonary fungal
infection
photosensitivity reaction
Invasive pulmonary
aspergillus infection
or recurrent hernia
cerebellar infarcts
rectal adenocarcinoma
gastric antral vascular
good
stent
infrarenal
Prostate carcinoma
desmoplastic reaction
biliary stones
Chronic hyponatremia
Incarcerated umbilical
hernia
infarction within the
vascular
heart burns
bone disease
myeloma FISH
internal hemorrhoid
ulcerations or wounds
significant coronary artery
disease
leiomyoma or benign
daytime somnolence
weight loss was weight
stone heart
lying
risk of kidney injury
Ruptured aortic aneurysm
chronic sinus disease
Chronic pelvic abscess
metastatic rectal cancer
infection or granulomatous
becomes
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C0423783 Monitoring
C0162869 Monitoring
C1262313
C0162830
C0276653
C0851807
C1835116
C0236073
C0149978
C0267211
C0205170
C0038257
C0226025
C0600139
C1511789
C0008350
C0268007

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0700253 Monitoring
C0011263
C0018834
C0005940
C2210831
C0265034
C0460766

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1299434
C0023267
C2219848
C0750414
C2938932
C0600261
C0582456
C0265010
C0748720
C0269024
C0861772
C1610637
C0429569

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

tinea infection
HBV
instead of
Chronic frontal sinusitis
Breast neoplasm
Papillary serous
endometrial
papillary serous
pancreatic duct dilatation
diverticular abscess
concerning weight
emesis
recent intentional weight
loss
px
meningitis
leakage
bile leak
Idiopathic pulmonary
fibrosis
Fatty liver disease
chronic therapy
Malignant neoplasm of
splenic calcifications
smoking history
coughing or deep breath
tibial
PICC line
chronic cellulitis
limited weight bearing
esophageal strictures
chest wall infection
breast skin thickening
Latent syphilis
herniorraphy
Indirect inguinal hernia
hemorrhage or vascular
anomaly
pelvic fractures
hip abscess
endemic
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C0040247
C0019169
C0425956
C0008683
C1458155

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0854924
C0334358
C0400535
C0581275
C2034380
C0042963

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2169614
C0332132
C0025285
C0015376
C0400997

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0085786
C0341447
C0749634
C0153340
C1404059
C1519384
C1276787
C0040184
C0179740
C0544781
C2080837
C0014866
C0438341
C1268720
C0039133
C0458169
C0019296

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0519029
C0149531
C0263120
C0243130

Monitoring
Monitoring
Monitoring
Monitoring

fungal pulmonary
infections
fevers or sweats
scrotal hernia
meniscal tears
smoking or risky behavior
Esophageal ulcers
nasal spray
Passing flatus
chronic granulomatous
disease
chronic diabetic
neuropathy
breaks in the skin
Hyperplasia of the breast
breast disease
subsegmental pulmonary
fragment these stones
IgA
ULCER RECTAL
gluteal
left inguinal hernia
incision hernia
sleep apnea
kidney stones were uric
acid stones
heaviest
ect
further
bowel or vascular
risk sexual behavior
chronically dry skin
Epidural abscess
Perianal skin tag
infection abd
flare up
pleural effusion
pulmonary process
chronic pancolitis
peripelvic cysts
resolution of chest
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C0024116
C0038992
C0019319
C0238218
C1519383
C0151970
C0461725
C0016204

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0018203 Monitoring
C0393830
C3842551
C0741698
C0006145
C0503868
C0400630
C0020835
C0400839
C1550262
C0262537
C0176963
C0037315

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2109383
C2711761
C0013806
C1517331
C0400883
C1261242
C2074685
C0270629
C0521605
C0438343
C3830105
C0032227
C0748169
C2711681
C0866184
C2318026

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

ulcer arthritis
chronic occipital
infected arthroplasty
Infection of implant
chronic atypical
lung induced lung disease
erythema around
Chronic Leukemia
requiring wound
infection related
insufficency
olfactory groove
meningioma
Gastric mucosal atrophy
radiotracer
breakthrough
or ischemia
site healed
collateral venous
or colon cancer
Forehead laceration
ureteral reflux
anxiety
CaOx stones
this
rheumatoid arthritis
lifelong
allergic fungal
Reflux kidney
poisoning as blood
CrCL
Ulcers in colon
eating food because it
Extraction of kidney stone
back discomfort
dysplasia
refusal to bear weight
lymphangitis
striae in the skin
Watches
again
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C1388566
C0744647
C0410808
C0405488
C1292772
C0599154
C2071472
C1279296
C0744501
C0085073
C0349073

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1335107
C0597736
C0597354
C0444503
C0745412
C2197765
C0265074
C0009375
C0561236
C0042580
C0003467
C1147841
C1080058
C0003873
C4274169
C1827192
C2123534
C0036690
C1846718
C0267491
C3275021
C0162428
C0235706
C0334044
C4054081
C0024225
C0152459
C0043012
C0723612

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

ulcers or infection
chronic health
chronic fractures
it was
esophageal spasms
PDT
inflammation of the blood
oliguria
infection/abscess
steatohepatitis
started
around
Infected sexual
Expected weight gain
raise blood
reaction to
swelling of nasal
formed stools
swelling or chest
inflammation from
rheumatoid
cholestatic liver disease
stone pancreatitis
planned weight loss
radiation esophagitis
myalgia
respiratory distress
chronic allergic sinusitis
Klebsiella pneumoniae line
infection
pneumoniae line infection
recent upper respiratory
infection
stage III lung cancer
infective endocarditis
inflammation is
pelvic hematoma
Gastric outlet obstruction
pancreatic adenocarcinoma
induration under the wound
port site infection
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C1407931
C0559278
C2712806
C4086960
C0014863
C0175486
C0042384
C0028961
C0400889
C2711227
C0439659
C0750503
C0036916
C2233528
C0235416
C0013182
C0581927
C2128963
C0347940

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0333423
C0860204
C0440736
C1814869
C0238113
C0231528
C0476273
C0748727

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0948802 Monitoring
C0729704 Monitoring
C2169609
C0862847
C1541923
C2678093
C0475319
C0162651
C0281361
C2116826
C4054168

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

anorexia weight loss
thrill in vascular
interstitial pulmonary
edema
inguinal lymphadenopathy
Nonalcoholic fatty liver
hereditary
promote weight weight
swelling of feet
in the transplant
stent thrombosis
stones blood in urine
myofascial
salmonella infection
intake and weight
squamous intraepithelial
lesion
Nasal abscess
tenderness
infection in
mechanical neck
Migraine headaches
submucosal
ordered as
cysts
berry aneurysms
gas
calf
senile dementia
coughing up green sputum
carbohydrate intake
stabbing
Anion gap acidosis
Well healed knee wound
chronic lung infection
mycobacterium infection
desmoid tumor
distal ureteral stone
No known liver disease
PI
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C0426583 Monitoring
C0241658 Monitoring
C0748120
C0578736
C0400966
C0439660
C2584705
C0574002
C2170316
C3897493
C0455909
C0262941
C0036117
C4263181

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0333873
C0264263
C0234233
C0003204
C3877575
C0149931
C1515025
C0508364
C0010709
C0005136
C0017110
C0230445
C0011268
C2126217
C0489461
C0418391
C0860062
C2142391
C3163798
C0026918
C0079218
C2006154
C3280432
C0031939

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

stopped drinking soft
drinks
fatty liver
insult
ASCVD
ulceration as
home
Chronic hyperkalemia
Chronic spinal
feelings
Breast implants
ideally weight
variceal or GI hemorrhage
therapy given
venous disease
chronic intractable
saddle anesthesia
Chronic pruritus
radiation fibrosis
Not drinking much water
chest weight
significant
chronic vessel
recommend weight
Warm skin
parallel
family weight
dz
Helicobacter pylori
infection
ileitis
chronic gallbladder
chronicity organizing
pneumonia
chronic radiation proctitis
sarcoid
profound vision loss
hypopituitarism
chronic rotator cuff
kidney cancer
perforated sigmoid colon
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C0425321
C0015695
C0598698
C3665365
C0509790
C0442519
C0268023
C3697550
C1527305
C0179412
C0421272
C0333106
C3699632
C0235522
C0476481
C0179052
C0748035
C2350622
C2077403
C0179897
C0750502
C3275069
C3853327
C0235218
C0233174
C2203029
C0062886

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0850666 Monitoring
C0020877 Monitoring
C1391788 Monitoring
C4039254
C0400829
C0036202
C3276857
C0020635
C0186620
C0740457
C4041049

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

decompensation of liver
disease
given
Cirrhosis of the liver
Bleeding internal
hemorrhoids
under live fluoroscopy
dry rales
chronic diverticulitis
bowel dilatation
swelling or skin
Mucinous cystic pancreatic
neoplasm
ureteral strictures
does not
wound continues to bleed
Sessile colon polyp
Histoplasma capsulatum
infection
infected chest seroma
jaundice or
lose weight to
Allergic sinusitis
septated renal cyst
ulcers or reflux
orthopedic
infection drainage
Contradictory
cardiac chest
chronic metabolic alkalosis
Diverticulosis in the
sigmoid colon
radiation colitis
Staph aureus infection
skin ulcerations
fluid retention
gun shot wound
infected toes
kappa light chain myeloma
Metab
infection or ocular
remnant thyroid
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C4075847 Monitoring
C1442162 Monitoring
C0023890 Monitoring
C0265036
C0846072
C0859999
C0859969
C3280831
C0281982

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1518872
C3887590
C1299585
C0241742
C0940597

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0153261
C3805093
C0474426
C0231247
C0748726
C0237039
C0362009
C0029355
C0559642
C4061957
C0190043
C0740894

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0012818
C0341339
C0748791
C0037299
C0268000
C0043252
C0555972
C1532715
C0025519
C0015403
C0266285

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

chest
staples in the skin
ataxia
ulceration under
Postinflammatory
pulmonary fibrosis
Exophytic right renal cyst
sustain weight loss
Klatskin tumor
Pneumobilia
accidental overdose
suicidal behavior
central retinal
flank
Biliary strictures
infection process
second vascular
sigmoid polyp
bone metastasis
Chronic interstitial cystitis
oligoarticular rheumatoid
arthritis
drip
Wound as
planned vascular
trying to drink
perioral numbness
cyanosis
perineural cysts
soft tissue infection
weight as
MAI pulmonary infection
swelling no
ulcers or venous stasis
apneic
burst
Chronic non
Flash pulmonary edema
choking on foods
pelvicaliectasis
talking to friends
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C0817096
C1139841
C0004134
C0585371

Monitoring
Monitoring
Monitoring
Monitoring

C0175999
C4229072
C4062926
C0206702
C1739097
C0151821
C1760428
C0858623
C0230171
C0597984
C0596824
C0751414
C0877441
C0153690
C0600040

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0157917
C0452837
C0270118
C4265958
C3641816
C0221730
C0010520
C0520720
C0149778
C0513476
C0026916
C0577599
C0042344
C0003578
C0439818
C0342087
C1168329
C0417813
C2242514
C3161682

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

but not as
Oral herpes simplex
infection
Allergic asthma
burden
chronic diffuse
intracerebral hematoma
tears as
interstitial pneumonia
Panic disorder
radicular lumbar
hip osteoarthritis
HDV
resolution
splenomegaly
20lb
labia majora
ductal epithelium
aortic atherosclerosis
vaginal itching
role in preventing
skin wound not healed
thyroid nodules
papilloma virus infection
lose weight after weight
praised
chronic cervical
Prostate hypertrophy
CVA tenderness
just
Cardiac anomaly
raise red
blastic
calcium levels in the blood
mucosal thickening
dry skin
Mono
radiopaque
stone passage
knee discomfort
as these
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C4036134 Monitoring
C0341012
C0155877
C2828008
C0343880
C0021870
C1385905
C0206061
C0030319
C1405960
C0029410
C0011220
C0300132
C0038002
C3364556
C0227760
C1512086
C0155733
C0042256
C0814407
C2039198
C0040137
C0343641
C2219985
C0557963
C0269062
C1739363
C0235634
C0442728
C0018798
C0427458
C1378512
C0729820
C3686502
C0151908
C0021345
C2930749
C2035063
C0745538
C1956388

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Hemangioma of liver
bladder infections
chronic healed
hepatic metastasis
other viral infection
abuse related
diff weight bearing
Urate Nephropathy
Lumbar disc disease
Thrombosis of
arteriovenous fistula
gastric variceal bleed
viral upper respiratory
infection
skin thickening
dark red blood
opf
abominal
healed scars
airway infection
infection of the larynx
infected site
digital rectal
Osteoarthritis of hands
hematoma in the groin
papilledema or retinal
Crohn disease
Osteomyelitis versus
abscess
after vascular
lobar pneumonia or
bleeding skin
fungal lung infection
chronic control
shadowing
sludge
CBD
better
responsive pulmonary
process
after weight gain
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C0238246
C0600041
C2368046
C0494165
C0343538
C1550478
C0563568
C2955673
C0221775

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0340909 Monitoring
C0267209 Monitoring
C0009443
C0241165
C2129029
C0658189
C3391308
C0008767
C4228019
C1400586
C0578491
C1384593
C0263746
C0585249
C0339604
C0010346

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0264053
C1392823
C1535472
C0574741
C0151874
C1171182
C0332554
C0750852
C0006863
C0332272

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0871261 Monitoring
C2126003 Monitoring

some vascular disease
Acinetobacter infection
refresh tears
hemmorhoids
chronic hemorrhoids
chronic wound healing
arachnoid cyst
testicular
serous serous drainage
BKA
chronic pericardial effusion
spread of disease
chronic throat
under the tongue
urination after
chronic arm
chronic D Diff infection
scleroderma GI disease
abscess in the stoma
sclerodactyly
symptomatic vascular
disease
Pill esophagitis
laceration
tinea cruris
Parastomal hernia
tinea pedis infection
chronic feet
bloating or
RUQ
Chronic eczema
eczema versus fungal
infection
hemorrhoid
dystonic movements
Sulfa caused vaginal
went away
in the skin
wants weight
bacteruria
Sigmoid volvulus
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C3549710
C0001139
C2962648
C0723400
C0744804
C3879688
C0078981
C0205070
C1822295
C1426785
C1850039
C3697425
C0155825
C1636188
C1821649
C0158382
C2074980
C0011644
C1142179
C0150988

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2936329
C0267099
C0043246
C1384589
C0341539
C0744135
C1276133
C0946092
C0439734
C0263222

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1322253
C0019112
C0013421
C1591349
C2169390
C0262988
C0421273
C0262380
C0149863

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

infection or stasis
tooth loss
related blood
infection status
solid
stable chest pains
risk of prostate cancer
inflammation warmth
maceration of the skin
Chronic idiopathic
constipation
Retroperitoneal
lymphadenopathy
refused
NASH induced liver
coughing up yellow sputum
Gastric diverticulum
containing inguinal hernia
chronic Lyme disease
was
recurrent epistaxis
renal findings
chondrocalcinosis
Abdominal aortic
atherosclerosis
chronic stomach
stasis edema
stool blood
line complications
flush skin
for liver disease
arterial inflow
about these
Chronic plaque
bloating after dairy food
stone not
stone nephrolithiasis
levels in the blood
chronic scar
Wound cellulitis
Moyamoya
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C1407921
C0080233
C1266852
C0517627
C0205208
C0742297
C1954276
C2087495
C0558143

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0267509 Monitoring
C0748390
C1705116
C3869479
C2126216
C0038355
C3809861
C2063079
C1421478
C3809715
C0426703
C0553730

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0398356
C0341172
C1135352
C1321898
C1275741
C0016382
C2584636
C0449613
C3898970
C0406317
C2198704
C0940852
C1578933
C0428249
C3258142
C0406832
C0026654

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

intracranial vascular
disease
blood in the stool
a weight
blanching of skin
photosensitivity of the skin
serious
chronic liver injury
do still
liver damage
weight loss management
Unspecified hernia repair
undergone
subcutaneous abscess
Basal cell skin cancer
profound weight loss
compartment syndrome
increased vascular
remaining
or supporting
microlithiasis
hereditary pancreatitis
groin
Cryptococcal infection
Wound care as
tracheoesophageal fistula
Scrotal cellulitis
chronic neutropenia
risk for liver disease
bridging fibrosis
small vessel disease
cauda equina
meningitis or systemic
infection
prandial
sternal wound infection
Anticardiolipin antibody
syndrome
within the skin
Blackout spell
Antral polyps
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C0007820
C3843741
C0745275
C0277941
C0349506
C0205404
C2242584
C3173472
C0151763
C0884421
C0198552
C3829754
C0241266
C0751676
C1848641
C0009492
C0232341
C1527428
C0409089
C0333027
C0238339
C0018246
C0740272
C0811367
C0040588
C0268927
C0746882
C1281905
C0334160
C2733158
C0007458

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0729584 Monitoring
C0376674 Monitoring
C2729214 Monitoring
C1608418
C2234621
C0312422
C0264239

Monitoring
Monitoring
Monitoring
Monitoring

ulceration not
spigelian hernia
Infected finger
air
mantle cell lymphoma
vascular abnormalities
chronic sinopulmonary
infection
vitiligo
as it would be
chronic pedal edema
OA knee
airway disease
Drainage Of Skin Abscess
cystic liver disease
infection or purulent
indwelling
muscle damage
Submental island flap
infection after
thing
before
clammy skin
chronic epistaxis
vascular event
vomiting or weight loss
Acute respiratory infection
chronic pericarditis
pseudomonas urinary tract
infections
cerebral vascular
Amyloid
remnant
adjuvant radiation therapy
fun
Subcapsular renal
hematoma
fill
groin wound
choroid plexus papilloma
inflammatory arthritis
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C1720140
C0392508
C0555974
C0001861
C0334634
C0241657

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1846546
C0042900
C3641844
C0747319
C0409959
C0699949
C0370367
C0158683
C1535040
C0439848
C0410158
C0440834
C0393390
C1551338
C0332152
C0392162
C1739141
C0038454
C2169616
C0339901
C0265143

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0577710
C0007787
C0002716
C3272697
C1706721
C2700434

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C3897450
C1708059
C1402898
C0205770
C0003864

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Not falls
under fluoroscopic
guidance
rectal exam
Moisturize
hypervolemia
unexpected
colonic lipoma
or septic arthritis
gap
gained much weight
breath away
stone retinal
deposition of crystals
chronic angle
Not taking oxycodone as
tubular
compression
dyspnea
salivary gland infection
polyp in the cecum
relief of bladder
found
massive blood loss
chronic shoulder
dislocation
Chronic right vision loss
comfort
rectal tumor
staghorn calculus
exertion or chest
vascular dementia
chronic fatigue
nylon in the skin
wound necrosis
fat or weight
lumbosacral radiculopathy
Prostate tenderness
papillary
Discolored skin
instability
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C0575123 Monitoring
C2321778
C0199900
C0868994
C0546817
C4055646
C0940607
C1692886
C0061928
C3175834
C3154057
C0154854
C0442844
C0154947
C3898453
C0332208
C0728907
C0013404
C0392318
C0742570
C0401615
C0150312
C0333279

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1403308
C3275688
C1331418
C0034885
C0333014
C0232288
C0011269
C0518656
C0856559
C1096115
C0521974
C0154738
C0240813
C0205312
C0151907
C1444783

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

urinary stones
Biliary stent
fibroids or endometrial
Thyromegaly
left axillary abscess
Stocking distribution
sensory loss
polyarticular
appendicitis
bladder spasm
vental incisional hernia
always
nocturia
Chronic dysuria
colloid nodule
purpuric skin rash
swelling in stump
bowel within the hernia
ulcerations dry skin
without parastomal hernia
retinal detachment
management of kidney
disease
ulcer bleed
Pharyngocutaneous fistula
urination difficulty
as
osler nodes
inflammation in the
raise uric acid
retroperitoneal abscess
graft thrombosis
pelvic infections
vulvar infection
reducible central hernia
coughing or chest
chronic urate nephropathy
swelling tenderness
obstructive coronary artery
blood or blood
infected vascular graft
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C0042018
C0183512
C1536487
C0018021
C4280975

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0277852
C0240789
C0003615
C0426390
C1532116
C1549493
C0028734
C0743334
C0342117
C0151882
C0740962
C1394743
C3494913
C3264414
C0035305

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1515005
C0333291
C0396009
C0241705
C0162635
C0240608
C0004690
C0857189
C0237962
C0919939
C0030790
C1400809
C1265757
C0876765
C0268769
C2055675
C0546319
C0371802
C0340896

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

pacing
chronic infundibular
nocardia infection
chronic effusions
gastric perforation
drainage of retroperitoneal
abscess
Peritoneal abscess
Wound related
infected dialysis
stump infection
bowel ischemia
Sickle Cell Trait
focal atelectasis
Splenic abscess
yellow nasal
debris
infection being
inflammation or erosions
any
dermoid cyst
bladded
swelling rectal
stool as
inflammation without
infection given ascites
Esophageal erosions
Abscess drain
intra abdominal abscess
anastomotic leak
RLQ abd abscess
Neck strain
gal
pseudoaneurysm
infected AV fistula
cervical or inguinal
lymphadenopathy
phrenic nerve palsy
Behcet disease
slurred speech
stones calcium
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C0562458
C0395990
C0028242
C0031144
C0235884

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0342976
C0267756
C2597978
C1400574
C0392042
C2004435
C0037054
C0264496
C0272412
C2203645
C0440266
C1855452
C0333357
C1552551
C0011649
C0156265
C0848365
C0423599
C0155354
C0919899
C0341117
C0333371
C0243001
C0919691
C0750795
C0262573
C1704676
C1510412
C0741319

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1850027
C1442879
C0004943
C0234518
C0797811

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

stones within the bladder
wound abscess
infected renal cyst
suspect infection
Mycoplasma infection
palpitation or chest
risky
pelvic lymphadenopathy
Locally advanced prostate
cancer
Aortobiiliac
metastatic disease
wound of skin debridement
controlling weight
hemorrhoid bleeding
hepatic ascites
kinking within the catheter
humoral rejection
Nail fungal infection
cellulitis infections
intellectual developmental
delay
Risk for hepatocellular
carcinoma
penile
in liver disease
bleeding after
interstitium
white
basal ganglia
ankle wound
pulmonary granulomas
constitutional symptoms
Prostate Weight
chronic smoker
or choking
yellow nodule under skin
risk for cardiovascular
events
uric acid levels in the blood
Dyspepsia
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C0005683
C0406105
C0403383
C0744970
C0026936
C0030252
C0871885
C1264124

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0677984
C0918078
C2939420
C0191342
C0920298
C0265031
C0401037
C3665945
C1608974
C0040261
C0743758

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1408678 Monitoring
C1862761
C0030851
C0393841
C0156406
C2328510
C0043157
C0004781
C1396654
C0235557
C0009812
C2142671
C0848477
C0546947
C2126329

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1273410 Monitoring
C0373739 Monitoring
C0013395 Monitoring

Unprovoked
low likelihood coronary
artery disease
Carotid atherosclerosis
Chronic plantar fasciitis
inguinal hernia repair mesh
chronic malnutrition
Ewing sarcoma
biventricular heart
head fractures
stone attacks
chronic recurrent
pancreatitis
subcutaneous nodules
foot infection
Cystoid macular edema
wound discharge
chronic degenerative disk
disease
probe
chronic heart
chronic relapsing
defers
soda
VRE urinary tract infection
Cardiac arrhythmias
chronic knee arthralgias
exit site
Focal calcifications
chronic coronary
Chronic leukopenia
Anemia of renal disease
vomiting or
discuss weight
infection or abscess
rectus sheath hematoma
or epidural abscess
chronic mouth
edema or chest
bowel volvulus
requiring skin graft
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C0541789 Monitoring
C3463819
C0577631
C1136148
C0405615
C0746367
C0553580
C0685095
C0744604
C3267184

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C2074913
C0151811
C0555973
C0024440
C0406834

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0685106
C0182400
C0175708
C0278787
C0205421
C0683086
C2368066
C0003811
C0741218
C0449669
C1265880
C1533195
C0745710
C0472713
C1822400
C0419897
C1542840
C0238408
C2875032
C0281800
C2732581
C0042961
C0748750

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

Acinetobacter Pneumonia
subclavian vein thrombosis
acute pancreatitis
Hemorrhagic renal cyst
Integrity
facial tic
IgE
C infections
continued loss
intertriginous
headaches or
gastric dilatation
swelling not
Metastatic gastric
adenocarcinoma
chronic dilatation
outpt
Congenital vascular disease
flaxseed oil
Psuedomonas
breast swelling
pneumocystis pneumonia
chronic pancytopenia
incarcerated inguinal
hernia
fingernail fungal infection
compression fracture
spicy food intake
stiffness in any joints
Subaortic stenosis
Unprotected sexual
intercourse
bread intake
Sessile polyp
shooting pains
Peripheral edema
pulmonary infiltrates
raise arm
tendon tears
or vascular lesion
atrophic skin
179

C2063075
C0749087
C0001339
C1168323
C0443238
C0338467
C0020846
C0010414
C2749246
C0205268
C0239885
C0038353
C2184237

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C3160888
C1265762
C0551586
C1275966
C0023754
C3460694
C0006152
C1535939
C0747203

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C0740375
C0744036
C0521169
C0559575
C0162298
C0340375

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1578545
C0556171
C0522621
C0278146
C0085649
C0235896
C0231810
C0850773
C0423793
C0151514

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

chronic urethritis
Kaposi sarcoma
Hydrops of gallbladder
Nontraumatic subdural
hemorrhage
chronic graft
Chronic eustachian tube
crohns colitis
chronic active colitis
misunderstood
arthritic pains
chronic systemic
chronic suprapubic
chronic flank
bladder irritation
healed fractures
hydronephrosis or renal
calculus

C0020740
C0002144
C0699241
C0025810
C0056732
C0024002
C0002658
C0040207
C0020404
C0033405
C0146011
C0053799
C0025242
C0010980
C0730920
C0663448
C0008783
C0053229
C0124498
C0025376

Medication
Ibuprofen
allopurinol
Nitrostat
Methylphenidate
Cyclobenzaprine
Lorazepam
Amphetamines
TICLOPIDINE
hydroxyzine
promethazine
tizanidine
Bisoprolol
Memantine
Dapsone
Thymoglobulin
Viagra
Cimetidine
Benzonatate
Kayexalate
Meperidine

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening

Other
joint
C0022417
renal
C0022646
vitamin
C0042890
Hepatitis C C0019196
chest
C0817096
sildenafil
C0529793
Neosporin
C0068536
Torsemide
C0076840
Vitamin C
C0003968
adjuvant
C1522673
claritin
C0701055
macrobid
C0591750
blood uric acid C0373739
attack of gout C2712871
Ventolin
C0033744
groin
C0018246
vitamin D
C0042866
Multivit
C0301532
stores
C1698986
David
C3809991
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C0150001 Monitoring
C0036220 Monitoring
C0152445 Monitoring
C0265080
C0301948
C0155430
C0156147
C2826588
C4061919
C0857177
C1290611
C0749927
C2074632
C2945586
C0162542

Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring
Monitoring

C1391794 Monitoring

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening

C0699177
C0033429
C0021246
C0015772

Plaquenil
Propafenone
indomethacin
Felodipine

Intervening
Intervening
Intervening
Intervening

C0033228
C1170736
C1579314
C0053091
C0720193

Fenofibrate
zetia
DtaP
benazepril
Enbrel

Intervening
Intervening
Intervening
Intervening
Intervening

C0072973
Ramipril
Intervening
C0012522 diphenhydramine Intervening
C0064636
lamotrigine
Intervening
C0069751
C0033209
C0025872
C0526512
C0279284
C0034259
C1170407

oxcarbazepine
probenecid
metronidazole
Synercid
Doxil
Pyridium
mucinex

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening

C0699770

Proventil

Intervening

C1570232

Lyrica

Intervening

C1636686
C0162723
C0002403
C0596004

byetta
zyrtec
amantadine
Hyoscyamine

Intervening
Intervening
Intervening
Intervening

C0087119
C0595425
C1505021
C0030049
C0700003
C0032143
C1996201
C0071097
C0721436

Elavil
Zanaflex
Cymbalta
oxycodone
Lopid
TPA
Actonel
pioglitazone
Lotensin

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening

blood
Flecainide
insomnia
hep C
evaluation of
chest
Betamethasone
Accolate
aleve
renal toxins
vitamin D
levels
blastomycosis
renal c
Hypophosphate
mia
twice
Synthroid
Atarax
stomach
toxins
insipidus
heart and
kidney
vitamin K
levels
Hepatitis C
liver
melatonin
assays
sickle C
FOSAMPREN
AVIR
pian
Pramoxine
Psycho
Gallstones
vitamin B
intertrigo
APAP
divalproex
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C0005767
C0016229
C0917801
C2148557

Intervening
Intervening
Intervening
Intervening

C0742295
C0005308
C0526502
C0718343
C0597372

Intervening
Intervening
Intervening
Intervening
Intervening

C0428586 Intervening
C0005716 Intervening
C0439042 Intervening
C0085682
C1948050
C0728762
C0684229
C0038351
C0040549
C0011848

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening

C0155602 Intervening
C0443768 Intervening
C1391577
C0025219
C1510438
C0019034

Intervening
Intervening
Intervening
Intervening

C1176315
C0043388
C0071810
C0871175
C0242216
C0042849
C0021807
C0000970
C0042291

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening

C0040610
C0004745
C2137913
C0592245
C0593507
C0700727
C0001617
C1174784
C1170019
C0068334
C0536495
C0728767
C0700517
C0876139
C0033148
C0591237
C0876226
C0663241
C0249529
C0936278
C0010137
C0687812
C0012093
C0127096
C0009316
C0305648
C0216784
C0249458
C0350186
C0008294
C1528494
C0066685
C0592157
C0701009
C0064238
C0015620
C0875968

Tramadol
Barbiturates
joint
corticosteroid
valtrex
advil
Sudafed
corticosteroid
Ranexa
Abilify
Nabumetone
Moxifloxacin
Marinol
Keflex
Protonix
Primidone
Casodex
Zyvox
Linezolid
febuxostat
vistaril
Cortisone
allopurinol
100mg
Dicloxacillin
Maxzide
COLISTIN
Citrucel
Valsartan
valACYclovir
TNG
Chlorthalidone
truvada
Moexipril
Tagamet
bumex
kaopectate
famotidine
Avelox

Intervening
Intervening

blood levels
danazol

Intervening
lupus
Intervening joint discomfort
Intervening
joint dis
Intervening
repeat
Intervening stomach upset
Intervening
Robert
Intervening Hep C RNA
Intervening
PMR
Intervening
joint pains
Intervening
upset
Intervening
attack
Intervening
aphonia
Intervening
hemostat
Intervening
joint c
Intervening
LVAD
Intervening
gloves
Intervening
backup
Intervening
Tracy
Intervening
sarcoid

C0151539 Intervening
C0010961 Intervening
C0024131
C3544124
C0022408
C0205341
C0235309
C0331964
C0973340
C0032533
C0003862
C3887804
C0004063
C0003564
C0019120
C0408229
C0181598
C0441051
C1552560
C3391642
C0036202

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening

Intervening
treatement
C0741107 Intervening
Intervening propylthiouracil C0033511 Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
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C0701281
C0592168
C0002645
C0700187
C0700016
C0075870
C0051696
C0678162
C0723893
C0013881
C1527845
C0876218
C0024027
C0012125
C0069177
C0594040
C0022209
C0034261
C0730987
C0282386
C1110594
C0380393
C0878174
C0075632
C0053526
C0013085
C0700023
C0038425
C0593342
C0719197
C0016365
C0591139
C1122245
C0876060
C1330412
C0707987
C0027358
C0060282

Biaxin
Tenormin
amox
macrodantin
Mysoline
tazobactam
amlodipine
pulmicort
Tricor
Librium
Vytorin
Xopenex
lovastatin
Dicyclomine
NyQuil
Nasacort
Isoniazid
pyridostigmine
Exelon
levofloxacin
Allegra
ziprasidone
Arimidex
SUMAtriptan
Bethanechol
Doxepin
bentyl
STREPTOMYCI
N
Requip
ceftin
fluoxetine
Bactrim
benicar
Keppra
Namenda
Claritin 10mg
Naloxone
FeSO4

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
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C1702177
Januvia
Intervening
C0720403
Feosol
Intervening
C0700798
indocin
Intervening
C0007555
cefotetan
Intervening
C0699932
Senokot
Intervening
C0017696
Glucan
Intervening
C0878061
Altace
Intervening
C0111046
creon
Intervening
C0022860
labetalol
Intervening
C0014695 Ergocalciferol Intervening
C0040805
Trazodone
Intervening
C0290795
Adderall
Intervening
C0031379 Phenazopyridine Intervening
C0723743
Tiazac
Intervening
C0666743
infliximab
Intervening
C0012091
diclofenac
Intervening
C1174767
Fosrenol
Intervening
C0061851
ondansetron
Intervening
C0876768
Vioxx
Intervening
C0483244
anusol
Intervening
C0040165 levothyroxine Intervening
C0721044
Imitrex
Intervening
C0004482
azathioprine
Intervening
C0718244
Actigall
Intervening
C0733842
Stelazine
Intervening
C1170286
Forteo
Intervening
C0722336
Oscal
Intervening
C1170079
Avodart
Intervening
C1174734
Uroxatral
Intervening
C0700899
benadryl
Intervening
C0064113
itraconazole
Intervening
C0722138
asprin
Intervening
C0699439
Nizoral
Intervening
C0210355
Arthrotec
Intervening
C0003289 antidepressants Intervening
C0069805
oxybutynin
Intervening
C0701348
Femara
Intervening
C0698978 Plaquenil 200mg Intervening
C0042553
Versed
Intervening
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C0244821
C0699547
C0019139
C0253563
C0011812
C1170699
C0723012
C0016277
C0939692
C0028833
C0165921
C0078844
C0292855
C0720318
C0674427
C0700524
C0974285
C0030863
C0070895
C1098320
C1631198
C0014563
C0875967
C0699065
C0939530
C0033798
C0718644
C0965129
C0246689
C0289313
C0701094
C0876064
C0057144
C0875952
C0700017
C0073374
C0009279

Ropinirole
Azulfidine
LMWH
eptifibatide
Dextroamphetam
ine
Ultracet
remicade
Fluconazole
DuoNebs
Octreotide
Entacapone
Zonisamide
zestoretic
evista
Sustiva
amoxil
amlodipine
10mg
Pentamidine
foscarnet
Olmesartan
Florastor
EPINEPHrine
Avandia
Thorazine
Welchol
PSEUDOEPHE
DRINE
arava
Rosuvastatin
Repaglinide
Rosiglitazone
Darvon
lantus
daptomycin
Aciphex
Naprosyn
Rifaximin
colestipol

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
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C0003138
C0876173
C0687813
C0591292
C1101609
C0004599
C0008273
C1314782
C0538927
C0591275
C0728743
C0123931
C0085795
C0069717
C0728751
C0981097
C0721298
C0690835
C1698963
C0042397
C0070384
C0006462
C0678117
C1602236
C0701331
C0595301
C0939412
C0014964
C0722882
C3215523
C1418193
C1145759
C1516119
C0702216
C1579761
C0699926
C0732355
C0594492

Antacid
tamiflu
Allopurinol
300mg
Corgard
viread
bacitracin
Chlorothiazide
Levemir
Celecoxib
Cogentin
Cefzil
irinotecan
amphotericin
oxaliplatin
Betapace
vitamin C 500mg
lamisil
Torsemide 10mg
Sutent
vasopressors
Percodan
busPIRone
Sandostatin
ferrex
Relafen
Avapro
Novolog
Ethambutol
Provigil
vitamin D pill
OTC
atazanavir
Sorafenib
Soma
Lunesta
Robaxin
Rituxan
Nasonex

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
186

C0689174 Ibuprofen 600mg
C0718711
Atacand
C0290883
Anastrozole
C1724016
Atripla
indomethacin
C0689206
50mg
hydroxychloroqu
C0020336
ine
C1450020
levothyrox
C0733418
Ticlid
C0037688
Sorbitol
C0700712
Micronase
C0017628
glyBURIDE
C1174890
levitra
C0171023
Olanzapine
allopurinol
C0795227
500mg
C0003360 antihistamine
C0678171
Pentasa
C0036557
sedatives
C0026078
Midodrine
C0591055
Aldomet
C0688870 flecainide 100mg
C1577528
Nifedical
C0699595
Septra
C1260298
tigecycline
C0591224
Capoten
C0701890
Duricef
C0762662
Rofecoxib
C0001367
Acyclovir
C0699279
imuran
C0007713
Cepacol
C0936148 Posaconazole

Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
Intervening
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